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ABSTRACT 
 
In vitro transformation of primary human fibroblasts has been commonly used to 
understand the specific steps required to generate neoplastic cells following the ordered 
introduction of cellular and viral oncogenes and/or the down-modulation of tumor suppressor 
genes. In this thesis I have applied this strategy to explore the pro-oncogenic function of class 
IIa HDACs. Class IIa histone deacetylases deregulation can contribute to cancer development 
and progression in different ways. However their real involvement in tumor biology is still 
debated. To clarify this issue I have investigated the role of HDAC4, a representative member 
of this class, in human immortalized foreskin fibroblast (BJ/hTERT). I have demonstrated that 
HDAC4 negatively influences the isolation of clones after retroviral infection. This effect is 
MEF2-independent and is in part due to the activation of an apoptotic response. Through the 
generation of BJ/hTERT cells expressing BCL-xL, a Bcl-2 family member characterized by a 
pro-survival function, it was possible to isolate clones expressing HDAC4 mutated in the 14-
3-3 binding sites, suggesting that HDAC4 deregulation can elicit apoptosis. Isolated clones 
were characterized, and alterations in the cell cycle profile were not observed. However 
strong repressive forms of HDAC4 were also subject to intense proteolytic degradation. The 
apoptotic response and the proteasome-mediated degradation were also described using a 
doxycycline-inducible system. In this case the nuclear resilient mutants of HDAC4 render 
BJ/hTERT cells more susceptible to apoptosis only when triggered by DNA damage and 
protein synthesis inhibition, but not by proteasome inhibitors or oxidative stress. In addition 
all the nuclear resident mutants evidenced a higher rate of proteasomal degradation. 
Finally, ectopically expressing in BJ/hTERT cells, a form of HDAC4 mutated only in NES 
sequence (HDAC4-L/A), allowed the isolation of clones characterized by a MEF2-repressed 
phenotype. This mutation causes the accumulation of the deacetylase in the nuclear 
compartment, without interfering with 14-3-3 binding. This result suggests a possible 
implication of these adaptor proteins in the HDAC4 anti-proliferative activity. In parallel 
murine fibroblast expressing the HDAC4-L/A mutant acquire the ability to growth in an 
anchorage-independent manner. 
Overall this thesis sheds some light on the HDAC4 potential of eliciting oncogenic 
conversion also in human cells managed also by the 14-3-3 binding. 
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Introduction 
 
 
1. Epigenetics 
 
The term “epigenetics” was originally coined by Conrad Waddington to describe the 
heritable changes in a cellular phenotype that were independent of alteration in the DNA 
sequence (Waddington, 1959) Chromatin structure and organization define the state of the 
genomic information influencing the ability of genes to be expressed or silenced. The basic 
functional unit of chromatin is the nucleosome, which comprise 147 base-pair (bp) of DNA 
wrapped around a core of positively charged proteins called histones. Basically, chromatin 
can be organized in two different ways: i) heterochromatin, which is an highly condensed, late 
to replicate and contains silenced genes; and ii) euchromatin, which adopts an open 
conformation and contains most of the active genes (Du Toit, 2012) (Dawson and Kouzarides, 
2012). 
These conformations are characterized by different epigenetic modifications that occur in 
the DNA and/or in the histone tails, protruding from the nucleosomes (Kouzarides, 2007). 
Changes in the chromatin status of specific genes can lead to their repression or activation. 
Several histone post-translational modifications (PTMs) have been described, including 
acetylation, methylation, phosphorylation, sumoylation, ubiquitylation, ADP ribosylation, 
deimination, proline isomerization and many others (Bannister and Kouzarides, 2011; Berger, 
2007). All together the histone PTMs constitute the so-called “histone code” that is read and 
recognized by additional proteins in order to regulate gene expression (Strahl and Allis, 
2000). These proteins are called epigenetics regulators and can be divided into distinct groups 
based on broad functions: epigenetic writers place epigenetic marks on DNA or histones; 
these marks are removed by epigenetic erasers and recognized by epigenetic readers 
(Falkenberg and Johnstone, 2015) (Figure 1). 
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Figure 1. Epigenetic regulators. Chromatin architecture and status are defined by different chemical groups 
attached to DNA or to the histone tails. Epigenetic regulators are proteins involved in the regulation and 
interpretation of chromatin status. The function of each group of proteins is described in the figure. Adopted 
from (Hojfeldt et al., 2013) 
 
Around fifty years ago, Vincent Allfrey and colleagues discovered the lysine acetylation of 
histones, demonstrating that acetylation of the ε-amino group of lysine residues on histones 
could play a role in gene expression (Allfrey et al., 1964; Gershey et al., 1968). The 
acetylation neutralizes the positive charge of the histone lysine residues, relaxing the 
chromatin conformation and augmenting chromatin accessibility.  
On histones, acetylation is generally associated with gene activation. On the opposite, the 
removal of acetyl groups induces chromatin condensation and gene transcriptional repression 
(Haberland et al., 2009). It is well established that lysine acetylation also occurs in a 
considerable number of non-histone proteins, such as transcription factors and cytoplasmic 
proteins, governing protein-protein interaction and also affecting gene transcription and other 
cellular processes (Glozak and Seto, 2007). Lysine acetylation is a reversible modification 
controlled by the antagonistic action of two families of enzymes, histone acetylases (HATs) 
and histone deacetylases (HDACs). HATs promote the transfer of acetyl groups from acetyl 
CoA to the ε-amino group of the lysine residue. On the contrary, HDACs catalyze the 
removal of the acetyl group from the acetylated residue, releasing an acetate molecule (Yang 
and Seto, 2007). The fine regulation of histones’ PTMs and epigenetic changes on DNA are 
important mechanisms for cells to have an appropriate patterns of gene expression during 
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different cellular programs, and an altered expression of epigenetic regulators have been 
described in cancer and in several human pathologies (Dawson and Kouzarides, 2012; 
Falkenberg and Johnstone, 2015). 
 
 
2.  Histone deacetylase family 
 
Nε-acetylation was extensively studied in the past decade and it is known that this 
modification not only occurs on the histone tails. (Choudhary et al., 2009; Choudhary et al., 
2014). In mammals 18 HDACs have been identified and characterized. They are grouped into 
four different classes, based on the sequence homologies to yeast orthologues (Figure 2). The 
four classes differ in structure and also for the sub-cellular localization and the enzymatic 
activity (Martin et al., 2007; Yang and Seto, 2008). 
Class I HDACs family consists of HDAC 1, 2, 3 and 8, which share homology with Rpd3 
(Yang and Seto, 2008). These HDACs are expressed ubiquitously in all tissues and 
predominantly localized in into the nucleus of the cells. They also display a high Zn2+-
dependent enzymatic activity toward histone substrate. They posses relatively simple structure 
(Figure 2) with short conserved C-terminus deacetylase domain and a brief amino-terminal 
region (Martin et al., 2007). 
Class II is constituted by 6 members: HDAC4, 5, 6, 7, 9, and 10, which show homology to 
the Hda1 yeast orthologus (Yang and Seto, 2008). They are also Zn2+-dependent proteins and 
have a tissue-specific expression in particular in muscle, brain, neurons, bone, thymocytes and 
endothelium (Martin et al., 2007). On the basis of their structural and functional features this 
class has been further subdivided in two subclasses: class IIa and class IIb. The first 
comprises HDAC4, 5, 7 and 9. These deacetylases display a very large N-terminal domain, 
which is involved in the interaction with other cofactors and differently from the others 
HDAC classes they are subjected to a nuclear-cytoplasmic shuttling, as a mechanism of 
functional regulation. Moreover they also have a conserved acetylates domain structurally 
located in the C-terminus of the proteins, but strangely they do not show its own enzymatic 
activity (Haberland et al., 2009; Martin et al., 2007). Class IIb comprises instead the other two 
members: HDAC6 and 10. Conversely, they are enzymatically active on some substrate such 
as for example tubulin (Martin et al., 2007). 
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Class III groups Sirt 1, 2, 3, 4, 5, 6 and 7. Also known as Sirtuins (Sir2 like-protein), they 
are homologous with Sir2 in yeast (Yang and Seto, 2008). They are widely expressed and 
localize in different subcellular compartments. Sirtuins differentially from other deacetylases 
require NAD+ as cofactor. They show a broad range of biological function such as regulation 
of oxidative stress, DNA repair, regulation of metabolism and aging (Bosch-Presegue and 
Vaquero, 2014). 
Finally, only HDAC11 belongs to class IV. HDAC11 contains conserved residues in the 
catalytic core region that are shared by both class I and class II HDACs with small amino- and 
carbossi-terminal regions. Its expression is enriched in kidney, brain, testis, heart and skeletal 
muscle, but its function has been less studied (Haberland et al., 2009). 
 
Figure 2. HDACs in humans. The 18 different HDACs proteins are subdivided in various families according to 
the homologies to the yeast orthologous. A schematic representation of the different classes and their structure 
are showed. Class IIa HDACs are characterized by an extended N-terminal domain, which on the opposite is 
very small in the other sub-families, and by an inactive deacetylase domain localized in the C-terminal end. Each 
HDACs show a typical intracellular localization. The expression levels differ also from various tissues and 
organs. Adopted from Clocchiatti et al 2011. 
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3. Class IIa histone deacetylases 
 
3.1 Structure 
Structurally, class IIa subfamily is characterized by a bipartite model (Figures 2 and 3) 
with a conserved C-terminal region and an extended N-terminal domain (Zhang et al., 2008), 
both absent in the other classes, justifying their classification into a different sub-group. The 
N-terminal region has an extension of around 600 amino acid (aa) in HDAC4, taking this as 
the major representative member of this class (Figure 3), however in the other members this 
region is between 500 and 600 aa long (Martin et al., 2007). Homology of the N-terminus, 
among the four members of this class scores between 30-45% of identity, except for some 
amino acids involved in specific functions (Di Giorgio et al., 2015; Martin et al., 2007). 
 
 
Figure 3. Class IIa structure representation. Schematic representation of class IIa HDACs highlighting the 
principal domains. As prototype of class IIa HDAC4 was selected. Certain interaction partners, as well as the 
relative HDAC4 sequences involved, are illustrated. The NLS represent the NLS1 that is the principal domain 
involved in the nuclear import (adopted from Di Giorgio 2015). 
 
The amino-terminal domain regulates the nuclear import, because there are two nuclear 
localization signals (NLSs). NLS1 (residue 244–279) (Figure 2) is the major NLS and is rich 
in basic amino acids, while NLS2 (residue 1–117) is a minor NLS (Nishino et al., 2008). 
These two regions are able to interact with importin-α and to mediate nuclear accumulation of 
the protein (Grozinger and Schreiber, 2000; Nishino et al., 2008). 
Within this large region is also sited a coiled–coil glutamine-rich domain that is peculiar of 
the family (Figure 2). This domain in HDAC4 have 26 glutamine residues, is organized in a 
single α-helix and is involved in the formation of homo- and hetero-dimers (Martin et al., 
2007). Curiously, this region is conserved in HDAC4, 5 and 9 but is absent in HDAC7. This 
peculiar domain of class IIa HDACs is important because is an adaptor domain devoted to 
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protein-protein interaction. Most of the interactors are with DNA-binding proteins, indeed 
HDAC4 lacks a DNA binding domain and any association with nucleic acids needs to be 
mediated by a partner (Wang et al., 1999). In addition, the N-terminal region contains specific 
residues that are subjected of various PTMs, such as proteolytic cleavage (Bakin and Jung, 
2004; Liu et al., 2004; Paroni et al., 2004), ubiquitination (Li et al., 2004), sumoylation (Kirsh 
et al., 2002) and most importantly phosphorylation. The latter is important because there are 
certain residues that act as docking site for 14-3-3 proteins, influencing the nuclear-
cytoplasmic-shuttling of the class IIa, which is one of the best characterized strategy for the 
regulation of these deacetylases (Grozinger and Schreiber, 2000; Martin et al., 2007; Wang et 
al., 2000) (see below). 
The C-terminal domain contains the catalytic deacetylase domain that is ineffective on 
acetylated lysine residues. The HDAC domain is made up of approximately 400 residues 
arranged into 21 α-helix and 10 β-strands organized in a single domain, structured around a 
central catalytic Zn2+ ion (Schuetz et al., 2008). It comprises 2 aspartates and a histidine that 
coordinate this Zn2+ while 2 other aspartates (Figure 3a), another histidine, a serine and a 
leucine coordinate two potassium ions (Bottomley et al., 2008; Vannini et al., 2004). This 
conformation is also conserved in class I HDACs, but despite this similarity, class IIa possess 
a bigger active site compared to class I HDACs (Figure 3b) (Di Giorgio et al., 2015; Lobera et 
al., 2013). The structural peculiarity responsible for this difference is the mutation of the 
tyrosine into a histidine, position 976 in HDAC4 (Lahm et al., 2007) (Figure 3). Histidine is 
sterically less cumbersome and induces the relaxation of the structure. As a consequence, this 
histidine is far from the central Zn2+ and is not able to form hydrogen bonds with the 
intermediate of the enzymatic reaction (Figure 3a). The intermediate is, therefore, very 
unstable, thus resulting in an ineffective reaction. Nevertheless, class IIa can efficiently 
process alternative substrates such as trifluoroacetyl-lysine, this probably due to the presence 
of the trifluoro group that should destabilize the amide bond, hence favoring the reaction even 
in the absence of transition-state stabilization (Lahm et al., 2007). Importantly, replacing back 
the Tyr generate class IIa HDACs with a catalytic efficiency 1,000-fold higher compared to 
the wild-type form (Bottomley et al., 2008; Lahm et al., 2007). Nonetheless, this mutant does 
not show enhanced repression respect to the wild-type, at least in the instance of MEF2-
dependent transcription, a well-known class IIa partner (Fischle et al., 2002). 
Class IIa HDAC possess another distinctive feature that is the existence of an additional 
Zinc Binding Domain (ZBD). The ZBD consists in a β-hairpin surrounded by two antiparallel 
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β-strands, forming a pocket-like structure that accommodates a second ‘‘structural’’ zinc ion 
(Schuetz et al., 2008). In the case of HDAC4 three cysteines (667, 669, 751) and one histidine 
(675), conserved only among class IIa HDACs, coordinate this Zn2+ and made the so-called 
‘‘core’’ of the domain (Bottomley et al., 2008) (Figure 3c). Importantly, respect to the Apo-
structure where Cys 669 and His 675 coordinates the zinc ion, in the inhibited status, these 
residues were replaced by His 665 and His 678 in the coordination of the Zn2+ (Di Giorgio et 
al., 2015). This domain is extremely flexible and the oxidation of the cysteines involved in 
Zn2+ coordination (667 and 669 in HDAC4) is sufficient to free the metal, with the 
consequent opening and deconstruction of the ZBD (Bottomley et al., 2008). Because this 
domain is head-to-head to the active site (Figure 3c), it contributes to make the class IIa 
HDACs’ catalytic site more accessible than that of class I HDACs (Figure 3b) and does not 
allow the formation of an efficient hydrophilic tunnel necessary for the release of the acetate 
reaction product (Bottomley et al., 2008; Vannini et al., 2004). 
In addition the C-terminal region is characterized by the presence of a nuclear exporting 
signal (NES) important for the export of HDACs from the nucleus and hence for the 
intracellular trafficking and regulation of the enzymes. This sequence is able to interact with 
CRM-1, a nuclear protein also known as exportin-1, capable of mediating the transit from the 
nucleus to the cytoplasm of a target protein through the interaction with nucleoporin. The C-
terminal region is also important for the interaction with the protein complex HDAC3-
SMRT/NCoR (Fischle et al., 2002) responsible for the enzymatic activity reveled after class 
IIa purification form human cells. 
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Figure 3. Representation of class I and class IIa catalytic sites (A,B) and the zinc binding domain (C). (A). 
Superimposition of the inhibitor (TFMK)-bound ribbon structure of class I HDAC8 (green) and of class IIa 
HDAC4 (white) catalytic sites. As mentioned in the text the His 976 is rotated away from the active site 
differently from Tyr 308 in HDAC8. (B) Surface representation of class I HDAC8 (green) and class IIa HDAC4 
(white) catalytic sites. The figure shows the hydrophilic tunnel necessary for the release of the reaction product 
in HDAC8 (green), while in HDAC4 (white) the His/Tyr substitution prevents tunnel formation. (C). 
Superimposition of the inhibitor (TFMK)-bound ribbon structure of class I HDAC8 (green) and of class IIa 
HDAC4 (white) catalytic site (right) and zinc binding domain of HDAC4 (left). b3 and b4 are the two 
antiparallel b -strands involved in the formation of the pocket-like structure in the zinc binding domain. 
Importantly, His 665 and His 678 in this inhibitor bound structure are replaced by Cys 669 and His 675 in the 
coordination of the zinc ion in the Apo-structure. Unfortunately the crystallization of Apo-HDAC4 was 
unsuccessful and these differences are deduced from crystallographic studies of the mutant GOF (H976Y) of 
HDAC4 (Bottomley et al., 2008). 
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3.2 Regulation of class IIa HDACs activity 
 
Cells use different strategies to influence class IIa HDACs functions. Transcriptional 
mechanisms have been described to control class IIa HDACs activities under different 
conditions, but also modulations at translation level, via specific microRNAs contribute to 
coordinate HDACs levels. 
 
 
3.2.1 Transcriptional and post-transcriptional regulation 
 
The transcriptional control of HDACs genes was not deeply investigated up today. A 
limited number of studies are reported in literature concerning this argument. Nevertheless, 
the transcription seems to be under the control of different mechanisms (Di Giorgio and 
Brancolini 2016 in press). For each class IIa HDACs member a set of splicing variants are 
present but for only few of them a regulation or function has been described (Di Giorgio and 
Brancolini 2016 in press). 
HDAC4 expression is repressed by mithramycin (Liu et al., 2006). This chemical 
compound is produced by Streptomyces plicatus and is able to bind GC-rich DNA sequences 
displacing Sp transcription factors (Sleiman et al., 2012). HDAC4 proximal promoter is 
characterized by the presence of high GC content and in fact binding of mithramycin 
interferes with Sp1-dependent transcription causing HDAC4 down-regulation (Liu et al., 
2006; Sleiman et al., 2012). Furthermore, also HDAC7 promoter seems to be under the 
control of Sp1 during differentiation (Zhang et al., 2010). 
This mechanism works in parallel with other additional circuits operating in a tissue-
specific manner. This is the case of atrophic muscles, where denervation raises HDAC4 
levels, thus influencing a metabolic shift (Tang et al., 2009). Due to the increased levels, 
HDAC4 re-localizes in the nucleus where induces myogenin activation, which in turn induces 
the deacetylase expression, thus alimenting a forward-feedback mechanism (Tang et al., 
2009). A similar, but negative, feedback mechanism operates during muscle differentiation 
(Haberland et al., 2007). In this case MEF2A, C and D, the foremost studies TFs partners of 
class IIa HDACs, are able to bind the promoter of HDAC9, induce its expression and thus 
fine-tuning their own expression (Haberland et al., 2007). Other evidences of transcriptional 
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regulation strategy were investigate in the case of stemness-maintenance (Addis et al., 2010), 
and others remain to be define (Barneda-Zahonero et al., 2013; Vega et al., 2004). 
The regulation of class IIa transcription impacts both on the synthesis of mRNA, but also 
on the control of the mRNA stability. MicroRNAs act at post-transcriptional level influencing 
both mRNA half-life and translation efficiency. Several miRNAs have been recognized to 
affect the expression of class IIa HDACs (Di Giorgio and Brancolini 2016 in press). Among 
them, miR-1 was the first reported to targeting HDAC4 (Chen et al., 2006). The study was 
achieved using a muscle differentiation model where miR-1 by targeting the 3’-UTR of 
HDAC4 mRNA promoted myogenesis (Chen et al., 2006). The effect was explained as a 
block in translation, since HDAC4 mRNA levels were not affected. After this first 
observation additional reports described the repressive role of miR-1 on HDAC4 also in other 
cellular contexts (Datta et al., 2008b; Nasser et al., 2008). In muscle also miR-206 and miR-
29 regulates HDAC4 activity (Winbanks et al., 2011). The levels of these two miRNAs can be 
down-regulated by TGF-β activation. Over-expression of both microRNAs resulted in the 
translational repression of HDAC4 in muscle cells promoting differentiation (Winbanks et al., 
2011). miR-206 expression is also enhanced during denervation where it is up-regulated by 
MyoD in order to buffer HDAC4 increase and thus favoring a possible re-innervation 
(Williams et al., 2009). About miR-29, its expression could be promoted by HDAC4 itself 
creating a negative-feedback loop (Mannaerts et al., 2013). Another miRNA sharing this 
feedback circuit is miR-220a. This miRNA target HADC4 3’-UTR region like miR-1, but 
with negative impact on mRNA levels; the deacetylase in turn, decreases miRNA-220a 
transcription disturbing the binding of Sp-1 to its promoter (Yuan et al., 2011b). In 
hepatocellular carcinoma (HCC) down-regulation of miR-200a enhances cells proliferation 
and migration, whereas its up-regulation inhibits these processes (Yuan et al., 2011b). Also 
miR-140 targets HDAC4 and it is involved in the onset of the endochondrial ossification in 
mice (Tuddenham et al., 2006). Moreover, in osteosarcoma and colon cancer cells, it is able to 
inhibit proliferation and increase chemoresistance, by inducing p53 and p21 and this response 
is less evident in cells characterized by mutations in p53 (Song et al., 2009).  
Several other miRNAs can influence HDAC4 expression in different contexts (for recent 
review see Di Giorgio and Brancolini 2016 in press): miR-22 (Huang et al., 2013; Lu et al., 
2015), miR-365 (Guan et al., 2011), miR-9 (Davila et al., 2014), miR-2861 (Li et al., 2009), 
miR-483-5p (Han et al., 2013) and miR-125a-5p (Nishida et al., 2011). Other members of 
class IIa are subjected to miRNA regulation as well: HDAC5 by miR-2861 (Fischer et al., 
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2015) and miR-9* (Roccaro et al., 2010). HDAC7 expression is under the regulation of miR-
140-5p and miR-34 involved, respectively, in the metastasis of tongue carcinoma and in 
resistance to therapy in breast cancer cells (Kai et al., 2014; Wu et al., 2014). Up to now only 
one miRNA against HDAC9 was identified: miR-188, which controls the osteogenetic 
program (Li et al., 2015). 
Taking together, these evidences suggest that different miRNAs specifically target class IIa 
HDACs to modulate specific cellular responses and biological functions in different cell 
types. 
 
 
3.2.2 Post-translational regulation 
 
The function, activity, and stability of proteins can be controlled by PTMs. Class IIa 
HDACs family is subjected to a wide spectrum of modifications after the translational process 
(Wang et al., 2014)Di Giorgio and Brancolini, 2016 in press). It’s known that the integration 
of all PTMs is an important code to understand the regulatory network operating on these 
enzymes involved in various physiological responses. Dissection of the modulation patterns 
operating on class IIa HDACs is mandatory to unveil all the cellular responses monitored by 
these enzymes. 
 
Phosphorylation and the sub-cellular localization 
An important and peculiar strategy adopted by cells to modulate class IIa HDACs activity 
is to shuttle these enzymes between the nucleus and the cytoplasm (Fischle et al., 2002). Since 
their repressive function is mainly exerted inside the nucleus, the cytoplasmic accumulation is 
in general considered as a negative regulation favored when transcription needs to be 
switched on (Clocchiatti et al., 2013a; Martin et al., 2007). This strategy could be considered 
as an immediate and quickly adaptive response to external stimuli. The nucleo/cytoplasmic 
distribution of class IIa HDACs is controlled by two separate domains: i) the NLS presents in 
the N-terminal region and ii) NES located in the C-terminal part (Grozinger and Schreiber, 
2000; Nishino et al., 2008). As above mentioned, NLS 1/2 and NES sequences, when are 
properly exposed, are able to interact with importin-α and CRM-1 respectively, important 
determinants to control the distribution in the two sub-cellular compartments of class IIa 
HDACs (McKinsey et al., 2001). In fact, inhibition of the exportin-1 receptor nuclear 
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transporter by leptomycin B treatment determines the nuclear accumulation of class IIa 
HDACs, suggesting that these proteins are continuously transported out from the nucleus. 
In 2000’s it was demonstrated for the first time that HDAC4 and HDAC5 are able to 
interact with 14-3-3 proteins and this interaction mediates their sub-cellular localization and 
hence influences the repressive power (Grozinger and Schreiber, 2000). This interaction is 
mediated by different serine residues, located in the amino-terminal region, that after the 
attachment of a phosphate group act as docking sites for 14-3-3 dimer binding. Nowadays, its 
well know that this control requires the phosphorylation of at least three (four for HDAC7) 
serine residues well-conserved among the family members (HDAC4: Ser246, 467, 632; 
HDAC5: Ser259, 497, 661; HDAC7: Ser155, 181, 321, 446; HDAC9: Ser220, 451, 611). 14-
3-3 dimers can influence class IIa HDACs localization through different mechanisms: i) by 
masking the N-terminal NLS and thus preventing recognition of importin-α; ii) unmasking the 
C-terminal NES, thus facilitating the nuclear export or iii) a combined action of these two 
mechanisms. Regarding the latter, in cardiomyocites, it was demonstrated that HDAC4 is 
phosphorilated by two different splicing isoforms of the Calcium/calmodulin-dependent 
protein kinase II delta (CaMKII δ), one localized in the nucleus and the other one in the 
cytoplasm (Nishino et al., 2008). This report provides a clear view of the 14-3-3 mechanism 
because Nishino and colleagues demonstrated that class IIa/14-3-3 interaction can occurs both 
in the nucleus and in the cytoplasm. Moreover they have also highlighted that 14-3-3 binding 
in the nucleus facilitates HDAC’s export and, on the contrary in the cytoplasm, this binding 
prevents the nuclear import. 
Different kinases are able to affect class IIa HDACs sub-cellular localization. The first 
family, historically described to modulate HDACs nuclear export, was the previously cited 
CaM kinase family. In particular, in an in vitro model of muscle cell differentiation the 
activation of CaMKI promotes cytoplasmic accumulation of class IIa HDACs favoring 
nuclear export (McKinsey et al., 2000). Not only CaMKI but also CaMKIV can monitor the 
subcellular localization of the deacetylases (Karamboulas et al., 2006). Although CaMKI and 
CaMKIV are promiscuous class IIa HDACs kinases, CaMKII manifest a specific activity 
against HDAC4 (Backs et al., 2006; McKinsey et al., 2001). In fact only HDAC4 has a 
CaMKII peculiar docking site centered on Arg601 (Backs et al., 2006). CaMKI and IV 
phosphorylate all class IIa HDACs and show preference for residues 246 and 467 in HDAC4 
(and the corresponding aa in other deacetylases), while CaMKII preferentially phosphorylates 
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able, thanks to its capability to form heterodimers with HDAC5 and HDAC9, to make them 
susceptible to CaMKII activity. On the contrary HDAC7, which lack the glutamine rich-
region, does not oligomerize with HDAC4 and hence is not influenced by this kinase. The 
calcium-mediated export of class IIa HDACs is involved in the regulation of many 
physiological processes, such as myogenesis, hypertrophy and neuronal survival (Bolger and 
Yao, 2005; Metrich et al., 2010; Shalizi et al., 2006). In 2005 Bolger and Yao discovered that 
the CaMKII-mediated HDAC4 export in the cytoplasm exerts a pro-survival role (Bolger and 
Yao, 2005). Accordingly, the pharmacological inhibition of CaMK with KN-93 causes the 
nuclear accumulation of HDAC4 and the induction of apoptosis (Bolger and Yao, 2005). In 
general, the pro-survival effect associated with HDAC4 nuclear export, depends on the 
activation of a MEF2-transcriptional response (Shalizi et al., 2006). 
Another serine/threonine kinase, also belonging to the same CaMK superfamily, is PKD. 
This kinase is a downstream effector of PKC pathway (Matthews et al., 2006). It is involved 
as an important regulator of class IIa HDACs during muscle remodeling (Kim et al., 2008) 
and cardiac hypertrophy (Vega et al., 2004). PKD takes also part in the B-lymphocyte 
maturation (Matthews et al., 2006) and in the T-lymphocytes thymus selection and apoptosis 
(Parra et al., 2005). In all these circumstances phosphorylation of class IIa HDACs induces 
their cytoplasmic accumulation and hence the de-repression of the target genes. 
In addition to CaMK and PKD, another important group of kinases govern the 
phosphorylation status of class IIa HDACs. The master regulator of this group is the well 
known tumor suppressor LKB-1, which operates on a spectrum of downstream kinases 
including AMP activated protein kinase (AMPK), microtubule affinity regulating kinases 
(MARK), SNF-related kinases (SNRK), NUAK family, BR-serine/threonine kinases (BRSK) 
and salt inducible kinases (SIK) (Hardie, 2011). Recent studies reported that MARK kinases 
phosphorylate class IIa HDAC members on a specific and conserved residue (i.e. Ser246 in 
HDAC4, Ser259 in HDAC5 and Ser159 in HDAC7). This base-line phosphorylation 
facilitates the subsequent signal-dependent phosphorylation by other kinases of the remaining 
residues required for 14-3-3 binding (Dequiedt et al., 2006). 
The metabolic state of the cells can also influence class IIa HDACs localization and 
functions, in particular under conditions of metabolic stress and upon energy depletion, with 
concomitant increase of AMP levels, AMPK kinase is activate inside the cells (Liang and 
Mills, 2013). After activation, AMPK is able to phosphorylate class IIa HDACs, thus 
inducing their nuclear export (van der Linden et al., 2007). Accordingly, from a physiological 
 Introduction | 15  
 
point of view, the stress induced after physical exercise determines the export of HDAC4 and 
HDAC5 and this correlates with the activation of AMPK and CaMKII (McGee et al., 2008). 
Recently, McGee and colleagues have reported that during exercise the regulation of HDAC5 
is under the supervision of an additional kinases, that is PKD (McGee et al., 2014). Inhibition 
of LKB1/AMPK pathway causes a nuclear re-localization of class IIa HDACs, a key event in 
order to promote the activation of gluconeogenesis in the liver (Mihaylova et al., 2011). In 
this context, after glucagon release, HDAC5 is accumulated in the nucleus and here it 
associates with HDAC3 deacetylase and activates FOXO1/3 that in turn stimulate the 
transcription of key enzymes of gluconeogenesis (Mihaylova et al., 2011). 
The other class of kinases which activity is modulated during metabolic changes is the SIK 
family. This group consists of 3 proteins named: SIK1, SIK2 and SIK3 (Katoh et al., 2004). 
Several papers reported the involvement of SIKs in HDACs re-localization also independently 
from a metabolic regulation (Berdeaux et al., 2007; Walkinshaw et al., 2013). SIK1 is able to 
phosphorylate and to re-localize HDAC5 out of the nucleus to switch on MEF2 
transcriptional program, thus influencing the myogenic program (Berdeaux et al., 2007). In 
the adipose tissue modulation of SIK2 influences HDAC4 phosphorylation in a multiprotein 
complex, which comprises also CREB-regulated transcription co-activator 2 and 3, as well as 
PP2A. This complex is under the supervision of PKA and is involved in the regulation of 
GULT4 transcription and glucose uptake (Henriksson et al., 2015). About SIK3, Yang group 
described that in HEK293 cells this kinase together with SIK2 causes a cytoplasmic re-
localization of HDAC5 and HDAC9, but not for HDAC4 and HDAC7 (largely cytoplasmic). 
Moreover, while SIK2 promotes the nuclear export through the phosphorylation of 14-3-3 
consensus sites, SIK3 is effective also on the 14-3-3 Ser/Ala mutants, thus demonstrating that 
SIK3-mediated export is both kinase activity and classical 14-3-3 binding sites independent 
(Walkinshaw et al., 2013). Finally, while SIK2 causes the de-repression of MEF2 and 
stimulates myogenesis in C2C12 cells, SIK3 is incompetent towards MEF2 activation 
(Walkinshaw et al., 2013). Whether these differences reflect cell lineage specific features or 
others conditions is currently unknown. 
Phosphorylation is a reversible PTM, which can be rapidly reverted by a phosphatase 
activity. This modulation can impact also on class IIa regulation/localization. In fact in 2000’s 
it was demonstrated that calyculin A, an inhibitor of PP1 and PP2a phosphatases, promoted 
the nuclear export of HDAC4 reducing the interaction with importin-α (Grozinger and 
Schreiber, 2000). Some years later, in 2008, the effective contribution of PP2A to class IIa 
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HDACs cytoplasmic accumulation was proved (Kozhemyakina et al., 2009; Martin et al., 
2008; Paroni et al., 2008). PP2A is able to bind the N-termial region of HDAC4. Here, PP2A 
recognizes and dephosphorilates the NLS1 domain, specifically on Ser 298, causing a nuclear 
accumulation of HDAC4. Ser 298 is also a target residue for GSK3β kinase, which regulates, 
under starved conditions, the phosphorylation-dependent poly-ubiquitylation of HDAC4 and 
with its consequent degradation (Cernotta et al., 2011). As consequence, PP2A-mediated 
dephosphorilation may therefore also protect HDAC4 from the nuclear degradation. Another 
serine residue controlled by PP2A is the 246 (in HDAC4). It has been shown that in 
chondrocytes, the parathyroid hormone-related peptite (PTHrP) suppresses MEF2 and 
RUNX2 transcriptional activities via PP2A, which dephosphorylates HDAC4 on Ser246. This 
modification results in chondrocytes hypertrophy. (Kozhemyakina et al., 2009). PP2A activity 
does not influence nuclear accumulation of HDAC4 during apoptosis. In fact, the amino-
terminal fragment (aa 1-289) generated by caspase cleavage enters in the nucleus without 
requiring the PP2A-mediated dephosphorylation and retains its effectiveness of repression on 
MEF2 (Paroni et al., 2007). ATM, a kinase mutated in the Ataxia telangiectasia syndrome, 
modulates PP2A activity. Here, HDAC4 exhibits nuclear localization and represses MEF2 
and CREB transcription factors, thus inducing both heterochromatinization and 
neurodegeneration (Li et al., 2012). 
PP1α e PP1β are two others kinases that mediate class IIa HDACs phosphorylation. The 
first one is able to interact also with MEF2 and to retain HDAC4 into the nucleus causing a 
repression of the MEF2-dependent gene expression (Perry et al., 2009). PP1β, instead acts in 
a multiprotein complex together with MYPT1, that are constituent of the myosin phosphatase 
complex. In smooth muscle, this complex is able to desphosphorylate HDAC7, thus 
stimulating its nuclear retention (Parra et al., 2007; Walkinshaw et al., 2013). Beyond this 
classic model of regulation, class IIa HDACs localization and functions can also be affected 
by other independent mechanisms. 
 
14-3-3 independent regulation of the subcellualr localization 
Phospho-mediated regulation of class IIa HDACs is a complex issue and sometimes 
phosphorylation does not correlate with cytoplasmic localization. 14-3-3 docking sites are not 
the only residues involved in shuttling regulation, as demonstrated few years ago using a 
combinatorial proteomics approach and phospho-mutant screening by Greco and colleagues 
(Greco et al., 2011). They have figured out that for HDAC5 there are at least 17 
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phosphorylation sites, 13 of which do not encompass the consensus for 14-3-3 proteins 
(Greco et al., 2011). In particular, the phosphorylation of serine 279 is essential to induce the 
nuclear import of the protein. This residue is conserved among all class IIa HDACs, with the 
exception of HDAC7 (Greco et al., 2011). The same residue is also target by the kinase 
Dirk1B, but in this case the phosphorylation reduces nuclear accumulation (Deng et al., 
2005). PKA and CDK5 are other two kinases capable of phosphorylate Ser279 on HDAC5. 
The effect on localization is puzzling and deserves further confirmation, since PKA retains 
HDAC5 into the nucleus (Ha et al., 2010) but, on the contrary, CDK5 promotes nuclear 
export in neurons (Taniguchi et al., 2012). This opposite influence on HDAC5 localization 
could be explained by the existence of other kinases targeting additional residues. Another 
evidence that support the role of Ser279 in mediating the 14-3-3-independent shuttling arises 
from a manuscript demonstrating that the Mirk/Dirk1B complex is able to phosphorylate 
HDAC5 on this residue (Deng et al., 2005). This serine leaves in the NLS region and is also 
conserved in HDAC4 and HDAC9 but not in HDAC7. During the cell cycle, HDAC4, 
HDAC5 and HDAC9, but not HDAC7 can be phosphorylated by Aurora B kinase, 
respectively on Ser 265, Ser 278, and Ser 242. These phosphorylations allow the re-
localization of deacetylases at the mitotic midzone during late anaphase, and in the midbody 
during cytokinesis (Guise et al., 2012). This phosphorylation-dependent re-localization 
abolishes the interaction with the NCoR complex, thus limiting part of class IIa deacetylase 
activity (Guise et al., 2012). Moreover, RAS oncogene was found to promote the nuclear 
localization of HDAC4 by stimulating its phosphorylation by extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) (Zhou et al., 2000). However, experiments demonstrating the direct 
phosphorylation of HDAC4 by ERK1/2 are still lacking and the specific PTMs involved are 
still mysterious. 
Another mechanism participating in the regulation of class IIa HDACs depends on the 
redox condition. Under oxidizing environment, a disulfide bridge is formed between cysteines 
667 and 669 (Ago et al., 2008). Cysteine 667 lies in the binding site for the structural zinc ion 
(Di Giorgio et al., 2015; Hudson et al., 2015). In a reducing environment, these two residues 
and the coordinated zinc ion fold the protein, bringing the ZBD in contact with the NES. In 
this way the CRM1 binding site is masked and the nuclear export is blocked. In the presence 
of oxidants, these cysteines are oxidized, the zinc is no longer coordinated, the NES is 
exposed to CRM1 and the protein is exported into the cytoplasm (Ago et al., 2008). This 
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mechanism acts during cardiac hypertrophy, a pathological condition characterize by an 
increase in the intracellular ROS (Haworth et al., 2012; Oka et al., 2009). 
 
Other strategies of regulation 
The control of class IIa HDACs activities is not limited to their sub-cellular localization. 
Additional PTMs can act on these HDACs. Ubiquitin-dependent degradation and proteolytic 
cleavage can influence class IIa HDACs behavior. Initially it was demonstrated that HDAC7 
degradation occurs mainly in the cytoplasm after its phosphorylation-mediated export from 
the nucleus (Li et al., 2004). The UPS-mediated HDAC7 cytoplasmic degradation was 
recently confirmed during endochondral ossification (Bradley et al., 2015). HDAC7, during 
chondrocytes maturation represses MEFs and RUNX2 in order to avoid endochondral 
ossification. Indeed HDAC7 is exported into the cytoplasm where it is degraded by the UPS 
and liberates β-catenin increasing the proliferation rate (Bradley et al., 2015). In muscle, 
degradation of class IIa HDACs plays a pivotal role during fiber type switching from fast and 
glycolytic to slow and oxidative (Potthoff et al., 2007b). In this case the degradation of 
HDAC4 and HDAC5, on the contrary takes place within the nucleus (Potthoff et al., 2007b). 
Nuclear degradation was also described in untransformed cells exposed to serum starvation 
(Cernotta et al., 2011). In this case GSK3β phosphorylates HDAC4 on serine 298 and this 
PTMs acts as a priming event required for its poly-ubiquitylation and nuclear degradation 
(Cernotta et al., 2011). In another study using a knock-out mouse model for HDAC4 and 
HDAC5, it has been pointed out that during osteoclast differentiation poly-ubiquitylation and 
degradation of HDAC4 is mediated by SMURF3 E3-ligase (Obri et al., 2014). 
Degradation of class IIa HDACs can also pass through lysosomes. In a rat osteoblastic cell 
line, stimulation with parathyroid hormone causes HDAC4 PKA-dependent phosphorylation 
on Ser740, its nuclear export and finally the degradation through the lysosomal pathway 
(Shimizu et al., 2014). 
Class IIa HDACs are also subject to non-reversible processing, this refers to proteolytic 
cleavage. HDAC4 is cleaved by caspase 2 and 3 (Paroni et al., 2004) while HDAC7 is 
processed by caspase8 (Scott et al., 2008), on residue 289 and 375 respectively. In both cases 
the cleavage products increase the apoptotic rate (Paroni et al., 2004; Scott et al., 2008), but 
only the HDAC4 amino-terminal fragment retains a repressive influence against MEF2-
dependent transcription (Paroni et al., 2004). Another proteolytic cleavage was observed on 
HDAC4 during the hypertrophic response in the heart (Backs et al., 2011). In cardiomyocites, 
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PKA activation causes the cleavage of HADC4 between the residues 201 and 202, by an 
unknown protease. The amino-terminal fragment generated, accumulated in the nucleus and it 
was able to repress MEF2 transcription being incompetent for SRF repression (Backs et al., 
2011). Among class IIa HDACs, only HDAC4 posses the binding site for PKA, located in the 
C-terminal region of the protein (residues 638-651). The anti-hypertrophic effect of PKA was 
sufficient to antagonize the pro-hypertrophic action of CaMKII, without affecting 
cardiomyocite survival (Backs et al., 2011). 
SUMOylation is an additional PTMs that can occur on class IIa HDACs. HDAC4, HDAC5 
and HADC9 can be SUMOylated on lysine 559, 605 and 549 respectively (Kirsh 2002 EDG). 
Conversely HDAC7, probably because this deacetylase does not possess the glutamine-rich 
domain, is not subjected to such modification (Guo et al., 2007). HDAC4, in particular, 
becomes SUMOylated by the SUMO E3 ligase RanBP2 on the nucleopore complex during 
the nuclear/cytoplasmic shuttling (Kirsh et al., 2002). SUMOylation increases the interaction 
with HDAC3 and therefore the class IIa repressive capability (Kirsh et al., 2002). Class IIa 
HDACs are not merely target of SUMO E3-ligases, but several evidences indicate that they 
could promote SUMOylation of some partners. Gregorie and coworkers have been 
demonstrated that class IIa HDACs are involved in the activation of Ubc9 SUMO E2-ligase 
(Gregoire et al., 2006). Through this mechanism, class IIa HDACs can promote SUMOylation 
of different proteins like as MEF2s (Gregoire et al., 2006), promyelocytic leukemia protein 
(PML) (Gao et al., 2008) and two nuclear receptors: LXRα/NR1H3 and LXRβ/NR1H2 (Lee 
et al., 2009). 
 
 
3.3 Biological functions 
 
3.3.1 Binding partners 
 
Class IIa HDACs have emerged as a transcriptional co-repressors (Wang et al., 1999), even 
if an ineffective deacetylase domain characterizes them. To exert their function on DNA, class 
IIa need to reside on chromatin. Since they lack a DNA binding domain, their recruitment on 
specific regulatory DNA regions is dependent on the ability to interact with different partners. 
As in part discussed above, class IIa HDACs are able to cooperate with a wide array of 
transcription factors (Clocchiatti et al., 2013a; Martin et al., 2007) and could thus potentially 
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control a plethora of genetic programs. Among the large list of class IIa interactors, the most 
characterized are members of the MEF2 family transcription factors, which fine tune 
differentiation, cell growth and survival (Potthoff et al., 2007b). Comparative in vitro binding 
studies have testified that the affinity of interaction, between HDAC4 and MEF2C or HDAC4 
and other putative partners such as SRF and RUNX2, differs enormously. MEF2 can be 
proposed as the preferred class IIa transcriptional partner (Paroni et al., 2007). The interaction 
with MEF2 involves 18 amino acid (residues 166-188 in HDAC4) located in the amino-
terminal portion, specifically in the glutamine-rich region of HDACs, and are highly 
conserved among the four members of this sub-group (Guo et al., 2007). As aforementioned, 
HDAC7 does not possess the glutamine-rich domain, but it is still able to bind MEF2 because 
it retains the key residues necessary for interaction, that are leucines 128 and 133 (Han et al., 
2005). The binding between MEF2s and class IIa HDACs takes place both in the nucleus and 
in the cytoplasm. The interaction with cytoplasmic MEF2s stimulates the nuclear import of 
class IIa HDACs (Borghi et al., 2001). The fact that MEF2 are the favorite class IIa partners is 
highlighted also from in vivo studies. The phenotypes of each knockout mice for class IIa 
HDAC family members can be explained as the effect of MEF2 hyper-activation in bone 
(HDAC4), heart (HDAC5/9) and cardiovascular system (HDAC7), in relation to the district in 
which the single HDACs are more expressed (Chang et al., 2004; Chang et al., 2006; Vega et 
al., 2004). 
RUNX2 transcription factor is another protein capable to interact with class IIa HDACs 
(Kang et al., 2005; Martin et al., 2007). This transcription factor is involved in the regulation 
of chondrocytes hypertrophy (Vega et al., 2004; Zheng et al., 2003) and also in endochondral 
bone ossification (Yoshida et al., 2004). Among class IIa HDACs, HDAC4 and HDAC5 are 
the main repressors of RUNX2-mediated transcription. Differently from MEF2 regulation, 
class IIa HDACs in addition to negatively regulate RUNX2 transcriptional program hindering 
their DNA-binding ability (Martin et al., 2007), they also stimulates RUNX2 UPS-mediated 
degradation (Jeon et al., 2006). 
To the same family of MEF2s, belongs also another class IIa HDACs partner that is SRF 
(Chang et al., 2006). 
Members of the nuclear factor activated T cells (NFAT) family of transcription factors are 
able to interact with class IIa. In particular, NFAT3c transcriptional activity is repressed by 
HDAC4, HDAC5 and HDAC9 (Dai et al., 2005). In contrast to the interaction with MEF2, 
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the recruitment of class IIa HDACs by NFAT is indirect and relies on a bridging cofactor, the 
chaperone mammalian relative of DnaJ (MRJ) (Dai et al., 2005). 
An important co-repressor, which cooperates with class IIa HDACs is CtBP. This protein 
interacts not only with class IIa members, but also with HDAC1 and HDAC3. The binding to 
CtBP is required, at least in part, for the repression of MEF2-mediated transcription. In fact, 
mutations of the CtBP-binding domain in MITR, a C-terminal deleted HDAC9 splice variant, 
abolishes its interaction with CtBP and impairs, but does not eliminate, the ability of MITR to 
inhibit MEF2-dependent transcription (Zhang et al., 2001). 
Other important partners of class IIa HDACs are the members of the FOXO family of 
transcription factors. The regulation of FOXO TFs seems to be both negative and positive 
(Clocchiatti et al., 2013a). In T lymphocytes it has been reported that class IIa HDACs inhibit 
FOXOP3 functions (Zhou et al., 2008), while on the contrary Mihaylova described that class 
IIa HDACs when in complex with HDAC3 stimulate FOXO1/3 deacetylation and thus their 
activation (Mihaylova et al., 2011). 
The list of class IIa HDACs partners is very long and inside that there are further proteins 
such as HP-1α and SUV39H1, two structural component of heterochromatin that are essential 
for DNA packaging (Zhang et al., 2002b), JARID1B which is co-regulated with HDAC4 
during mammary gland morphogenesis (Barrett et al., 2007) and TRPS1 a regulator of 
chondrocyte proliferation and differentiation, which silencing effect was almost completely 
rescued by HDAC4 over-expression (Wuelling et al., 2013). Another interactor of HDAC4 
defined by immunoprecipitation is the activating transcription factor 4 (ATF4) (Kikuchi et al., 
2015). In this study, conducted in multiple myeloma cells, the authors showed that HDAC4 
interacts with ATF4 and inhibits activation of endoplasmic reticulum (ER) stress-associated 
pro-apoptotic transcription factor CHOP (C/EBP homologous protein). HDAC4 knockdown 
or inhibition can enhance apoptosis under ER stress condition by up-regulating both ATF4 
and CHOP. Accordingly, HDAC4 knockdown showed modest cell growth inhibition (Kikuchi 
et al., 2015). 
All these class IIa binding partners, described till now, are associated among each other by 
the fact that are nuclear localized (for review see Martin et al 2007). But, as aforementioned, 
class IIa HDACs can also lie in the cytoplasm where they are also able to interact with other 
partners carrying out additional functions. Hypoxia-inducible factor (HIF) is one of them. In 
particular HIF-1α is a transcription factor that are highly degraded under normal oxygen 
condition while is activated during hypoxia. In the latter case, class IIa HDACs bind HIF-1α 
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in the cytoplasm deacetylating and thus stabilizing the transcription factor (Kato et al., 2004). 
Similarly to HIF-1α, also STAT1 was reported being deacetylated by HDAC4 in the 
cytoplasm (Stronach et al., 2011a). It seems that HDAC4 could mediate resistance to 
chemotherapy mainly through the modulation of the JAK-STAT pathway (Kaewpiboon et al., 
2015). Instead, in the cytoplasm of muscle cells HDAC4 acts on MEKK2, a member of the 
MAPK family. HDAC4-mediated deacetylation provokes MEKK2 activation that culminates 
in muscle remodeling during denervation (Choi et al., 2012). 
To assess their repressive functions class IIa HDACs needs to be associated with class I 
HDACs and to reside in the nucleus. As aforementioned this interaction involves the 
deacetylase domain of class IIa proteins. It has been demonstrated that class IIa HDACs 
enzymatic activity is mainly due because of the recruitment of class I enzyme in a 
multiprotein complex together with SMRT and NCoR (Fischle et al., 2002). Recently has 
been shown, by in vitro studies using recombinant proteins, that the amino acid involved in 
the coordination of ZBD (i.e. 667, 675 and 751) are essential for the interaction with SMRT-
NCoR complex (Hudson et al., 2015). In the cytoplasm the interaction with HDAC3 is weak 
and thus it seems that class IIa HDACs don’t have a cytoplasmic activity (Fischle et al., 
2001). Not only the C-terminal region is important for class IIa HDACs repressive function. 
The first evidence come from MITR, a N-terminal splice variant of HDAC9, able to repress 
MEF2-dependet transcription (Zhang et al., 2001). Furthermore, the amino-terminal fragment 
of HDAC4, generated after caspase cleavage (aa1-289) is a stronger repressor of RUNX2 and 
SRF than the full-length protein (Paroni et al., 2007). Another recent example described the 
major repressive function of the N-terminal fragment, in particular on some apoptotic genes 
showing a pro-survival role of HDAC4 (Guo et al., 2015), Guo and colleagues reported that in 
mice affected by retinisis pigmentosa, a blindness caused by rod cells death, the 
overexpression of the N-terminal fragment (1-251) is able to reduce rod cells death. They 
reported that HDAC4 1-251 is able to suppress apoptosis because of a major stability of the 
protein fragment. 
There are many class IIa HDACs binding partners. It implies that the presence of the 
peculiar extended N-terminal domain is important because it mainly mediates interaction with 
other proteins. Similarly also the deacetylase domain is important for the modulation of the 
dynamic protein-protein interactions network. This complexity could justify both the long list 
of interactors as well as the various genetics programs regulated by class IIa HDACs. 
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3.3.2 Regulation of skeletogenesis 
Most of the bones in vertebrate skeleton are formed from cartilaginous template in which 
chondrocytes undergo hypertrophy, followed by apoptosis. Thereafter, osteoblast, blood 
vessel and other cell types invade and produce the bone matrix in the space lefts by 
chondrocytes. HDAC4 plays a central role during skeleton formation and in vivo it is 
expressed in pre-hypertrophic chondrocytes (Vega et al., 2004). It has been reported that mice 
deficient in HDAC4 die within two weeks from birth displaying a deregulated osteogenesis, 
resulting from premature and ectopic bone calcification. This defect results from excessive 
hypertrophic chondrocyte differentiation and inadequate endochondral ossification (Vega et 
al., 2004). Initially the HDAC4 null phenotype was explained by an altered regulation of 
RUNX2 (Vega 2004 EDG), but some years later this pathway has been redefined, thanks to 
other observations discovering the essential role of MEF2 activation in this developmental 
process (Arnold et al., 2007). The excessive endochondral ossification exhibited by Hdac4 
null mice can be partially rescued after deletion of one Mef2c allele (Arnold et al., 2007). 
However, HDAC4-mediated regulation of RUNX2 intervenes in this differentiating program. 
VEGF is a target gene of RUNX2, and it is implied in the vascularization step. HDAC4, 
through the inhibition of RUNX2, is able to inhibit VEGF thus blocking the endochondral 
bone ossification (Zelzer et al., 2001). Therefore, HDAC4 participates in the TGF-β mediated 
inhibition of osteoblast differentiation (Kang et al., 2005). The complete deletion of TRPS1, a 
multi zing finger nuclear regulator of chondrocytes proliferation and differentiation able to 
bind HDAC4, causes defect in cell cycle progression that could almost rescued by HDAC4 
over-expression (Wuelling et al., 2013). 
 
3.3.3 Regulation of cardiomyogenesis and of the vascular system 
A variety of intrinsic and extrinsic stimuli, such as stress, exercise or cardiovascular 
disorders, provoke an adaptation response of cardiac cells, becoming enlarged because of 
hypertrophic growth (Backs and Olson, 2006). MEF2 integrates many stress signals in the 
adult myocardium and regulates the expression of numerous fetal cardiac genes (McKinsey et 
al., 2002). All class IIa members are detectable in mouse heart suggesting a functional role for 
the MEF2 class IIa HDACs axis in cardiac hypertrophy (Zhang et al., 2002a). Indeed, 
expression of constitutively repressive mutants of HDAC4, 5 and 9 prevents hypertrophic 
gene expression in primary rat cardiomyocytes (Backs and Olson, 2006; Vega et al., 2004; 
Zhang et al., 2002a). In contrast, disruption of HDAC9 leads to hyperactivation of MEF2-
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dependent transcriptional activity in response to pathologic cardiac hypertrophic signals 
(Zhang et al., 2002a). Curiously, mice lacking Hdac4 or Hdac9 are vital, but exhibit 
exacerbated cardiac hypertrophy triggered by hormonal stress-related signals (Chang et al., 
2004) showing spontaneous onset of cardiac hypertrophy with advancing age (Zhang et al., 
2002a). Furthermore, the contemporary loss of Hdac5 and Hdac9 causes perinatal death due 
to heart developmental abnormalities (Chang et al., 2004). Interestingly, cardiac hypertrophy 
is characterized by altered levels of intracellular calcium, condition that activates Ca2+-
dependent kinases such as the CaMK family and the PKD. These kinases, as aforementioned, 
are all involved in controlling class IIa HDACs intracellular shuttling (Backs et al., 2006; 
Vega et al., 2004). In cardiomyocites, CaMKII activation induces nuclear export of HDAC4, 
with consequent de-repression of MEF2 and NFAT, thus promoting a hypertrophic growth 
(Backs et al., 2006). In miR-22 null mice, cardiac miR22 was found to be essential for 
hypertrophic growth in response to stress, through directly targeting of Sirt1 and HDAC4 
(Huang et al., 2013). 
Class IIa HDACs, play also a key role during the differentiation of vascular structures 
(Chang et al., 2006). Mice deficient in Hdac7 show embryonic lethality at day 11, resulting 
from a failure to form tight junctions in the developing circulatory system, which affect its 
integrity leading to dilatation and hemorrhages (Chang et al., 2006). This phenotype could be 
explained by the over activation of MEF2 that causes the up-regulation of the matrix 
metalloprotease 10 (MMP10) (Chang et al., 2006). Moreover, the silencing of HDAC7 in 
HUVEC cells dramatically affects the generation of capillary structure in vitro, thus 
confirming the essential role of this HDAC in the regulation of angiogenesis (Mottet et al., 
2007). 
It has also been demonstrated that HDAC7 could be regulated by vascular endothelial 
grow factor (VEGF) (Wang et al., 2008). In this case, the regulation is mediated by PKD, that 
through the phosphorylation of 14-3-3 docking sites induces the nuclear export of HDAC7 
and thus the activation of VEGF-mediated gene expression. These target genes can be 
dependent, as well as independent, from MEF2 transcription factors. Overall they influence 
the proliferation and migration capability of endothelial cells (Wang et al., 2008). 
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3.3.4 Muscle differentiation 
Class IIa HDACs and MEF2 transcription factors act as main regulators in skeletal muscle 
development (McKinsey et al., 2000). In particular HDACs function as the fine tuning 
regulator of the differentiation program. MEF2s alone do not posses intrinsic myogenic 
activity. They need to cooperate with other transcription factors, like as the basic helix-loop-
helix (eg. MyoD), which instead own this ability (Olson et al., 1990). In fact MEF2 proteins 
act to amplify and potentiate the myogenic differentiation program (Potthoff and Olson, 
2007). This dependence from other myogenic factors does not mean that MEF2s are not 
necessary during muscle differentiation. In fact muscle specific knock-out mice of Mef2c is 
lethal because of rapidly deterioration of myofibers after birth (Potthoff et al., 2007a). Also 
HDACs are important in this differentiation program. Class IIa HDACs localize into the 
nucleus repressing the MEF2-dependent transcriptional program in undifferentiated cells. 
When cells, following the exposure to differentiative stimuli stop to proliferate, class IIa 
HDACs are translocated into the cytoplasm and thus MEF2s target genes are activated and 
myoblast undergo to myotubes differentiation (Lu et al., 2000). The calcium-dependent 
kinases CaMK II and IV act during muscle differentiation to trigger HDAC4 and HDAC5 
phosphorylation and their cytoplasmic accumulation (McKinsey et al., 2000). This effect 
elicits the dissociation of MEF2-HDAC repressive complex provoking the de-repression of 
MEF2 target genes. 
Class IIa HDACs intervene also in the regulation of skeletal muscle remodeling. In fact it 
is reported that after denervation HDAC4, which is present at the neuro-muscolar junction., is 
up-regulated and translocated into the nucleus, where it promotes muscular atrophy by 
repressing DUSH2, a negative regulator of myogenin (Cohen et al., 2007). Consequently, also 
myogenin target genes, like the E3-ligase Atrogin-1 and MURF1, are activated (Moresi et al., 
2010). All these mechanisms activate the atrophy-program and, in parallel, also miR-206 
expression, which targets the 3’UTR of HDAC4 and HDAC5. This response is part of a 
negative feed-back loop that try to re-induce muscle innervations (Moresi et al., 2010). 
Moreover, also HDAC9 participates in atrophy progression, but on the contrary of HDAC4, it 
is down-modulated. Importantly the Hdac9 knock-out mice are exaggeratedly sensitive to the 
denervation responses in skeletal muscle (Mejat et al., 2005). In this case, it is important to 
consider that Hdac9 expression, as part of a negative feed-back loop, is also regulated by 
MEF2 (Haberland et al., 2007), which acts on producing more myogenin and hence inducing 
atrophy. 
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In atrophy condition, class IIa deacetylases were described to be involved also in 
metabolism regulation, through their influence on the fiber type shift (Tang et al., 2009). In 
denervated muscles, Tang and colleagues reported that HDAC4 acts as strong repressor of 
glycolysis, probably through MEF2 repression, and as strong activator of oxidative gene 
program, favoring the switch from fast-glycolytic type II to the slow-oxidative ones (type I) 
(Tang et al., 2009). 
 
3.3.5 The immune system 
Class IIa HDACs affect also the development and the function of the immune system 
(Parra, 2015). They take part in the process of negative selection in the thymus, to eliminate 
the self-reacting T-cells (Dequiedt et al., 2003). Among the various class IIa HDACs, HDAC7 
is the most expressed in developing thymocytes at the CD4+ CD8+ double-positive stage 
(Dequiedt et al., 2003). Under basal condition, HDAC7 localizes in the nucleus, where it 
exerts transcriptional repressive functions (Dequiedt et al., 2003; Kasler and Verdin, 2007). In 
this context, HDAC7 was found to repress the transcription of the orphan nuclear receptor 
Nurr77, leading to the inhibition of apoptosis that cause the negative selection of T cells 
(Dequiedt et al., 2003). After T-cell receptor activation, PKD1 is activated and it 
phosphorylates HDAC7, which is exported into the cytoplasm, thus resulting in the activation 
of Nur77. This gene is a MEF2 target involved in the induction of apoptosis of T cells (Parra 
et al., 2005). HDAC7 was subsequently reported to be involved not only in repression of 
Nur77, but also in the transcriptional regulation of a large number of genes involved in both 
positive and negative selection of thymocytes (Kasler and Verdin, 2007). More recently 
Kasler and colleagues presented evidences for the role of HDAC7 in T-cell development. 
Using a conditional knock-out mouse model, they demonstrated that specific deletion of 
Hdac7 in double positive thymocytes results in a significant positive selection of single-
positive CD4+ cells (Kasler et al., 2011). HDAC7 is also crucial for the proper function of 
cytotoxic T cells (Navarro et al., 2011). HDAC7 is not the only class IIa HDAC involved in 
the regulation of T cells. HDAC9 plays a central role in the control of T regulatory cells 
(Treg). Hdac9 KO mice present higher number of T-reg and increased immune suppressive 
functions. This effect is due to the unrestricted activity of Foxp3, an important transcription 
factor for development and function of these regulatory cells (Tao et al., 2007). Also in B 
cells the engagement of the B cell receptor promotes the activation of PKD, which drives 
class IIa HDACs out of the nucleus (Matthews et al., 2006). Recently, it has been reported 
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that HDAC7 is highly expressed in pre-B lymphocytes but is not present in myelod cells such 
as macrophages (Tao et al., 2007). In this lineage HDAC7 interacts with MEF2C and is 
recruited to the promoter of macrophage genes in B-cell precursor (Tao et al., 2007). 
Knocking-down HDAC7 in B lymphocytes leads to the de-repression of myeloid genes, 
indicating that HDAC7 may be an essential lineage specific-transcriptional repressor (Tao et 
al., 2007). 
 
3.3.6 Neurons 
An increasing body of evidences indicate a crucial role for class IIa HDACs in 
physiological and pathological neuronal functions (Parra et al., 2015). HDAC4 is expressed at 
high level in neurons, where it’s mainly located in the cytoplasm (Majdzadeh et al., 2008). 
Mice deficient of Hdac4, in addition of having severe skeletal abnormalities they also exhibit 
brains that are 40% smaller than the control (Majdzadeh et al., 2008). Recently an important 
role of HDAC4 in neuronal synaptic plasticity and memory formation was proposed (Kim et 
al., 2012; Sando et al., 2012). Kim and co-workers showed that a specific deletion of Hdac4 
in mice forebrain resulted in the impairment of memory, behavioral learning and long-term 
synaptic plasticity defects (Kim et al., 2012). Sando et al., found that, when present in the 
nucleus, HDAC4 governs the gene transcriptional program characteristic of the central 
synapses, affecting information processing in the brain (Sando et al., 2012). Interestingly, 
alteration of HDAC4 physiological activities through the expression a truncated catalytic 
domain form of the protein, specifically in the forebrain of transgenic mice resulted in defects 
in spatial learning and memory (Sando et al., 2012). The potential neurotoxicity of HDAC4 
was confirmed by its functional abnormalities coupled to different neurodegenerative disease 
(for review see Falkenberg et al., 2015). A very interesting report was on ataxia telangiectasia 
(ATM) disorder (Li et al., 2012), in which it was demonstrated the double face of HDAC4 
medal. It means that Li and colleagues described two opposite functions of HDAC4 in 
neurons. In particular nuclear-resident HDAC4 exhibits neurotoxic effect with induction of 
the apoptotic response (i.e. activation of caspase-3). The other face of the medal was the 
protective function of the HDAC4 cytoplasmic fraction, that hinder the activation of caspase-
3 and improved the motor behavior of ATM mice (Li et al., 2012). The protective function 
was also acquired by blocking the nuclear accumulation of HDAC4 though the inhibition of 
PP2A a well known phosphatase able to induce HDAC4 nuclear import (Li et al., 2012). 
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Also HDAC5 participates in neuronal development programs. Two studies of the same 
group showed that HDAC5 is involved in axonal regeneration (Cho et al., 2015; Cho et al., 
2013). It has been reported that axon injury induces the nuclear export of HDAC5 in a 
calcium- and PKC-dependent manner (Cho et al., 2013). The cytoplasmic accumulation is 
necessary for axon regeneration as testified by the expression of a nuclear resident phosphor-
mutant HDAC5, which interferes with axon regeneration (Cho et al., 2013). The CNS-
dependent regulation of HDAC9 was observed too (Sugo et al., 2010). In fact, Hdac9 is 
expressed in the mouse cerebellar cortex during post natal cortical development (Sugo et al., 
2010). After spontaneous neuronal activity, HDAC9 is exported to the cytoplasm leading 
activation of c-Fos gene and thus promoting dendritic growth (Sugo et al., 2010). 
 
3.3.7 Metabolism 
Several kinases like as LKB1, AMPK or the SIK family, which hold in check class II 
HDACs are also well known metabolic regulators (Mihaylova et al., 2011; van der Linden et 
al., 2007). Hence, it is not surprising that class IIa HDACs govern central aspect of 
metabolism. Mihaylova and colleagues reported that HDAC4, HDAC5 and HDAC7, are 
expressed in the liver (Mihaylova et al., 2011). During fasting, the release of glucagon in the 
liver activates the gluconeogenesis, at least in part through the inhibition of the AMP-kinase 
(Mihaylova et al., 2011). The inhibition of AMPK causes a massive accumulation of class IIa 
HDACs in hepatocytes’ nucleus. Here, they associate with HDAC3 that deacetylates and 
activates FOXO transcription factors (FOXO1 and FOXO3). FOXO proteins, then stimulate 
the transcription of two key enzymes of the gluconeogenesis, the glucose-6-phosphatase and 
the phosphoenolpyruvate carboxy kinase (Mihaylova et al., 2011). Knock-down of class IIa 
HDACs, in murine liver cells, results in inhibition of Foxo target genes, lower blood glucose 
levels and augmented glycogen storage (Mihaylova et al., 2011). In parallel, in a study 
performed in Drosophila, it was observed that during feeding conditions, HDAC4 is 
phosphorylated and localized into the cytoplasm (Wang et al., 2011). The kinase responsible 
for such re-localization is SIK3. During fasting SIK3 becomes inactivated, resulting in the 
dephosphorylation and nuclear translocation of HDAC4, thus allowing FOXO deacetylation 
(Wang et al., 2011). Recently, it has been shown that also SIK2, another member of the SIK 
family kinases, is able to modulate HDAC4 localization in the adipose tissue. Here HDAC4 is 
involved in the regulation of the GLUT4 transcription and glucose uptake (Henriksson et al., 
2015). Furthermore, HDAC4 has been characterized as an immune-metabolic sensor. In 
 Introduction | 29  
 
particular under over-nutrition, leptin reduces the expression inflammatory genes under the 
control of NF-kB through HDAC4 nuclear accumulation (Luan et al., 2014). Accordingly, 
HDAC4 variants have been associated with both body mass index and waist circumference 
(Luan et al., 2014) and its expression is down-modulated in the fat from obese subjects (Abu-
Farha et al., 2013). 
HDAC9 is another class member, which can contribute to adipogenesis and obesity 
(Chatterjee et al., 2014; Chatterjee et al., 2011). HDAC9-deficient pre-adipocytes show 
accelerated adipogenic differentiation, indicating that HDAC9 may act as a negative regulator 
of adipogenesis (Chatterjee et al., 2011). The same laboratory demonstrated a role for 
HDAC9 in obesity (Chatterjee et al., 2014). In response to chronic caloric excess, the 
differentiation of pre-adipocytes into functional adipocytes is compromised. After 
administration of a chronic high-fat diet in mice, HDAC9 deficiency was found to result in 
improvement of adipogenic differentiation and establishment of a better metabolic state with a 
diminished weight gain, and have improved glucose tolerance, insulin sensitivity and reduced 
hepatosteatosis (Chatterjee et al., 2014). 
 
 
3.4 Class IIa HDACs and cancer 
 
A Class IIa histone deacetylases role in tumor pathology is not clear depicted. From 
literature emerges a dual role of the members of this family of HDACs. Various reports 
described them as positive regulators of cell growth and cancer progression, whereas other 
studies define class IIa as onco-suppressive factors (Barneda-Zahonero and Parra, 2012; 
Clocchiatti et al., 2011) (Figure 5). 
Initial observation pointed-out significant mutations of HDAC4 in human breast cancer 
samples (Sjoblom et al., 2006). In addition, a genome-wide approach evidenced HDAC4 
homozygous deletion in melanoma cell lines (Stark and Hayward, 2007). HDAC4 expression 
was also up-regulated within a sub-group soft tissue sarcomas, specifically in leiomyosarcoma 
(Di Giorgio et al., 2013). Class IIa HDACs were described to be associated with poor 
prognosis of estrogen receptor positive (ER+) breast tumors (Clocchiatti et al., 2013b). 
Mutation of HDAC7 has been reported in non-Hodgking lymphoma (Morin et al., 2011). 
High level of cytoplasmic HDAC7 have been observed in pancreatic cancer patient (Weichert, 
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2009). Similarly, in children with acute lymphoblastic leukemia (ALL), high level of HDAC7 
and HDAC9 expression were associated with poor prognosis (Moreno et al., 2010). The up-
regulated expression of HDAC9 was associated also with poor survival in medulloblastoma 
patients (Milde et al., 2010). HDAC9 levels were on the contrary highly repressed in 
glioblastoma (Clocchiatti et al., 2011). Conversely HDAC7 and HDAC5 were activated and 
over-expressed in glioblastoma (Clocchiatti et al., 2011). Together with HDAC9, also 
HDAC5 was found to be over-represented in high-risk medulloblastoma patients, 
demonstrating a relation between its expression and poor survival (Milde et al., 2010). 
Finally, HDAC4 was recently described as a prognostic marker in glioma tumors (Cheng et 
al., 2015). In this report low levels of HDAC4 were correlated to the low-grade of gliomas. 
Hence, HDAC4 was proposed as a new prognostics marker which can refine the prognosis of 
glioma (Cheng et al., 2015). 
A link between class IIa HDACs expression and cancer was also established by multiple 
studies on cell lines. These studies suggest that, depending on the cellular context, class IIa 
HDACs can act either as pro-proliferative factors or as a tumor suppressors (Barneda-
Zahonero and Parra, 2012; Clocchiatti et al., 2011) and again a clear picture could not be 
depicted. Class IIa HDACs pro-oncogenic activity is supported by a series of evidences 
underling their participation in cell proliferation. First of all the involvement of class IIa 
HDACs in regulation of cell growth could be easily supposed from the phenotype of the 
knock-out mice (Vega et al., 2004). In fact, HDAC4 -/- mice are characterized by premature 
and ectopic endochondral ossification (Vega et al., 2004). Because of an inner balance of 
HDAC4 regulation inside the cells, its dysfunction could be deleterious. Stimulation with 
mitogens, like EGF in osteoblasts, can modify this equilibrium, inducing an increase in 
HDAC4, thus enhancing RUNX2 repression and hence osteoblasts proliferation (Zhu et al., 
2011b). Both HDAC4 and HDAC7 oncogenic potential was recently well demonstrated in 
mouse fibroblasts (Di Giorgio et al., 2013). The transforming capability depends mainly, from 
the modulation of a limited set of genes, most of which are MEF2 target (Di Giorgio et al., 
2013). Over-expression of HDAC4 or HDAC7 nuclear resident forms induced acquisition of 
tumorigenic phenotype with high proliferation rate, cytoskeleton modification, high mobility, 
ability to growth in an anchorage-independent manner and tumor formation in mice (Di 
Giorgio et al., 2013). The involvement of HDAC4 in cancer cells growth was also 
demonstrated in p53 deficient HeLa cells (Cadot et al., 2009). In this report HDAC4 silencing 
showed a negative effect specifically on cancer cell line proliferation, whereas no influence 
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was observed in normal fibroblasts. In particular, it was shown that HDAC4 down-
modulation causes G2/M arrest because of defects in chromosomes segregation (Cadot et al., 
2009). This effect was also demonstrated in colorectal carcinoma cells where HDAC4 is 
necessary to promote efficient mitotic segregation of chromosomes. Similarly its down-
modulation induces an accumulation in the G2 phase (Wilson et al., 2008). These effects 
mostly depend on the capability of HDAC4 to repress p21/CDKN1A transcription in a p53-
independent manner (Wilson et al, 2008). Both the nuclear localization and the deacetylase 
activity are required for HDAC4-mediated repression of p21 (Wilson et al., 2008). HDAC4 
was identified as a repressor of p21 expression also in breast cancer cells, through the binding 
to FOXP3 transcription factor (Liu et al., 2009). HDAC4 p21-mediated oncogenic behavior 
was highlighted in gastric cancer (Kang et al., 2014). In particular HDAC4 was able to repress 
p21 and its silencing decrease proliferation of cancer cells line and arrest cells in G1 phase, 
because of induction of p21. HDAC4 silencing induces also autophagy and apoptosis. 
Deregulation of HDAC4 expression was also observed in HCC where its levels are 
increased because of a lack of post-transcriptional controls mediated by the miR-1, miR-22 
and miR200a (Datta et al., 2008a; Yuan et al., 2011b; Zhang et al., 2010). In all these cases 
HDAC4 down-regulation reduced HCC cells proliferation. Interestingly, HDAC4 negatively 
regulates the transcription of miR200a, by repressing Sp1 TF. As a consequence of HDAC4 
destabilization, miR200a can influence the acetylation of p21/CDKN1A promoter and its 
transcription (Yuan et al., 2011a). The down-regulation of miR-1 and the coupled increase in 
HDAC4 levels were also observed in lung cancer (Nasser et al., 2008). 
HDAC4 appears to be linked with the resistance to chemotherapy. In breast cancer 
HDAC4 determines the resistance to 5-fluorouracil, a common drug utilized for anti-tumor 
therapy, through the deacetylation of the SMAD4 promoter and the repression of its 
transcription (Yu et al., 2013). In ovarian tumor cells resistant to cisplatin, HDAC4 is over-
expressed together with STAT1 and depletion of both proteins is sufficient to re-sensitize 
cancer cells. Mechanistically, HDAC4-STAT1 interaction takes place only in the cytoplasm 
of resistant cells. Under this condition HDAC4 deacetylases STAT1, thus promoting its 
phosphorylation and nuclear import. Furthermore STAT1 deacetylation seems to be 
independent from HDAC3 (Stronach et al., 2011b). As aforementioned, HDAC4 in the 
cytoplasm interacts also with HIF-1α inducing its transcriptional activation, through the 
prevention of its degradation, and thus promoting the expression of VEGF and angiogenesis 
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in cancer (Qian et al., 2006). Binding of HDAC4 to HIF-1 generates a complex that regulated 
glycolysis and cytotoxic stress of cell adaptation to hypoxic conditions (Geng et al., 2011). 
In contrast to these pro-oncogenic activities, HDAC4 shows an opposite behavior in 
lymphomas, being its down-modulation linked to leukemogenesis. In this tumor miR-155 is 
up-regulated and one of its direct target is HDAC4. In agreement, over-expression of HDAC4 
in diffuse large B-cell lymphoma results in a reduction of cell proliferation, lower clonogenic 
potential and induction of apoptosis (Sandhu et al., 2012). 
Among the class IIa members, HDAC5 was similarly reported to have a contradictory role 
in cancer. In U2OS osteosarcoma cells, SY5Y neuroblastoma cells and MCF7 breast 
carcinoma cells it inhibits cell proliferation when ectopically expressed (Huang et al., 2002). 
These tumor-suppressive roles were largely dependent on the activation of the tumor necrosis 
factor (TNF) pathway, followed by the induction of apoptosis (Huang et al., 2002). Secretion 
of TNFα and of other pro-inflammatory cytokines was influenced by HDAC5 in macrophage 
after inflammatory stimulus (Poralla et al., 2015). 
On the contrary, HDAC5 was recently identified as a promoter of osteosarcoma 
progression, through the up-regulation of TWIST1 expression, with a still unknown 
mechanism (Chen et al., 2014). The oncogenic role was described also in HCC (Feng et al., 
2014). In this situation low levels of HDAC5 inhibit cells cancer proliferation by the 
induction of cell cycle arrest and apoptosis (Fan et al., 2014). Peixoto and colleagues reported 
another mechanism by which HDAC5 participates in cancer cell growth. They showed that 
HDAC5 is necessary for replication fork advancement. In particular they demonstrated that 
the silencing of HDAC5 induced a slowing down of the cell cycle progression, because of the 
replication fork stalling. This condition induced DNA double-strand breaks and the activation 
of apoptosis (Peixoto et al., 2012). In neuroblastoma cells HDAC5 can block differentiation 
and can induce proliferation (Sun et al., 2014). In particular HDAC5 is induced by N-MYC, 
and in a feedback loop HDAC5 stabilizes N-MYC protein. Both proteins, when assembled in 
a complex are able to repress a set of tumor suppressor genes (Sun et al., 2014). Previously, in 
2007 the same group reported that TLX, an orphan nuclear receptor, recruits HDAC5 and 
HDAC3 on its target promoter genes, including the tumor suppressor p21 and PTEN, turning 
off their transcription (Sun et al., 2007). 
As aforementioned for HDAC5, HDAC9 is positively associated with high-risk 
medulloblastoma (Milde et al., 2010). Its silencing in medulloblastoma cell lines decreases 
cell growth and induces apoptosis with caspase activation (Milde et al., 2010). By contrast, 
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qRT-PCR studies in brain tumors have reveled a down-regulation of HDAC9 in glioblastoma 
compared to low-grade astrocytoma and normal brain (Clocchiatti et al., 2011). Altered 
expression of HDAC9 together with HDAC7 was observed also in bone marrows of children 
with acute lymphoblastic leukemia, associated with bad tumor prognosis (Moreno et al., 
2010). Nowadays, the role of HDAC9 in tumor progression and how it impact on cell growth 
and survival is not clear, further investigations are necessary for a more clear picture. 
Using a high-throughput approach, HDAC7 was identified as a potential oncogene for 
hematopoietic cells (Rad et al., 2010). Its contribution to cancer cells proliferation was 
proposed to be partially due to the regulation on c-Myc (Zhu et al., 2011a). Silencing of 
HDAC7 resulted in a significant G1/S cell cycle arrest in different cancer cell lines. This cell 
cycle block occurred through the suppression of c-Myc expression and the augmentation of 
p21 and p27 protein levels. Interestingly, it was noted that HDAC7 silencing induces cellular 
senescence, revised by c-Myc re-expression (Zhu et al., 2011a). 
Differently from HDAC4, HDAC7 is able to interact with HIF1-α but is not involved in its 
activation. It seems to be necessary for the HIF-1α mediated repression of cyclin D1 
expression (Wen et al., 2010). It has been suggested that this mechanism nourishes 
chemoresistance. Another important strategy that has been proposed being important for the 
effect on tumorigenesis of class IIa HDACs involves the β-catenin pathway. In particular, 
Margariti and co-workers figured out that either over-expression or down-regulation of 
HDAC7 prevent G1/S phase transition and decrease the proliferation rate of HUVEC cells 
(Margariti et al., 2010). This intrinsic contradiction was explained by the fact that HDAC7 
over-expression suppresses endothelial cells proliferation through the retention of β-catenin in 
the cytoplasm and the down-regulation of cyclin D1. On the opposite HDAC7 deficiency 
enhances nuclear translocation of β-catenin, increasing Rb levels, which results in 
hypertrophic cells (Margariti et al., 2010). An explanation for this paradox arises from a study 
on smooth muscle cells (Zhou et al., 2011). Here it has been demonstrated that HDAC7 exists 
in 2 isoforms: spliced and unspliced. Usually, HDAC7 lies in the cytoplasm as unspliced 
isoform, where binds and hold in check β-catenin, thus preventing its nuclear translocation. 
After growth stimuli HDAC7 is spliced, the new isoform releases β-catenin, thus permitting 
its translocation in the nucleus, where it is able to activate a set of genes that induce cells 
proliferation (Zhou et al., 2011). This pathway was confirmed in chondrocytes. Here the 
down-regulation of HDAC7 increases proliferation because of β-catenin activation with the 
consequent induction of cyclin D3 and repression of p21/CDKN1A (Bradley et al., 2015).  
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Clearly class IIa seem to influence cell growth in lineage-dependent manner. For example 
in breast cancer cells the triple silencing of HDAC4, HDAC5 and HDAC9 determines a 
decrease in the proliferation of MCF7-ER+ cells but not of MDA-MB-231 ER- cells 
(Clocchiatti et al., 2013b). The anti-proliferative effect of the triple silencing was the 
consequence of an apoptotic response elicited by Nur77 up-regulation (Clocchiatti et al., 
2013b). Recently, it has been reported that HDAC7, influences the proliferation of breast 
epithelial cells (Clocchiatti et al., 2015). HDCA7 seems to have a pro-oncogenic effect, 
sustaining the proliferation of acini in a 3D culture model. In this model HDAC7 levels are 
under the regulation of HER2 signaling. This effect is mediated by the down-regulation of 
MEF2-mediated transcription (Clocchiatti et al., 2015). On the opposite, in particular type of 
ALL, the pre-B-ALL, and in B-cell lymphoma HDAC7 is down-modulated and exhibits an 
onco-suppressive role (Barneda-Zahonero et al., 2015). In this case the effect of HDAC7 
over-expression was the activation of the apoptotic response and the down-regulation of an 
important oncogene such as c-Myc. Both the HDAC7 amino-terminus, containing the MEF2 
binding site, as well as the catalytic domain are important to exert this pro-apoptotic function. 
The importance of c-Myc down-modulation was described by the rescue of cells viability 
after the re-introduction of c-Myc in cells overexpressing HDAC7 (Barneda-Zahonero et al., 
2015). 
 
Figure 5 Class IIa HDACs influences on cell fates in relation to cancer. Schematic representation of the 
different influences exerted by Class IIa on cancer-related cellular functions. Class IIa HDACs can participate in 
different cancer-related processes. According to the context they could behave as tumor promoter or tumor 
repressive players. (from Clocchiatti et al, 2011) 
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Overall these studies indicate that, depending from the cellular context, class IIa HDACs 
can display different influences on the transformation process. It is possible that the number 
of genes and the signaling pathways governed by class IIa HDACs can vary depending from 
the cell lineages. Epigenetic stages, the gene expression landscape and mutational status could 
in principle swift toward pro-oncogenic or tumor suppressive outcomes. Certainly, further 
investigations are important to better clarify the roles of each class IIa HDACs member. 
 
 
3.5 Transformation of human cell lines 
 
Definition of the genetic alterations driving the conversion of normal cells into malignant 
cells is a process commonly defined as “transformation”. It is an important in vitro approach 
to clarify the basic mechanisms of cancer development. The vast majority of these 
experiments were assessed with mouse cell lines and only a limited set of studies were 
performed with human cells. It is empirically known that human cells are more resistant to 
oncogenic transformation (Akagi et al., 2003). More than 30 years ago, through extensive 
studies in rodent models, it was established that primary rodent cells can be transformed by 
two oncogenic “hits”, such as the combination of ectopic expression of c-myc and the 
activated H-RAS or either the activated H-RAS and the adenovirus protein E1A or also the 
activated H-RAS and simian virus 40 (SV40) (Land et al., 1983; Ruley, 1983); whereas the 
normal human cells cannot be fully transformed by such oncogenes combination or even by 
additional ones (Akagi et al., 2003; Rangarajan et al., 2004). These observations suggest that 
mouse and human cells possess distinct requirements to fully alter the proliferative features 
and, from an evolutionary point of view, human cells have acquired strong mechanisms 
counteracting the malignant transformation process. It has been speculated that the different 
susceptibility to transformation between human and mouse cells may be due to differences in 
DNA repair capacity, response to oxidative stress, maintenance of genome stability or 
epigenetic controls of gene expression (Akagi et al., 2003). 
Empirically, keeping in culture primary mouse and human fibroblasts some differences can 
be appreciated. Primary mouse cells after few passages tend to acquire a particular phenotype 
characterized by enlarged and flattened morphology with simultaneous block of the cell cycle, 
typical of the onset of senescence, a defensive mechanism against uncontrolled proliferation. 
But after 8 passages, some clones of spontaneously immortalized fibroblast began to emerge. 
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On the contrary, primary human fibroblasts have a longer lifespan because the senescent-like 
morphology appears only after 50 cell divisions. Once entered in this growth-arrested status, 
human fibroblasts remain in most of the cases forever because it is an irreversible mechanism 
(Rangarajan et al., 2004). 
Senescence can also be induced by oncogenes both in primary rodent and human cells. In 
particular the first and among the foremost studied oncogene able to induce senescence in 
primary mouse and human fibroblast was H-RAS (Serrano et al., 1997). The phenotype 
observed after RAS activation is peculiar, since, initially it is characterized by a boost of 
growth, then cells acquire the senescent-like phenotype with a specific morphology and 
markers. The positivity of associated acidic-β-galactosidase enzyme activity assay, the 
positivity for DNA-damage foci (i.e. γ-H2AX) and the presence of peculiar senescence-
associated heterochromatin foci (SAHF) are features of OIS (oncogene induced senescence) 
(Di Micco et al., 2006). More recently also Akt was discovered to induce senescence in 
fibroblast, but the phenotype is completely different, because is not characterized by the initial 
growth phase, it showed absence of DNA damage hallmarks and SAHF foci, instead the 
morphology is always flattened and spread and cells have the cell cycle blocked (Astle et al., 
2012; Kennedy et al., 2011). 
A debated characteristic distinguishing mouse from human cells behavior about the 
transformation process is the regulation of the telomerase catalytic subunit (TERT) that 
control telomeres length. Commonly, TERT expression in tightly suppressed in the somatic 
cells of humans (Kim et al., 1994), whereas it is constitutively expressed in mouse somatic 
cells (Prowse and Greider, 1995). The constitutive expression of TERT and hence the long 
telomere have been assumed to be the biological basis for the relatively frequent spontaneous 
immortalization observed in mouse cells, which is supposed to be a prerequisite for malignant 
transformation (Hahn et al., 2002). In fact, the ectopic expression of the human TERT 
(hTERT) in various human cell lineages was capable of immortalization, avoiding the 
replicative senescence (Bodnar et al., 1998). However, in the same year Seger and colleagues 
reported that hTERT is dispensable for human transformation, because combing the ectopic 
expression of adenovirus E1A, activated RAS and MDM2 without the additional expression 
of TERT was sufficient to elicit a transformed phenotype (Seger et al., 2002). They also add, 
that proceeding with cell cultivation the induction of hTERT arise spontaneously, thus they 
conclude that in humans TERT is important for maintenance of tumor and not for its own 
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onset (Seger et al., 2002). So, it seems that TERT in human malignancies has a role, but the 
mechanisms by which it acts still remains to be clarified. 
In summary it is widely accepted that human and mouse cells need a set of genetic changes 
to get transformation, which are substantially very different (Hahn et al., 1999). In fact as 
explained above, the two hints model valid for rodent primary cells is not sufficient to 
transform human fibroblasts. The minimal model used to study human transformation require 
at least three hits: hTERT, SV40 expression (including LT and ST) and H-RAS activation 
(Akagi et al., 2003; Hahn et al., 1999). Another model used, is the aforementioned 
overexpression of E1A, RAS oncogenic mutation plus the p53 loss (or MDM2 
overexpression) (Seger et al., 2002). In both cases there are oncoviral proteins, SV40 and 
E1A, which are not physiologically present inside the cells, touching various cellular 
pathways. Hence, these models are not perfect to study the transformation process and human 
cancer. 
RAS mutations are frequently observed in different human cancers and its activation is a 
fundamental prerequisite for the transformation process. In fact also some of its downstream 
partners (Raf, Ral and PI3K) are sufficient to transform human cells in various combination 
with SV40 and hTERT (Rangarajan et al., 2004). To gain oncogenic transformation, it is not 
only important to engage proliferative signaling pathways, but it is also relevant to overcome 
mechanisms, which protect cells from uncontrolled replication. These safeguard mechanisms 
are represented by the above mentioned OIS, all the death stimuli such as apoptosis and 
necrosis, the cell-cycle checkpoints and the immune system surveillance (de Visser et al., 
2006; Kastan and Bartek, 2004; Kerr et al., 1994). All these mechanisms are controlled by a 
group of genes with suppressive functions against tumor onset and growth.  
Cellular senescence depends critically on two powerful tumor suppressor pathways: the 
p53 and pRb/p16INK4a pathways (Campisi and d'Adda di Fagagna, 2007; Serrano et al., 
1997). In particular, RAS-arrested cells are characterized by augmented levels of p53 and 
p16INK4a proteins (Serrano et al., 1997). p16INK4a is able to directly associate with CDK4 
and CDK6 and to inhibit their activities (Serrano et al., 1993). The primary function of the 
CDKs is to phosphorylate the retinoblastoma tumor suppressor protein (Rb) allowing the 
progression of the cell cycle towards the S phase (Weinberg, 1995). The over-expression of 
p16INK4a inhibits the cyclin-dependent kinases and leads to G1 cell cycle arrest. Primary 
murine fibroblasts lacking either p53 or p16INK4a are transformed by the oncogenic ras 
alone, on the contrary in human fibroblasts the inactivation of p53 or p16INK4a alone with 
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concomitant RAS activation is not sufficient to bypass OIS (Serrano et al., 1997). 
Accordingly, as discussed above, human fibroblast exhibit a stronger resistance to the 
uncontrolled proliferation and in fact to get the fully transformed phenotype is necessary to 
inactivate both p53 and pRb/p16INK4a pathways (permitted by the overexpression of SV40 
LT), together with the ectopic expression of hTERT and mutated RAS (Serrano et al., 1997). 
In many instance p53 and Rb are activated to promote senescence by products of the 
INK4a/ARF locus (Lowe and Sherr, 2003). This locus encodes two tumor suppressor: the 
already cited p16INK4a and p14ARF (p19ARF in mice), expressed from partially 
overlapping nucleotides sequences read in alternative reading frame. p16INK4a inactivate the 
Rb pathway by inhibiting CDKs, as described above. On the contrary, p14ARF increases the 
growth suppressive function of p53 by interfering with its negative regulator Mdm2. Both 
p16INK4a and p14ARF accumulates in senescent cells, in fact mutations that affect the 
INK4a/ARF locus are frequently found in cancer and immortalized cells (Lundberg et al., 
2000).The most studied onco-suppressive gene, called also the guardian of the genome, is 
p53. In the absence of cellular stress, the p53 protein is maintained at low steady-state levels 
and exerts very little effect on cell fate. However, in response to various types of stress, p53 
becomes activated. p53 activation is reflected in elevated protein levels, as well as augmented 
biochemical capabilities. As a consequence of p53 activation, cells can undergo marked 
phenotypic changes, ranging from increased DNA repair to senescence and apoptosis (Oren, 
2003). p53 was found to be mutated in numerous cancer types, this implies that in the 
transformation process it plays a fundamental part (Muller and Vousden, 2013). 
Although p53 has a key role in human cancer, combining the activation of RAS, with the 
down-regulation of p53 in human foreskin fibroblast (BJ) is able to bypass OIS but is 
insufficient to fully transform cells (Boehm et al., 2005). Adding to this setting (RAS 
activation + p53 loss) the over-expresson of c-Myc, which as mentioned above in mouse 
induce transformation already in combination with RAS mutation, is still again not sufficient 
to transforms human fibroblast, also with the hTERT expression (Boehm et al., 2005). To 
observe at least the anchorage-independent growth capability of human immortalized 
fibroblast it is necessary to add at the p53 loss and activation of RAS background one of the 
protein encoded by the SV40 genome, that is small T antigene (ST) which modulates PP2A 
phosphatase activity (Ahuja et al., 2005). On the contrary to obtain the complete 
transformation and to permit also the formation of tumors in xenograft mice, it has been 
demonstrated that is necessary also the ectopic expression of another protein of the SV40 
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virus, in that case is the large T antingen (LT) (Rangarajan et al., 2004). The LT protein, 
regulates completely different cellular pathways (Ahuja et al., 2005). In particular LT inhibit 
two very important pathways: the p53 and the pRB through different protein domains (Ahuja 
et al., 2005). This suggests that the further hint necessary to induce malignant transformation 
in human cells is the loss of the pRB cellular control. Ragarajan and coworkers suggest that in 
BJ cells expressing hTERT, the minimal combination to form tumor in nude mice is: ectopic 
expression of activated RAS, over-expression of ST protein (it means a deregulation of PP2A 
activity) and the loss of both p53 and pRB pathways (Rangarajan et al., 2004). This result is 
in conflict with Sager and colleagues in with they say that p53 (over-expression of MDM2) 
and pRB loss are sufficient to transform human cells in RAS activated background, even 
though without the hTERT over-expression (Seger et al., 2002). Importantly, differences in 
transformation can be observed among human fibroblasts isolated from different sources 
(Boehm et al., 2005). Both reports where assessed using functional deletion mutants of the 
viral E1A and SV40 proteins. These oncoproteins operate by interfering with different growth 
suppressive cellular pathways and the effect is indirect. 
From all these reports emerge clearly how human cells are much resistant, compared to 
murine cells, to transformation and how many pathways need be de-regulated in order to get 
the fully malignant phenotype. 
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Materials and methods 
 
 
Plasmid construction and retroviral infection 
pWZL-Hygro constructs expressing HDAC4 and its mutants were previously described 
(Cernotta et al., 2011), Bcl-xL was subcloned into pBabe-Puro restricted by using EcoRI 
restriction site (NEB). Retroviral vectors were transfected in the amphotropic packaging cell 
line HEK293T with the calcium phosphate method (15μg of each construct were transfected). 
After 48h post-transfection, viral supernatants were collected, filtered, supplemented with 8 
μg/ml polybrene, and combined with fresh medium in order to infect BJ cells. Following 24h 
of infection with virons, cells were selected with hygromycin (150μg/mL) for 5 days. 
pCW (Tet-One System “All-in-one” purchuased from Addgene) plasmids expressing 
HDAC4 doxycycline-inducible transgenes were generate by PCR from the pWZL-Hygro 
constructs and subsequently cloned using NehI/BamHI-BglII restriction sites (NEB). 
 
Cell cultures and reagents 
BJ/Tert cells were cultured in Earl’s Salt Minimal Essential Medium (EMEM) (Hyclone) 
completed with non-essential amino-acids (NEAA, Hyclone). All other cell lines were grown 
in Dulbecco modified Eagle medium (DMEM; Lonza). All medium were supplemented with 
10% fetal bovine serum (FBS), L-glutamine (2mM), penicillin (100U/ml), and streptomycin 
(100µg/ml) (Lonza). For analyses of cell growth 2x104 cells were seeded and the medium was 
changed every 2 days. 
In all trypan blue exclusion assays, at least 300 cells from three independent samples were 
counted for each data point. Data were represented as arithmetic mean±SD for at least three 
independent experiments. 
 
Immunofluorescence 
Cells were fixed with 3% paraformaldehyde and nuclei were stained with To-Pro®3 stain 
(Thermo-Fisher). The cells were imaged with a Leica confocal scanner SP equipped with a 
488 λ Ar laser and a 543 to 633 λ HeNe laser. 
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Western Blotting 
Proteins obtained after an SDS denaturating lysis and sonication were transferred to a 0.2-
μm pore- sized nitrocellulose membrane and incubated with the specific primary antibodies. 
After several washes, blots were incubated with peroxidase-conjugated goat anti-rabbit or 
goat anti-mouse (Sigma) for 1h at room temperature. Finally, blots were developed with 
Super Signal West Dura, as recommended by the vendor (Pierce). For primary antibody 
stripping, blots were incubated for 30 min at 60°C in stripping solution (62.5mM Tris-HCl pH 
6.8, 2% SDS) containing 100 mM β-mercaptoethanol. 
 
Reagents and Antibodies 
The following chemicals were used (the final concentrations are indicated), 2c (2μM) 
(Cersosimo et al., 2015); Bortezomib (250nM), Leptomycin and Camptothecin (10μM) (all 
from LC laboratories); Doxycycline, 2,3- Dimethoxy-1,4-naphthoquinone (DMNQ) (10μM), 
dimethyl sulfoxide (DMSO) (all from Sigma-Aldrich), SMAC mimetic (Lecis et al., 2012) 
(100nM), TRAIL (100ng/mL). Primary antibodies: GFP (Paroni et al., 2004), Actin (Sigma-
Aldrich), RAS and E1A(M73) (Abcam), RACK1 (Santa Cruz Biotechnology) 
 
RNA extraction and quantitative qRT-PCR 
Cells were lysed using Tri-Reagent (Molecular Research Center). A total of 1 µg of total 
RNA was retro-transcribed by using 100U of Moloney murine leukemia virus reverse 
transcriptase (Invitrogen). Quantitative reverse transcription-PCR (qRT-PCR) analyses were 
performed using Bio-Rad CFX96 and SYBR Green technology. The data were analyzed by 
use of a comparative threshold cycle using GAPDH and HPRT (hypoxanthine 
phosphoribosyltransferase) as normalizer genes. All reactions were done in triplicate. 
 
Soft agar assays. 
Equal volumes of 1.2% agar and DMEM were mixed to generate 0.6% base agar. A total 
of 40.000 NIH-3T3 cells expressing the different transgenes were seeded in 0.3% top agar, 
followed by incubation at 37°C in humidified conditions. The cells were grown for 15 days, 
and the culture medium was changed twice per week. Foci were visualized by using MTT 
staining. 
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Statistics 
For experimental data, a Student t test was used. A P value of 0.05 was chosen as the 
statistical limit of significance. Unless otherwise indicated, all of the data in the figures are 
arithmetic means + the standard deviations from at least three independent experiments. 
*=p<0.05; **=p<0.01; ***p=<0.005 
 Results| 43  
 
 
Results 
 
 
1. HDAC4 prevents isolation of clones following retroviral infection of 
immortalized human fibroblasts 
 
The role of HDAC4 in tumor development is still not clear. Hence to further prove the 
involvement of these epigenetic regulators in the process of tumorigenesis, we investigated 
the capability of HDAC4 to elicit in vitro transformation of human fibroblasts. We decided to 
use the sequential insertional approach, in order to identify the essential oncogenic 
combination requested to acquire a fully transformed phenotype in vitro. Human foreskin 
fibroblasts (BJ) were selected as a model of study. Since, primary human fibroblasts are 
characterized by a long-lifespan, after a certain number of passages in culture they undergo to 
senescence (Rangarajan et al., 2004). To overcome this physiological replicative block, BJ 
cells have been engineered to constitutively express the catalytic subunit of the human 
telomerase (hTERT), which contributes to bypass the senescent status and permits the 
establishment of an immortalized cell population. 
Initially BJ/TERT cells stably expressing HDAC4 were generated. Cells were engineered 
to express different forms of HDAC4. In particular, in addition to the wild-type allele, 3 
mutant proteins were ectopically expressed: i) a super-repressive mutant, herein referred as 
TM, in which the three serine residues, which upon phosphorylation are required for the 
binding to 14-3-3 proteins are mutated into alanine (S246A, S467A, S632A) (Grozinger and 
Schreiber, 2000); ii) a nuclear mutant with highest repressive capability, where in addition to 
the three serines mutated into alanines (TM), it brings a point mutation in the NES sequence 
(herein referred quadruple mutant/QM). This additional mutation consists in a substitution of 
the lysine 1062 in an alanine (L1062A), which favours the nuclear retention (McKinsey et al., 
2001) and finally iii) an HDAC4 mutated in the 14-3-3 docking site but carries also a small 
deletion in the MEF2-binding site, between the aa 166 and 184 (Di Giorgio et al., 2013). This 
mutation generates a nuclear resident HDAC4, unable to complex MEF2 transcription factor 
and was named HDAC4-TMΔMEF2 mutant. GFP and E1A were used as negative and 
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positive control respectively. All the over-expressed proteins, with the exception of E1A, 
were GFP-tagged, in order to easily discriminate them from the endogenous ones. 
To get a stable expression of the ectopic HDAC4 proteins we decided to transduce 
BJ/hTERT cells with retroviral vectors. After virus particles formation, virions were used to 
infect cells for 24h. The transduced cells were selected with hygromycin for 5 days and the 
positive clones in each plate were counted at the end of the selection. As showed in figure 7A 
the forced expression of TM, TMΔMEF2 and QM mutants have a strong negative effect on 
the number of clones/plate emerged after 5 day of selection (Figure 7A). The latter mutants 
led to a reduction of over 50% of the number of clones counted respect to WT form, which is 
characterized by a slight reduction when compared to GFP-infected cells. Moreover, keeping 
the isolated clones in fresh cultivation medium for additional 5 days, it was observed further 
dramatic drop in the number of resistant clones when the mutated forms of HDAC4 (TM, 
TMΔMEF2 and QM) were transduced (Figure 7A–10 Days). 
This result suggests that in human fibroblasts expressing hTERT, introduction of different 
forms of HDAC4 incompetent for 14-3-3 binding could affect cell survival. Also the number 
of clones expressing the WT allele was further reduced after 10 days of culture, thus 
indicating a less pronounced but still present spontaneous cell death (Figure 7A-10 Days). 
These results suggest a possible implication of HDAC4 in the activation of a cell death 
program. 
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Figure 7. Negative influence of HDAC4 on cell survival and proliferation in BJ/hTERT cells. A/B) Percentage of 
clones, obtained after retroviral infection of BJ/hTERT (A) and BJ/hTERT/BCL-xL (B) cells, counted after 5 
day of hygromycin selection, and after 5 additional days of culture in normal medium. C) Confocal pictures of 
BJ/TERT/BCL-xL cells expressing the different HDAC4-GFP proteins. Nuclei were stained with TO-PRO-3 
iodide staining. D) Immunoblot assay were performed to visualize the levels of expression of the different 
transgenes. The antibody used was anti-GFP in order to detect the GFP-tagged HDAC4 E) Quantification of 
exogenous HDAC4-GFP subcellular localization in BJ/TERT/BCL-xL cells. For each experiment, at least 300 
cells were counted (n=3). F) The mRNA levels of selected HDAC4 target genes were measured using qRT-PCR 
in BJ/TERT/BCL-xL fibroblasts. The mRNA levels were relative to the GFP-expressing cells. 
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The involvement of HDAC4 in apoptotic cell death was previously demonstrated in 2004 
(Paroni et al., 2004). It was reported that the amino-terminal nuclear fragment generated after 
caspase cleavage is able to repress MEF2-transcrptional program and to trigger the apoptotic 
cell death. 
To prove that the ectopic expression of nuclear HDAC4 alleles is able to render BJ/hTERT 
more susceptible to apoptotic cell death, we generated BJ/hTERT cells stably expressing 
BCL-xL, a member of the Bcl-2 family of proteins, which acts as a pro-survival protein by 
preventing the release of mitochondrial factors that trigger the intrinsic apoptotic response. To 
assess this hypothesis the retroviral infections with HDAC4-WT and its derivative mutants 
TM, TMΔMEF2 and QM was performed in cells overexpressing BCL-xL. The over-
expression of BCL-xL allowed the isolation of a significant higher number of clones, both at 
5 and 10 days from selection for each transgene, inducing a partial rescue of cell survival as 
evidenced by the percentage of clones/plate relative to the GFP scored (Figure 7B compare 
with Figure 7A). Accordingly, after isolation, almost all the resistant clones are able to growth 
in normal medium and were propagated (Figure 7B-10 Days). 
The expression and localization of the relative transgenes in BJ/TERT/BCL-xL was 
verified by immunofluorescence (Figure 7C) and immunoblotting (Figure 7D). The 
immunoblot assay highlighted that the TM and the QM mutants were expressed at lower 
levels. Furthermore bands with low molecular weight, possibly corresponding to proteolytic 
cleavage products were evident, particularly in the case of the QM mutant (Figure 7D). The 
intracellular localization of each HDAC4-GFP protein was also quantified (Figure 7E). It is 
interestingly to note that with the exclusion of WT all the others HDAC4 alleles should be 
characterized by a nuclear accumulation, but inexpertly they also showed a cytoplasmic 
localization, stronger in the case of TM and of TMΔMEF2 mutants. This effect could be 
explained by the fact that some 14-3-3 independent mechanisms of HDAC4 regulation exist 
in this cell line. Furthermore it is also possible that in the case of QM the binding with 14-3-3 
protein causes a steric cumbersome that block the interaction with the importin-α of HDAC4, 
hindering the nuclear import of the protein (Grozinger and Schreiber, 2000). In literature it is 
also reported that the interaction with cytoplasmic MEF2 TFs contributes to nuclear localize 
HDAC4 (Borghi et al., 2001) thus explain also in part the TMΔMEF2 cytoplasmic fraction. 
Furthermore it should also take into account the observed proteolytic processing (Figure 7D) 
of the HDAC4 that could generate fragments incompetent for nuclear localization. 
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Finally, through qRT-PCR, were assessed the repressive ability of HDAC4 mutants 
(Figure 7F). The selected target genes were also well known MEF2 target (Di Giorgio et al., 
2013). The nuclear resilient forms of HDAC4 represented by TM and QM mutants were able 
to repress strongly the selected target genes (i.e. RHOB and KLF4) respect to the WT form. 
Accordingly, the mutant lacking the MEF2 binding site did not influence the mRNA levels of 
the same targets (Figure 7F). 
On the other hand, none of the HDAC4 mutants showed an effect on cell cycle profile 
(data not shown) as recently observed in other cell lineages (Clocchiatti et al., 2015; Di 
Giorgio et al., 2015; Wilson et al., 2008), which is mirrored by the absence of p21/CDKN1A 
mRNA down-regulation (Figure 7F). 
 
 
2. HDAC4 biological effect on BJ/Tert is not linked neither to aggresome 
formation nor to viral infection or LTR repression 
 
Class IIa HDACs structure is characterized by the presence, in the N-terminal domain, of 
the glutamine-rich region (Figure 3). As discussed in the introduction, this domain is basically 
involved in protein-protein interaction and in the formation of dimers. It has been 
demonstrated that over-expression of HDAC4 induced the formation of aggresome and 
subsequent ubiquitin-mediated degradation (Cernotta et al., 2011). In order to exclude the 
possibility that aggregates formation and accumulation elicits an unfolded protein response 
(UPR) which in turns activates apoptosis thus hindering clones isolation in BJ/hTERT 
fibroblasts, we decided to stably express HDAC7. This class IIa HDAC is the sole that do not 
possess the glutamine-rich region and hence it is not susceptible to aggresome formation. 
BJ/hTERT cells were infected with the wild-type form of HDAC7 and also with the nuclear 
super-repressive mutant named HDAC7 S/A, that carried the substitution of the 4 serine 
residues, necessary for the 14-3-3 binding, into alanine, mimicking the HDAC4-TM mutant. 
Also HDAC7 constructs were GFP-tagged. GFP alone was considered as negative control. 
Cells were selected with hygromycin for 5 days and clones were counted on each plate 
(Figure 8A). Ectopic expression of HDAC7-WT did not influence clones number formation, 
while on the contrary HDAC7 mutated in the 14-3-3 binding sites induced a significant 
reduction of the number of clones during the selection process, similarly to HDAC4-TM 
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expression. After additional 5 days in culture, cells expressing HDAC7-S/A undergo to 
spontaneous cell death. This experiment indicates that the anti-proliferative effects of 14-3-3 
mutant versions of class IIa HDACs is independent from the glutamine-rich region and 
aggresome formation (Figure 8A-10 Days). 
A connection between HDAC4 and virus seems to exist (Lomonte et al., 2004; Palmisano 
et al., 2012; Shirakawa et al., 2013). HDAC4 acts as a repressor against viral gene, because 
HDAC4 could elicit some epigenetic modifications inducing the formation of 
heterochromatin through the interaction with viral protein. Hence, we wondered whether 
HDAC4 could influence viral particles formation and/or transduction or could repress viral 
promoters regulating the genes encoded by the retroviral constructs, thus hindering its own 
expression. To assess this hypothesis we performed an infection with HDAC4 constructs on 
HEK-293 cells. Cells were infected with all the HDAC4 proteins (WT, TM, TMΔMEF2 and 
QM) tagged with GFP and virus particles were kept in contact with cells for 24h, then 
immediately collected and analyzed through FACS analysis in order to score the GFP positive 
cells. Figure 8B showed the percentage of GFP positive cells. Although the rate of infection is 
not high, the results suggest that all the different HDAC4 constructs were able to infect 
BJ/hTERT cells with the same percentage/efficiency, even if the HDAC4 mutant lacking the 
MEF2 binding site showed a slight, but statistically significant, capability to infect cells 
(Figure 8B). 
On the other hand considering the ability of HDAC4 to repress viral genes (Shirakawa et 
al., 2013) we hypothesized that HDAC4 could exert its repressive ability on the LTR viral 
promoter governing the hygromicyn resistance gene thus hindering its expression and hence 
the isolation of positive clones. To verify this point, we transiently transfect HEK-293 cells 
with different plasmids. Three different conditions were performed. The empty pWZL 
retroviral vector, used in the previous infection, carrying the resistance gene under the control 
of an LTR viral promoter was transfected in all the conditions. The pEGFPc1vector 
expressing the GFP protein was also used in the three conditions as control of transfection. 
Finally, HDAC4-TM tagged with FLAG peptite (pFLAG-HDAC4-TM) was co-trasnfected 
with the others transgenes. pFLAG-HDAC4/WT was co-transfected in parallel in order to 
compare the repressive ability of the HDAC4 when subjected to nuclear/cytoplasmic 
shuttling. pFLAG empty plasmid was used as a negative control condition. 24h hours after 
transfection cells were collected and the relative mRNA levels of HDAC4 and hygromycin 
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gene were quantified by qRT-PCR. The results showed that relative to the GFP control, 
HDAC4 is higher express both for WT and TM mutants (Figure 8C). The levels of the 
hygromycin mRNA in the case of WT are not be subjected to substantial variation while the 
HDAC4 TM nuclear proteins unexpectedly activated hygromycin transcription (Figure 8D) 
excluding any repressive effect of HDAC4 on LTR viral promoter regulating the expression 
of hygromycin gene resistance. 
 
 
Figure 8. Characterization of the anti-proliferative effect of HDAC4 mutants in 14-3-3 binding sites. A) 
Percentage of clones, obtained after retroviral infection of BJ/hTERT cells with HDAC7-WT and S/A mutant, 
counted after 5 days of hygromycin selection, and after 5 additional days of culture in normal medium. B) 
HEK293 GFP positive cells scored with FACS analysis after retroviral infection with the indicated constructs. 
C/D) mRNA levels of HDAC4-WT and TM (C) and of hygromycin (D) were measured with qRT-PCR in HEK-
293 cells. 
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Together these data suggest that the adverse effect of HDAC4 on clones isolation is not 
linked neither to aggresome formation and UPR response, nor to the viral particles 
transduction or to the repression of LTR promoter regulating the hygromycin gene. A high-
throughput approach based on shRNA library or CRISPR technology could be more helpfully 
in order to identify genes and the possible pathways involved in this phenomenon. 
 
 
3. DNA-damage induction and proteins synthesis inhibition trigger 
apoptosis in BJ/hTERT expressing nuclear HDAC4. 
 
To further investigate the hypothesis that HDAC4 mutated for 14-3-3 binding render 
human immortalized fibroblasts more susceptible to apoptosis, we adopted a different 
experimental approach. We generated a doxycycline-inducible system to exogenously express 
WT, TM, TMΔMEF2 and QM forms of HDAC4 in BJ/hTERT cell line and to get a 
conditional expression among the various HDAC4 mutants thus avoiding the negative effect 
of the constitutive expression during clones isolation. In this case the empty vector was used 
as a negative control and the oncoviral gene E1A was used as the positive one. 
After retroviral infection all the different constructs did not affect cell survival (data not 
shown). Next, the protein levels of the different transgenes were assessed by immunoblot 
analysis after 6h of doxycycline induction (Figure 9A).  With the exception of HDAC4/-
TM, which showed a reduced level of expression, the WT and the other mutant proteins were 
expressed at comparable levels. To assess the repressive activity of each HDAC4 form, a 
qRT-PCR analysis was carried out (Figure 9B). Three genes KLF2, RHOB and 
p21/CDKN1A, previously recognized as targets of MEF2-HDAC axis were selected. The 
qRT-PCR analysis confirmed that the super-repressive mutants (TM and QM) show a 
stronger repressive effect respect to the WT. Curiously in BJ/hTERT cells up-regulation of 
HDAC4 was insufficient to repress KLF2 expression (Figure 9B). As expected the HDAC4-
TMΔMEF2 was unable of suppressing these genes. CDKN1A mRNA levels were not 
regulated by induction of the different HDAC4 proteins, by contrast E1A suppressed its 
expression (Figure 9B). 
Additionally, an immunofluorescence assay was performed in order to assess both the 
expression levels and the intracellular localization of the different isoforms. Representative 
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pictures are shown in figure 10A. As evidenced from the quantitative analysis(Figure 10B) 
the localization of the HDAC4-TM mutant is not completely localized into the nucleus, but is 
more nuclear respect to the same isoform constitutively expressed in BJ/hTERT/BCL-xL 
(compare Figure 7C) Since the HDAC4-QM is completely accumulated into the nucleus this 
suggests that a secondary mechanism, in addition to the classical 14-3-3 binding, can affect 
the intracellular trafficking of HDAC4. Furthermore to evaluate the nuclear/cytoplasmic 
trafficking we treated cells with leptomycin B, an inhibitor of CRM-1-dependent nuclear 
export. The block of the nuclear export induced a rapid nuclear accumulation of all WT and of 
TM mutants (Figure 10B), thus indicating that HDAC4 proteins are subjected to 
nuclear/cytoplasmic shuttling and that CRM-dependent export operates also in the case of 
HDAC4 mutants defective in the 14-3-3 binding. 
The ectopic expression of HDAC4-TM in mouse-immortalized fibroblast induces the 
acquisition of a transformed phenotype, including a greater proliferative potential (Di Giorgio 
et al., 2013). To assess whether the HDAC4 mutants influence the BJ/hTERT proliferation, 
we analyzed the growth profile of each HDAC4 protein. As emerge from the figure 9C, the 
expression of the HDAC4 mutants for 10 days did not significant influence cell proliferation. 
By contrast the E1A oncogene confers a significant proliferative growth advantage as 
expected. 
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Figure 9. Doxycycline-inducible HDAC4 characterization. A) BJ/hTERT cells stably integrating the 
doxycycline-inducible vectors encoding the relative transgene, were treated with doxycycline (600ng) and 
protein levels were assessed by immunoblot after 24h of induction. B) mRNA levels of the selected MEF2-
HDAC target genes were measured following 24h with doxycycline treatment. C) Cell growth assay in 
BJ/hTERT with continuous doxycycline induction. D) BJ/hTERT cells engineered with the doxycycline-
inducible system were pre-treated with doxycycline for 24h and then with the indicated molecules. The 
appearance of cell death was scored with trypan blue staining after 48 hours. 
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Figure 10. Subcellular localization of inducible HDAC4. A) Confocal pictures of BJ/hTERT cells 24h after 
doxycycline induction (left panels) or with additional leptomycin B treatment (5 ng/ml) for 3h. 
Immunofluorescence analysis was performed to visualize HDAC4 subcellular localization. B) Quantification of 
the subcellular localization of the different HDAC4 isoforms. Nuclei were stained with TO-PRO-3 iodide 
staining. For each experiment at least 300 cells were counted (n=3). 
 
 
Unexpectedly, induction of HDAC4 mutated in 14-3-3 binding sites was insufficient to 
trigger cell death (data not shown). Hence to clarify whether the different HDAC4 isoforms 
are able to influence the susceptibility to apoptosis, cells were treated with different stimuli in 
order to engage different death pathways (Figure 9D). Expression of the different HDAC4 
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proteins was induced with doxycicline 24h before the treatment with the specific death 
stimuli. 
2c is a synthetic isopeptidases inhibitor that triggers apoptosis in several cell lines 
(Cersosimo et al., 2015). Unexpectedly, 2c did not induce a stronger apoptotic response 
(Figure 9F/2c). This effect could be justified by the fact that these cells are not fully 
tumorigenic.. By contrast, in the presence of DMNQ, a molecule that stimulate a necrotic cell 
death, the induction of HDAC4 isoforms mutated in the 14-3-3 binding sites generates a 
slightly protective effect on cells (Figure 9F/DMNQ). 
HDAC4 was reported to be involved in DNA damage response (Basile et al., 2006). For 
this reason we decided to treat cells with camptothecin, a molecule able to induce DNA 
damage. After treatment with camptothecin cells showed a different response to trypan blue 
assay, in particular TM and QM mutants were characterized by a higher percentage of cell 
death relative to WT protein and controls. This increased death response possibly depends on 
MEF2 repression since the mutant lacking the MEF2 binding site behaves like the negative 
control (Figure 9F/Camptothecin). As expected the E1A oncogene strongly increased cell 
death in response to DNA damage. Similar results were obtained when cells were treated with 
hygromycin, an inhibitor of the protein synthesis, the same compound used for the selection 
of cells after retroviral transduction. Also in this case the TM and QM mutants showed an 
increase in the percentage of positive trypan blue cells, and the TMΔMEF2 allele did not 
shown any increase (Figure 9F/Hygromycin). 
To gain further insight into the apoptotic response elicited by HDAC4 exogenous 
expression, we decided to treat cells with a stimulus engaging the extrinsic apoptotic pathway 
(Figure 11). A combination of SMAC mimetic and TRAIL, the ligand of death receptors, or 
either agent alone were used. In this case, the single treatment with SMAC or TRAIL alone, 
following the doxycycline induction of HDAC4-WT and TM mutant, did not produce any 
effect on cell death. The full engagement of the extrinsic pathway by the combination of the 
two stimuli elicited apoptosis but this response was not influenced by the different HDAC4 
isoforms (Figure 11). 
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Figure 11. BJ/hTERT cells apoptosis in response to an extrinsic apoptotic stimulus. BJ/hTERT cells, after 24h 
pre-treatment with doxycycline, were incubated with SMAC mimetic and recombinant TRAIL for additional 
24h. Appearance of cell death was scored by trypan blue staining. At least 300 cells were counted for each 
replicate (n=3). 
 
 
4. The intrinsic instability of the HDAC4 14-3-3 mutants could explain 
their limited impact on cell survival and proliferation 
 
This study points to a profound difference in terms of cell proliferation when the HDAC4 
mutated in the 14-3-3 sites were expressed constitutively or transiently upon induction with 
doxocycline. To clarify this incongruence we decided to verify the protein levels of the 
different HDAC4 isoforms during a prolonged period of induction, we monitored the protein 
levels of each HDAC4 isoform by immunoblot (Figure 12A). We decide to check the level of 
expression at the same time point of the growth curve. It was evident how the expression 
levels in a longer period were different among the different proteins. In particular it is 
interestingly that both the stronger MEF2-repressive mutants (TM and QM) were much less 
expressed, subjected to proteolitic cleavage and their levels decline through the time although 
the cells were cultured in the presence of doxycycline (Figure 12A). 
The ubquibitin-mediated degradation of nuclear HDAC4 was previously demonstrated by 
Cernotta and colleague (Cernotta et al., 2011). To confirm this hypothesis cells were treated 
with bortezomib, an inhibitor of the proteasome at different time points (Figure 12B). Already 
after 4 hours of bortezomib treatment, the levels of the HDAC4-TM mutant were overtly 
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augmented. This stabilization was less evident in the case of the HDAC4-WT form (Figure 
12B). This result indicates that a nuclear HDAC4 mutated in the 14-3-3 binding sites is prone 
to be targeted for proteasomal degradation. This rapid turn-over could in part justify the 
absence of an effect on cell proliferation and survival when the expression of the different 
HDAC4 isoforms was performed with an inducible system. 
 
 
Figure 12. HDAC4 is subjected to proteasomal degradation. A) BJ/hTERT cells were inducted with 
doxycycline for 8 days and the expression levels were detected at the indicated time points. B) Cells were pre-
treated with doxycycline for 24h and then bortezomib was added to culture medium. Protein levels were assessed 
by immunoblot at the indicated time points. 
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5. HDAC4 mutated in the NES sequence rescues clones formation in 
BJ/hTERT cells and allow the anchorage-independent growth of NIH-
3T3 
 
HDAC4 functions are modulated by various mechanisms as discussed in the introduction 
with the foremost characterized being the nuclear/cytoplasmic shuttling mediated by 14-3-3 
proteins. The binding with 14-3-3 can occur both in cytoplasm as well in the nucleus 
preventing HDAC nuclear import in the first case and facilitating the export in the other one 
(Nishino et al., 2008). 14-3-3 binding on HDAC4 could also influence HDAC4 functions 
because of steric hindrance which could prevent the recruitment of other co-factors and/or the 
recruitment of HDAC4 on other protein complexes. To investigate whether this aspect could 
play a role in the HDAC4 pro-death effect, well evident in the case of the constitutive 
expression as scored by number of clones isolated or following the co-treatment with certain 
apoptotic insults (in the case of the inducible expression), we generated a GFP-tagged 
construct which encode for HDAC4 with an alanine instead of a lysine residue in position 
1062 (HDAC4-L/A). This mutation lies in the NES sequence inducing HDAC4 to be 
localized inside the nuclear compartment, without interfering with 14-3-3 binding. 
After retroviral infection, we generated BJ/hTERT cells stably expressing this transgene. 
Cells were selected with hygromycin for 5 day in order to isolate only the positive clones 
expressing the ectopic construct. Following the selection the number of clone/plates generated 
were counted. HDAC4-TM was used as positive control and the GFP alone was considered as 
the negative one. Figure 13A shows how the expression of the nuclear resident HDAC4-L/A 
does not affect the number of clones isolated after retroviral infection (5 days). The number of 
clones/plates was also counted after further 5 days of culture in normal medium (10 days). All 
clones generated were able to grow and they did not shown overt markers of cell death 
(Figure 13A). Subsequently, protein levels were assessed by immunoblot analysis and as 
evidenced in figure 13B all the constructs evidence a comparable expression levels. 
Considering the repressive function of HDAC4, we also assessed the ability of HDAC4-L/A 
mutant to repress at transcriptional levels the selected MEF2-target genes (Figure 13C). 
Compared to HDAC4-WT the L/A mutant shows a stronger repressive potential, with the 
exception for CDKN1A, as already described for TM and QM proteins. 
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As aforementioned, HDAC4-TM isoform was previously characterized for the ability to 
confer a transformed phenotype in mouse NIH-3T3 fibroblasts both in vitro and in vivo (Di 
Giorgio et al., 2013). Moreover, taking into account that human fibroblast are more resistance 
to oncogenic transformation (Akagi et al., 2003), we decided to generate NIH-3T3 mouse 
fibroblast stably expressing HDAC4-L/A mutant in order to clarify its ability to induce the 
oncogenic transformation in murine cells. Following the generation of stable cell lines 
integrating the TM and L/A alleles, protein expression levels were evaluated with immunoblot 
(Figure 13D). Here, GFP and RAS expressing cells were considered as negative and positive 
controls respectively. At transcriptional level the repressive ability was evaluated through a 
quantitative RT-PCR (Figure 13E). Relative to the TM allele, the L/A mutant shows a 
stronger repressive ability versus RhoB and NR4A1 target genes and less pronounced against 
KLF4. Here again, CDKN1A mRNA levels were not modulated by the NES mutated protein 
(Figure 13E). One of the hallmark conferred by HDAC4-TM to murine fibroblasts is the 
ability to growth in an anchorage-independent manner. We performed a soft agar experiment 
to assess this feature in the case of HDAC4-L/A mutant. As shown in figure 13F, HDAC4-
L/A expressing cells developed a significant number of colonies in soft agar, similarly to H-
RAS/G12V and HDAC4-TM expressing cells. All these data suggest that, the HDAC4 
mutated only in the exporting sequence is able to influence somehow the previously described 
negative effect on human fibroblast clones isolation in vitro. In addition, HDAC4-L/A 
permitted the acquisition of an important oncogenic feature, which is the ability of 
immortalized mouse fibroblasts to growth in an anchorage–independent manner. Further 
investigations are necessary to better characterize the mechanism below this phenotype. 
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Figure 13. HDAC4-L/A characterization in human and mouse fibroblasts. A) Percentage of clones, obtained 
after retroviral infection of BJ/hTERT cells, counted after 5 day of hygromycin selection (gray bar), and after 5 
additional days of culture in normal medium (black bar). B/D) Immunoblot assay were performed to visualize 
the levels of expression of the different transgenes in BJ/hTERT (B) and in NIH-3T3 (D) fibroblasts. The 
antibody used was anti-GFP in order to detect the GFP-tagged HDAC4. C/E) The mRNA expression levels of 
five HDAC4 target genes were measured using qRT-PCR in BJ/hTERT (C) and mouse NIH-3T3 (E) fibroblasts. 
The mRNA levels were relative to the GFP-expressing cells. F) Quantitative results of colony formation in soft 
agar of NIH-3T3 cells expressing the indicated transgenes. **, P < 0.01; ***, P < 0.001 
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Discussion 
 
 
Despite several years of studies, the role of class IIa HDACs during the neoplastic 
transformation is still not completely understood. Reports on class IIa HDACs are copious 
and sometimes controversial. In summary a dual role emerges from the literature. Various 
studies described these deacetylases as positive regulators of cell growth and cancer 
progression, whereas other studies propose to class IIa onco-suppressive activities (Barneda-
Zahonero and Parra, 2012; Clocchiatti et al., 2011). The large body of these studies was 
conducted on immortalized human cancer cell lines (Barneda-Zahonero et al., 2015; Huang et 
al., 2002), and the involvement of class IIa was associated with their ability to influence cell 
proliferation. Despite these evidences, a direct in vitro demonstration that class IIa are 
involved in the acquisition of cancer hallmarks was performed only in 2013 by Di Giorgio 
and colleagues (Di Giorgio et al., 2013). In this paper the authors demonstrated in NIH-3T3 
mouse immortalized fibroblasts, that the over-expression of a nuclear resilient HDAC4, 
mutated in 14-3-3 sites elicits the induction of a tumorigenic phenotype characterized by 
elongated morphology, loss of contact inhibition, anchorage-independent growth and 
tumorigenicity in xenograft assay. 
With the attempt to implement the state of the art about the relationship between class IIa 
and cancer, we decided to investigate whether in vitro tumorigenic potential of HDAC4 could 
be translated also in human immortalized foreskin fibroblasts. We decided to take advantage 
from a sequential insertional approach in order to identify the essential oncogenic 
combination requested to gain a fully transformed phenotype, in cooperation with HDAC4. 
Starting with the ectopic expression of the 14-3-3 mutant of HDAC4 in BJ/hTERT, the 
first evidence described was a negative effect on cell survival scored as clones isolation after 
retroviral infection. Subsequently, it was postulated an activation of a cell death program, 
because of the drastic drop in the number of isolated clones during the first 10 days of 
propagation. The different mutants studied are characterized by mutations of three serine 
residues, involved in 14-3-3 binding, into alanine. We selected this kind of mutations in order 
to have a hyper-active form of the protein derived from its forced localization into the nucleus 
(i.e. TM and QM). We also utilized the TMΔMEF2 construct which is unable to bind MEF2 
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and thus helps to discriminate between MEF2-dependent and independent effects. The 
negative effect on cell survival was observed with all three mutants, thus suggesting that this 
effect is linked to the absence of 14-3-3 binding and is not MEF2-dependent. 
An involvement of HDAC4 in the apoptotic response was previously described. In 
particular, it was demonstrated that HDAC4 is a substrate of caspase-2 and -3 (Paroni et al., 
2004). Cleavage of HDAC4 occurs at Asp 289 and disjoins the carboxy-terminal fragment, 
localized into the cytoplasm, from the amino-terminal fragment, which accumulates into the 
nucleus. In the nucleus, the caspase-generated fragment of HDAC4 is able to trigger 
cytochrome c release from mitochondria and cell death in a caspase-9–dependent manner. 
This pro-death effect was proposed being dependent on the repressive activity towards MEF2 
target genes. We demonstrated that the co-expression of BCL-xL, a member of Bcl-2 family 
with pro-survival functions, rescues in part the negative effect on clones survival, described 
for HDAC4 mutated forms and allows also to propagate the isolated clones expressing the 
mutated deacetylases. Although the assessed percentage of infect cells was not high (Figure 
8), among the different constructs no differences were observed in terms of infected cells, but 
the levels of expressed proteins detected were lower with nuclear localized mutants respect to 
the WT allele. In addition the 14-3-3 mutated isoforms were characterized by an intense 
proteolytic fragmentation (Figure 7D). Nevertheless, nuclear localized isoforms showed a 
greater repressive ability on MEF2-target genes compared to wt, thus indicating that the lower 
amount of proteins expressed maintains its stronger repressive ability. Even though all these 
three forms are characterized by mutations in 14-3-3 binding sites, which should result in 
nuclear localization because of the inability to bind 14-3-3 proteins and are not able to be 
translocated in the cytoplasm, they showed a conspicuous cytoplasmic fraction when stably 
expressed in BJ/hTERT/BCL-xL cells. This fact could be explained by the existence of 
additional mechanism of sub-cellular regulation mediated by other aminoacid residues. For 
example serine 279 is a residue conserved among all class IIa HDACs, with the exception of 
HDAC7, which leaves in the NLS region (Greco et al., 2011). This residue is targeted by 
various kinases such as Dirk1B, PKA and CKD5 and controversial roles were described. 
Dirk1B and CDK5 reduce nuclear accumulation (Deng et al., 2005; Taniguchi et al., 2012), 
while PKA retains class IIa HDACs into the nucleus (Ha et al., 2010). This opposite influence 
could be explained by the existence of other kinases targeting additional residues. 
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Another evidence that supports the role of Ser279 in mediating the 14-3-3-independent 
shuttling arises from a manuscript demonstrating that the Mirk/Dirk1B complex is able to 
phosphorylate HDAC5 on this residue (Deng et al., 2005). In addition, the proteolytic activity 
hitting these HDAC4 mutants could result in some protein fragments not competent for 
nuclear localization. Furthermore, in the case of the TMΔMEF2 mutant the inability to bind 
MEF2 could also reduce the nuclear fraction. Also the environmental influence could play a 
role in HDACs sub-cellular distribution. The redox condition could influence so much 
HDAC4 localization in fact a disulfide bridge is formed between cysteines 667 and 669 under 
oxidizing condition, on the contrary in a reducing environment, these two residues and the 
coordinated zinc ion fold the protein, bringing the ZBD in contact with the NES. In this way 
the CRM1 binding site is masked and the nuclear export is blocked (Ago et al., 2008). 
HDAC4 is involved in various cellular functions, including the maintenance of silencing 
against exogenous genomes (Palmisano et al., 2012). We have demonstrated that HDAC4 in 
BJ/hTERT human fibroblasts is not able to engage a repressive activity against the viral 
genome and virus particles formation. 
In order to dissect in more detail the anti-proliferative effect of the 14-3-3- mutant versions 
of HDAC4, we decided to adopt a different investigation strategy, by generating a conditional 
expression model, using the doxycicline-dependent system. This strategy allowed the 
investigation of the cell cycle profile, which did not present any differences among the 
different HDAC4 mutants. This absence of phenotype could depend on the high rate of 
proteasomal degradation showed by the HDAC4 nuclear forms (Figure 12). Concerning the 
apoptotic response, only when treated with specific apoptotic insults induction of HDAC4-
TM and QM mutants rendered cells more susceptible to apoptosis. Interestingly apoptosis was 
triggered only by the induction of DNA damage and the inhibition of the protein synthesis of 
HDAC4 mutants augmenting the cell death rate. 
Further investigations are necessary to clarify why the increased responsiveness to 
apoptosis is linked only to certain stimuli and in particular is important to discover the 
partners playing with HDAC4, because our results seem to exclude MEF2 involvement. 
Surprisingly a HDAC4 mutated in the NES sequence when introduced in BJ/TERT did not 
explicated any overt anti-proliferative effect although it maintained the ability to repress 
MEF2 transcription targets (Figure 13). This result in conjunction with the pro-apoptotic 
effect of the TMΔMEF2 mutant indicates that MEF2-repression is unrelated to the anti-
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proliferative activity of the ectopically expressed 14-3-3 mutants. It is important also to 
consider that the NES mutation allows the formation of a complex between the 14-3-3 
proteins and HDAC4 and this complex could hinder the formation of another complex that 
could activate the anti-proliferative response. Vice versa it is possible that interaction with 14-
3-3 proteins is necessary to activate some survival pathway. 
Because of a higher resistance to in vitro oncogenic transformation, mainly due to the need 
of human fibroblast to have a combination of different oncogenic hits (Akagi et al., 2003), 
and also to complete the state of art about the role of HADC4 in mouse oncogenic 
transformation we decide to engineered NIH 3T3 immortalized mouse fibroblasts with 
HDAC4-L/A allele in order to define a plausible oncogenic potential of this HDAC4 mutant. 
In parallel with the characterization, which showed a comparable repressive ability of MEF2 
selected targets respect to the already characterized TM and QM isoforms, the acquisition of a 
transformed phenotype was observed. NES mutated HDAC4 allows NIH 3T3 to growth in an 
anchorage-independent manner forming a slight higher number of colonies in soft agar assay 
than TM allele (Figure 13). This phenotype should be better characterized in the future. 
The L/A mutant can represent an interesting tool to investigate the pro-oncogenic potential 
of class IIa HDACs in human cells. In this context this study can be considered a preliminary 
investigation aimed to tackle the question in the complexity of the human refractoriness to 
transformation. A very interesting evidence emerged from this thesis is that HDAC4 is not 
well tolerated by human fibroblast perhaps because of its involvement in cell cycle 
progression. Human cells, which have evolved multiple options to counteract the oncogenic 
transformation, reject the hyper-active forms of the protein both by translocating the 
deacetylases into the cytoplasm and by inducing their degradation. Another important aspect 
is that in order to get a phenotype, HDAC4 seems need to reach a threshold expression level. 
Hence, it is important to develop new expression systems which are able to produce a 
significative amount of protein and better maintained together with the inhibition of the UPS. 
Although future studies will be directed to find the minimal essential combinations of 
oncogenes needed to get a fully transformed phenotype together with the L/A mutant in 
human fibroblasts, a reverse approach consisting in the silencing of HDAC4 using the new 
CRISPR/Cas9 technology could be more useful to understand the oncogenic potential of this 
class of proteins in human cells. 
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Additional work 
 
 
During the three years of the PhD program I have been focused also in other experimental 
works. In particular I have been involved in the investigation of MEF2s TFs in the regulation 
of the cell cycle. 
We have discovered a complex regulation of MEF2s during cell cycle progression. MEF2s 
are activated at the G0/G1 transition by phosphorylation to orchestrate the expression of the 
immediate early genes in response to growth factor stimulation. We have observed that, 
MEF2 activities are subsequently down-regulated during G1 progression. MEF2s down-
regulation is mainly mediated by the interaction with the E3 ligase F-box protein SKP2, 
which induces degradation of these TFs through the ubiquitin proteasome system. The SKP2-
MEF2 interaction is mediated by a cyclin-dependent kinase 4 (CDK4)/cyclin D1 complex 
which is able to phosphorylate specific MEF2 residues inducing the binding to SKP2. MEF2 
anti-proliferative effects were manly operated via the CDK inhibitor p21/CDKN1A gene. 
This cell cycle regulator is a MEF2 target gene. In particular my work has been focused on 
the investigation of MEF2 binding on CDKN1A promoter. Initially, through a bioinformatics 
approach, different MEF2 binding sites on CDKN1A promoter were predicted. Next, to 
confirm which of the putative binding sites were effectively recognized by MEF2s, chromatin 
immunoprecipitation assays (ChIP) were performed. Two different MEF2s members were 
evaluated: MEF2C and MEF2D. These TFs were able to bind within the first intron of the 
CDKN1A gene at +2,1 kb from the TSS. Importantly, this genomic region was previously 
characterized by ENCODE project as enriched in histone H3 lysine 27 acetylation (H3K27ac) 
and histone H3 lysine 4 monomethylation (H3K4me1), two markers of open chromatin. 
Finally, I demonstrated that the presence of MEF2D was important to regulate the H3K27ac 
in the genomic region bound by the transcription factor this suggest a possible implication of 
MEF2 in maintaining the open chromatin status. 
These results will be not discussed in this thesis, since the work has been already published 
(see the enclosed published manuscript). 
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The Control Operated by the Cell Cycle Machinery on MEF2 Stability
Contributes to the Downregulation of CDKN1A and Entry into S
Phase
Eros Di Giorgio, Enrico Gagliostro, Andrea Clocchiatti, Claudio Brancolini
Department of Medical and Biological Sciences, Università degli Studi di Udine, Udine, Italy
MEF2s are pleiotropic transcription factors (TFs) which supervise multiple cellular activities. During the cell cycle, MEF2s are
activated at the G0/G1 transition to orchestrate the expression of the immediate early genes in response to growth factor stimula-
tion. Here we show that, in human and murine fibroblasts, MEF2 activities are downregulated during late G1. MEF2C and
MEF2D interact with the E3 ligase F-box protein SKP2, which mediates their subsequent degradation through the ubiquitin-
proteasome system. The cyclin-dependent kinase 4 (CDK4)/cyclin D1 complex phosphorylates MEF2D on serine residues 98 and
110, and phosphorylation of these residues is an important determinant for SKP2 binding. Unscheduled MEF2 transcription
during the cell cycle reduces cell proliferation, whereas its containment sustains DNA replication. The CDK inhibitor p21/
CDKN1A gene is a MEF2 target gene required to exert this antiproliferative influence. MEF2C and MEF2D bind a region within
the first intron of CDKN1A, presenting epigenetic markers of open chromatin. Importantly, H3K27 acetylation within this regu-
lative region depends on the presence of MEF2D. We propose that following the initial engagement in the G0/G1 transition,
MEF2C and MEF2D must be polyubiquitylated and degraded during G1 progression to diminish the transcription of the
CDKN1A gene, thus favoring entry into S phase.
In vertebrates, the family of MEF2s comprises 4 members—MEF2A, -B, -C, and -D—as well as some splicing variants (1).
Common features of all MEF2 members are the MADS box
(MCM1, agamous, deficiens, serum response factor) and the ad-
jacent MEF2 domain positioned within the highly conserved ami-
no-terminal region (1). These domains are involved in recogniz-
ing the YTA(A/T)4TARDNAmotif, inmediating the formation of
homo- and heterodimers, and in the interaction with different
cofactors (1). The carboxy-terminal half is much less conserved. It
encompasses the transactivation domains and the nuclear local-
ization signal (2). The different family members exhibit specific
but also overlapping patterns of expression, during either em-
bryogenesis or adult life (1, 3). MEF2s are subjected to intense
supervision by environmental signals, in order to couple the gene
expression signature to the organism requirements (1). MEF2s
oversee the expression of several genes, depending on and in co-
operation with other transcription factors (TFs) (3, 4). In addi-
tion, MEF2s can also operate as repressors of transcription when
in complexes with class IIa histone deacetylases (HDACs) (5, 6, 7,
8).
The extent of genes under the influence of MEF2s justifies the
pleiotropic activities and the assorted cellular responses attributed
to these TFs. During development, in general, expression ofMEF2
is linked to the activation of differentiation programs (1). In var-
ious scenarios, the onset of MEF2 expression coincides with the
withdrawal from the cell cycle (9). Specific ablation of MEF2C in
neural/progenitor cells impacts differentiation but not their sur-
vival or proliferation (10). Also, in muscle, simultaneous ablation
of different MEF2s impacts differentiation of satellite cell-derived
myoblasts but does not alter proliferation (11).
In oncogene-transformed fibroblasts, induction ofMEF2 tran-
scription can trigger antiproliferative responses, which are re-
sponsible for reverting the tumorigenic phenotype (7). In other
contexts, MEF2s seem to be involved in sustaining rather than
inhibiting cell proliferation (12).During the cell cycle,MEF2 tran-
scriptional activities are upregulated when quiescent cells are
stimulated to re-enter G1 (13). Here, they contribute to the ex-
pression of the immediate early genes in response to serum (14,
15). Paradoxically, signaling pathways elicited by growth factors,
and in particular, the phosphoinositol 3-kinase (PI3K)/Akt path-
way can also repress MEF2-dependent transcription (7). This re-
pression is exerted mainly through the ubiquitin-dependent deg-
radation of the TFs (7).
Overall, these results suggest that, during different proliferative
stages, MEF2 transcriptional activities could be subjected to mul-
tiple and complex adaptations. To better understand the contri-
bution of MEF2s to the regulation of cell growth, in this study we
investigated MEF2C and MEF2D expression, regulation, and ac-
tivities during distinct phases of the cell cycle, using murine and
human fibroblasts as cellular models.
MATERIALS AND METHODS
Cell cultures and reagents. BJ/TERT cells were cultured in Earle’s salts
minimal essential medium (EMEM) (HyClone) completed with nones-
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FIG 1 MEF2C and MEF2D levels are regulated during the cell cycle. (A) Immunoblot and densitometric analysis of MEF2 family members in NIH 3T3 cells
grown for the indicated times in 10% FCS. The fraction of cells synthetizing DNA was scored after BrdU staining. p120 was used as a loading control. (B) mRNA
expression levels of three MEF2 target genes (Klf2, Klf4, and RhoB), Mef2c, and Mef2d in NIH 3T3 cells grown for the indicated times in 10% FCS. mRNA levels
are relative to the first time point (12 h). Gapdh was used as a control gene. Data are means and SD (n 5 3). *, P , 0.05; **, P , 0.01. (C) Immunoblot and
densitometric analysis of MEF2C and MEF2D levels in NIH 3T3 cells grown for the indicated times in 10% FCS and treated for 10 h with MG132 or not treated,
as indicated. p120 was used as a loading control. (D) Immunoblot and densitometric analysis of MEF2C and MEF2D in NIH 3T3 cells, reintroduced into the
growth cycle with 10% FBS, after serum starvation for 48 h. Cellular lysates were collected at the indicated time points. Cytofluorimetric analysis of cell cycle
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sential amino acids (NEAA; HyClone). All other cell lines were grown in
Dulbecco modified Eagle medium (DMEM; Lonza). All media were sup-
plemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), pen-
icillin (100 U/ml), and streptomycin (100 mg/ml) (Lonza). Cells express-
ing the inducible form of MEF2 were grown in DMEM (Sigma-Aldrich)/
EMEM (Life Technologies) without phenol red. For analyses of cell
growth, 104 cells were seeded, and the medium was changed every 2 days.
The following chemicals were used: 20 mM LY294002 (LY), 10 mM
PD9800591, 0.5 mM okadaic acid (LC Laboratories); 2.5 mM MG132, 1
mM 4-hydroxytamoxifen (4-OHT), 10 mg/ml cycloheximide (CHX), 5
mM roscovitine, 3 mM PD0332991, 1 mM p38i IV, 1 mM staurosporine, 1
mM isopropyl-b-D-thiogalactopyranoside (IPTG), 100 nM microcystin
L1, 50 mM ATP, protease inhibitor cocktail (PIC), and dimethyl sulfoxide
(DMSO) (all fromSigma-Aldrich); 100 nMTorin1 (Cayman); and 20 mM
SKP2in [3-(1,3-benzothiazol-2-yl)-6-ethyl-7-hydroxy-8-(piperidin-1-
ylmethyl)-4H-chromen-4-one] (UkrOrgSyntez Ltd.).
Plasmid construction, transfections, retroviral/lentiviral infec-
tions, and silencing. The pEGFPC2, pFLAG CMV5a, and pGEX-4T1
constructs expressing MEF2C, MEF2D, and SKP2 were generated by PCR
and subsequent cloning, using EcoRI/SalI restriction sites (NEB). Phos-
phodefective (Ser-Thr/Ala) and phosphomimicking (Ser/Asp) MEF2D
mutants were generated using a Stratagene QuikChange Lightning kit
(Agilent). The MEF2D and MEF2D S98A S110A deletion mutants were
generated by PCR and cloned into pEGFPC2 and pGEX-4T1 plasmids.
pWZL-Hygro-MEF2-VP16-ER, pWZL-Hygro-MEF-DDBD-VP16-ER, pWZL-
Neo-p53DN (175H) were previously described (7). To generate pWZL-
Hygro and pBABE-Puro plasmids expressing SKP2, SKP2DN, SKP2DDD
(lacking the first 8 amino acids of the destruction domain), MEF2D-
FLAG, and MEF2D-S98A/S110A, the relative cDNAs were subcloned into
pWZL-Hygro and pBABE-Puro plasmids using the PCR method. The
fidelity of all generated plasmids was verified by DNA sequencing.
pLKO plasmids (15897 and 274054, referred to here as 15 and 27)
expressing short hairpin RNAs (shRNAs) directed against MEF2D were
obtained from Sigma-Aldrich. For retroviral infection, HEK293 Ampho
Phoenix cells were transfected with 12 mg of plasmid DNA. After 48 h at
32°C, virions were collected and diluted as appropriate to get the same
multiplicity of infection (MOI) for all genes. For lentivirus-based knock-
down, HEK-293 cells were transfected with 5 mg of VSV-G, 15 mg of D8.9,
and 20mg of pLKOplasmids. After 36 h at 37°C, virionswere collected and
opportunely diluted in fresh medium. Unless otherwise specified, all
transfection experiments in 293 and IMR90-E1A cells were performed
with a standard calcium phosphate method. Silencing of BJ/TERT and
BJ/TERT/p53DN was performed with 73 nmol of SKP2 small interfering
RNAs (siRNAs) (GGUAUCGCCUAGCGUCUGA; Invitrogen) and 56
nmol of CDKN1A siRNAs (AGACCAGCAUGACAGAUUU; Qiagen).
Production of recombinant proteins and immunoblots. pGEX plas-
mids expressing wild-type MEF2D with amino acids 1 to 190 deleted,
MEF2D S98A/S110A, MEF2D S98D/S110D, full-length SKP2, and Rb
with amino acids 379 to 928 deleted (16) were transformed in BL-21
bacterial cells. Recombinant protein expression was induced with 1 mM
IPTG at 30°C for 30 min, and proteins were purified using glutathione-
Sepharose beads (GE Healthcare). Immunoblots were performed as pre-
viously described (17), and relative quantitative measurements were
achieved by densitometric analysis of Western blot films, normalized to
the corresponding p120 or p62/nucleoporin or CRADD (loading con-
trols) values. Each immunoblot experiment was repeated at least twice
with similar results, and each densitometric analysis refers to the figures.
Immunoprecipitation and glutathione S-transferase (GST) pull-
down. Cells were lysed in a hypotonic buffer (20 mM Tris-HCl, pH 7.5; 2
mM EDTA; 10 mM MgCl2; 10 mM KCl; and 1% Triton X-100) supple-
mented with protease inhibitors. For each immunoprecipitation 1 mg of
antibody was used.
Portions (2 mg each) of recombinant proteins were used as baits in
each pulldown experiment. MEF2D-green fluorescent protein (GFP) and
SKP2-GFP were obtained from transfected HEK-293 cells, lysed with a
hypertonic buffer containing 300 mM NaCl in order to destroy the com-
plexes as much as possible. Pulldown was conducted at 4°C with rotation
for 2 h.
Antibodies. Antibodies used were those against MEF2C C-17
(sc13268; Santa Cruz Biotechnology), VP16 (Santa Cruz Biotechnology),
MEF2C CB (raised against a bacterially produced segment of MEF2C
[amino acids 341 to 473]), MEF2D (BD Bioscience), extracellular signal-
regulated kinase (ERK), phosphorylated ERK (pERK), AKT, pAKT
(Ser473), RAN, nucleoporin p62, p120 (Cell Signaling), SKP2-8D9 (Life
Technologies), p21 CP74 and FLAG M2 (Sigma-Aldrich), GFP (17),
CRADD (18), ubiquitin (Covance), and H3K27ac (ab4729; Abcam).
RNA extraction and quantitative qRT-PCR. Cells were lysed using
Tri-Reagent (Molecular Research Center). A total of 1 mg of total RNA
was retrotranscribed by using 100 U of Moloney murine leukemia virus
reverse transcriptase (Invitrogen). Quantitative reverse transcription-
PCR (qRT-PCR) analyses were performed using Bio-Rad CFX96 and
SYBR green technology (Resnova). The data were analyzed by use of a
comparative threshold cycle using the b2 microglobulin gene and HPRT
(encoding hypoxanthine phosphoribosyltransferase) as normalizer genes.
All reactions were done in triplicate.
Cell cycle FACS analysis and BrdU assay. For synchronization in G0/
G1, NIH 3T3 cells and BJ/TERT cells were serum starved for 48 and 72 h,
respectively, and then reactivated by addition of fetal calf serum (FCS).
For fluorescence-activated cell sorting (FACS) analysis, cells were fixed
with ethanol (overnight), treated with 10 mg RNase A (Applichem Life-
science), and stainedwith 10mg propidium iodide (Sigma-Aldrich). Data
were analyzed with Flowing software (http://www.flowingsoftware.com/).
For S-phase analysis, cells were grown for 3 h with 50 mM bromodeoxy-
uridine (BrdU). After fixation, coverslipswere treatedwithHCl.Mouse anti-
BrdU (Sigma) was used as the primary antibody. Nuclei were stained with
Hoechst 33258 (Sigma).
In vitro phosphorylation studies. Cellular lysates from 2.5 million
NIH 3T3 cells for each time point were obtained. Cells were lysed for 10
min in native buffer (10 mM HEPES [pH 7.4], 0.1% Triton, 20 mM
MgCl2, 1 mM MnCl, 1 mM phenylmethylsulfonyl fluoride [PMSF], PIC,
10 mM NaFl, 5 mM NaVO4, 0.5 mM okadaic acid, 100 nM microcystin
L1). Two micrograms of GST fusion proteins bound to resin in GST-
binding buffer (50mMTris [pH 7.4], 140mMNaCl) was next added. The
kinase reaction was carried out by incubating for 1 h at 30°C the glutathi-
one-bound proteins with cellular lysates supplemented with 50 mM ATP
and 1 mCi g-ATP (Perkin-Elmer). After several washes, sample buffer was
parameters is provided in the lower panel. BrdU positivity is shown in the histogram. (E) mRNA expression levels of three MEF2 target genes (Klf2, Klf4, and
RhoB) in NIH 3T3 cells collected 12 h after seeding (growing) or grown for an additional 48 h in 0.5% FBS (starved) and then reintroduced into the growth cycle
for the indicated times. mRNA levels are relative to growing condition. Gapdh was used as a control. Data are means and SD (n 5 3). *, P , 0.05; **, P , 0.01;
***, P , 0.005. (F) mRNA expression levels of three MEF2 target genes (KLF2, TRIB1, and RHOB), MEF2C, and MEF2D in growing BJ/TERT cells (16 h)
compared to density-arrested cells (96 h). mRNA levels are relative to the first time point (16 h). The b2 microglobulin gene was used as a control gene. Data are
means and SD (n 5 3). *, P , 0.05; **, P , 0.01; ***, P , 0.005. (G) Immunoblot and densitometric analysis of MEF2 family members in human BJ/TERT cells.
Cellular lysates were collected at different times after seeding, as indicated. The fraction of cells synthetizing DNA was scored after BrdU staining. p120 was used
as a loading control. (H) Immunoblot and densitometric analysis of MEF2 family members in BJ/TERT cells collected at different times after seeding and treated
with the proteasome inhibitor MG132, as indicated. p120 was used as a loading control. (I) Immunoblot and densitometric analysis of MEF2 family members in
BJ/TERT cells, starved for 72 h, reactivated with 10% FBS, and collected at different times after reactivation, as indicated. Cell cycle analysis results are provided
in the lower panel.
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added to the beads. When the recombinant cyclin-dependent kinases
(CDKs) were used, 250 ng of cyclin D1/CDK4 or cyclin E1/CDK2 (Sigma-
Aldrich) was incubated with GST-MEF2D proteins.
Chromatin immunoprecipitation and promoter study. The se-
quence of the CDKN1A-proximal promoter (10 kb upstream and 10 kb
downstream from the transcription start site [TSS]) was recovered from
ENCODE. The presence of a putative MEF2 binding site was predicted
using CisterZlab (http://zlab.bu.edu/;mfrith/cister.shtml) and JASPAR
(http://jaspar.binf.ku.dk/) algorithms.
For each chromatin immunoprecipitation (ChIP), 2.5 3 106 cells were
used and ChIP was performed as previously described (7). Anti-MEF2C
(CB), anti-MEF2CC-17, anti-MEF2D, anti-H3K27ac, and anti-FLAGM2
antibodies were used, and preimmune serum was used as an unrelated
control.
Statistics. For experimental data, a Student t test was used. A P value of
0.05 was chosen as the statistical limit of significance. Unless otherwise
indicated, data in the figures are arithmetic means and standard devia-
tions from at least three independent experiments.
RESULTS
MEF2C and MEF2D protein stability is regulated during the cell
cycle. We recently showed that suppression of the PI3K/Akt path-
way elicits the upregulation of MEF2C and MEF2D expression
(7). This upregulation is mediated by the stabilization of MEF2
proteins, because of a reduced targeting to the ubiquitin-protea-
some system (UPS). Regulation ofMEF2 protein half-life could be
a general phenomenon, linked not to PI3K-induced transforma-
tion alone but rather to distinct proliferative states of the cells. To
explore this hypothesis, we decided to investigate the regulation of
MEF2s during different proliferative conditions in untransformed
cells. NIH 3T3 fibroblasts were selected for these studies, and we
initially assessed MEF2 levels during growth arrest, as induced by
density-dependent inhibition. Figure 1A illustrates that MEF2C
and MEF2D levels increase when cells exit the cell cycle. Densito-
metric analysis further proved this upregulation. Analysis of BrdU
incorporation confirmed entry into the quiescence state following
contact inhibition. In parallel, levels of mRNAs of MEF2 target
genes (Klf2, Klf4, and RhoB), including Mef2c and Mef2d them-
selves, rise during density-dependent growth inhibition (Fig. 1B).
Experiments using MG132 proved that the UPS plays a key role in
the control ofMEF2s levels under the different growth conditions.
Blocking the proteasome-mediated degradation efficiently aug-
mented MEF2C and MEF2D levels only in growing cells (Fig. 1C).
Finally, when G0 serum-deprived cells were restimulated to grow,
by addition of 10% FCS, MEF2C and MEF2D levels decreased as
cells entered the S phase (Fig. 1D).
Previous studies demonstrated that MEF2s are engaged in the
transcription of serum-induced immediate early genes (13, 14,
15). Hence, we decided to follow the expression levels of MEF2
target genes after serum stimulation of quiescent cells. The time
course analysis (Fig. 1E) confirmed that at early times after serum
addition, expression of these genes is augmented. Also, Mef2c and
Mef2d mRNAs were upregulated, but at a very modest level (data
not shown). However, these upregulations were transient, and 3 h
after stimulation for Klf2 and Klf4, or 6 h in the case of RhoB,
mRNA levels were reduced compared to those in quiescent cells.
These results are in agreement with the described downregulation
of MEF2C and MEF2D proteins occurring during late G1/S phase
(Fig. 1D). Interestingly after 12 h of stimulation, when cells are
mainly in S phase, expression of theMEF2 targets was significantly
reduced compared to exponentially growing cells.
To confirm our observations, we also investigated the regula-
tion of MEF2C and MEF2D genes during the cell cycle in human
fibroblasts. Immortalized BJ cells expressing TERT gene were ar-
rested in a density-dependentmanner. Figure 1F shows thatMEF2
target genes, in particular TRIB1 and RHOB, were induced follow-
ing density-dependent inhibition. Immunoblot analysis con-
firmed that MEF2C and MEF2D levels increase during growth
arrest (Fig. 1G). The strong discrepancy between the changes in
RNA and protein levels of MEF2C and MEF2D (compare Fig. 1F
and G) further indicates the involvement of the UPS. In fact, as
reported for murine fibroblasts, proteasomal inhibition increased
MEF2C and MEF2D levels in growing cells, but it had a lower
impact on density-arrested cells (Fig. 1H). Also in human fibro-
blasts, reintroduction of serum-deprived cells into the growth cy-
cle was coupled to an S-phase-mediated MEF2C and MEF2D
downregulation (Fig. 1I).
SKP2 regulates MEF2C and MEF2D stability. A key point of
MEF2C and MEF2D regulation during the cell cycle is their tar-
geting of the UPS. To identify the ubiquitin E3 ligase involved in
such a task, we compared gene expression profiles of growing
versus quiescent cells, as well as of cells transformed with RAS and
PI3K oncogenes versus the normal counterpart. All conditions
were marked by a decreased half-life of MEF2 proteins (7) (data
not shown). Among the ubiquitin E3 ligases upregulated in both
transformed and growing cells, we focused our attention on SKP2
(S-phase kinase-associated protein 2), also known as FBXL1 (19).
qRT-PCR analysis revealed that expression levels of Skp2 inversely
correlate with the MEF2 target genes (Klf2, Klf4, and RhoB), dur-
ing density-dependent inhibition and in RAS- or PI3K-trans-
formed murine fibroblasts (Fig. 2A). Furthermore, analysis of
publicly available gene expression profiles in different tumors re-
vealed a significant inverse correlation between the expression of
MEF2 target genes and SKP2 in soft tissue sarcomas, gastric can-
cer, metastatic skin carcinoma, metastatic melanoma, and acute
lymphoblastic leukemia (see Fig. S1 in the supplemental mate-
rial).
To prove the relationships between SKP2 and MEF2s, we per-
formed coexpression studies in human fibroblasts expressing the
E1A oncogene. The amount of ectopically expressed MEF2C-GFP
(Fig. 2B) was dramatically reduced in the presence of coexpressed
SKP2, and proteasomal inhibition recovered its levels. Similarly,
MEF2D-GFP levels were downregulated by the simultaneous co-
expression of SKP2. Moreover, a deletion-containing version of
the E3 ligase acting as dominant negative (DF box) (20) efficiently
rescued MEF2D-GFP levels (Fig. 2C).
We next investigated whether MEF2D could interact with
SKP2. MEF2D was selected for this analysis because of its higher
expression, compared to MEF2C, in fibroblasts (21). After coim-
munoprecipitation, a complex between endogenous MEF2D and
SKP2 was purified from cells expressing SKP2-GFP, and the
amount of MEF2D bound to SKP2 was dramatically increased
following MG132 treatment (Fig. 2D). MEF2D-GFP expressed in
293 cells was polyubiquitylated, and coexpression with SKP2 in-
creased this polyubiquitylation, whereas SKP2DN reduced it (Fig.
2E). When the dominant negative version of SKP2 was stably ex-
pressed in NIH 3T3 cells, levels of MEF2C and MEF2D proteins
increased. In contrast, introduction of a hyperactive version of
SKP2, SKP2DDD (22), caused a dramatic reduction of both
MEF2C and MEF2D levels (Fig. 2F).
When NIH 3T3 cells are challenged with MG132 or with the
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FIG 2 SKP2 binds and mediates the ubiquitylation of MEF2C/D. (A) mRNA expression levels of MEF2 target genes (Klf2, Klf4, and RhoB) and of Skp2 in NIH
3T3 cells grown for the indicated times in 10% FBS or expressing p110-CAAX and H-RAS. The scheme highlights the inverse correlation between MEF2 target
expression levels and Skp2. (B) IMR90-E1A cells were transfected with pEGFP-N1-MEF2C (1 mg) and 2 mg of pFLAG-CMV5a SKP2 or pFLAG-CMV5a GFP as
a control. After 24 h, cells were treated with MG132 or left untreated, and after 12 h, cellular lysates were generated and subjected to immunoblot analysis using
the indicated antibodies. p120 was used as a loading control. (C) IMR90-E1A cells were transfected with pEGFP-C2-MEF2D (1 mg), 2.5 mg of pFLAG-CMV5a-
SKP2, pFLAG-CMV5a-SKP2DN, or empty pFLAG-CMV5a as a control and 200 ng of pEGFP-C2. After 36 h, cellular lysates were generated and subjected to
immunoblot analysis using the indicated antibodies. (D)Cellular lysates fromHEK-293 cells, transfectedwith 5mg of pEGFP-N1-SKP2 orwith empty pEGFP-C2
plasmids and treated for 8 h with 2.5 mM MG132 or left untreated, were immunoprecipitated with an anti-GFP antibody. Immunoblots were performed using
the indicated antibodies. (E) HEK-293 cells were cotransfected with the HA-ubiquitin gene (1 mg) and MEF2D-GFP (2 mg) or GFP and SKP2-FLAG or
SKP2DN-FLAG or an empty plasmid (4 mg). Twenty-four hours later, cells were treated for 8 h with 2.5 mM MG132 or left untreated. GFP fusions were
immunoprecipitated using an antibody against GFP and were subjected to immunoblotting using an antiubiquitin antibody. After being stripped, the filter was
probed with anti-GFP and anti-FLAG antibodies. Inputs are included. (F) Immunoblot analysis of MEF2 family members and SKP2 in NIH 3T3 cells stably
expressing the dominant negative form (DN) or the hyperactive form (DDD) of SKP2 or the control gene (Hygro). Immunoblotting was performed using the
indicated antibodies. p120 was used as the loading control. (G) Immunoblot and densitometric analysis of MEF2 family members and SKP2 in NIH 3T3 cells
stably expressing the dominant negative form (DN) of SKP2 or the control gene (Hygro) and treated 12 h after the seeding with LY294002 for 24 h and for the
last 12 hwithMG132, or left untreated, as indicated.Untreated cells were harvested after 36 h from seeding. p120was used as the loading control. The lower arrow
points to ectopically expressed SKP2/DN. The higher arrow points to a band showing the same size of the endogenous SKP2. (H) Immunoblot and densitometric
analysis of MEF2 family members in NIH 3T3 cells stably expressing the dominant negative form of SKP2 (SKP2DN) or the control (HYGRO) and treated for the
indicated timeswith 10 mg/ml of CHX. (I) Immunoblot and densitometric analysis ofMEF2 familymembers inNIH3T3 cells stably expressing SKP2DN, starved
for 48 h, reactivated with 10% FBS, and collected at different times after stimulation, as indicated. BrdU positivity is shown at the bottom.
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FIG 3 Mapping of SKP2 binding to MEF2C/D and characterization of SKP2 interference. (A) Immunoblot and densitometric analysis of MEF2 family members
SKP2 and p21 in BJ/TERT cells transfected for 36 h with SKP2 siRNA. Transfections were performed 24 h or 48 h after seeding, as indicated. p120 was used as the
loading control. BrdU positivity is shown at the bottom. (B) BJ/TERT cells were transfected with SKP2 siRNA. After 24 h cells were treated for 8 h with 2.5 mM
MG132 or left untreated. MEF2C complexes were immunoprecipitated using an antibody against MEF2C and were subjected to immunoblotting using an
antiubiquitin antibody. After being stripped, the filter was probed with an anti-MEF2C antibody and an anti-SKP2 antibody. Inputs and p62 (nucleoporin), as
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PI3K inhibitor LY294002 (LY), MEF2C and MEF2D abundance
increases (7). In cells expressing SKP2/DN, the levels of the two
MEF2s were higher than control levels. Treatment with LY,
MG132, or both failed to further increase the quantities of these
TFs (Fig. 2G). This result indicates that SKP2 is the crucial E3
ligase engaged by the PI3K pathway to switch off MEF2 activities.
To further prove the contribution of SKP2, we also used cyclohex-
imide (CHX). In proliferating cells, a block of protein synthesis
elicited a reduction of MEF2C and MEF2D, already appreciable at
6 h from CHX addition. This reduction was abolished in cells
expressing SKP2/DN (Fig. 2H). Finally, the downregulation of
MEF2C and MEF2D observed in serum-deprived cells stimulated
with 10% FCS was also abrogated in SKP2/DN-expressing cells
(compare Fig. 2I and 1D). Not surprisingly, these cells exhibited a
reduced ability to enter S phase after serum stimulation. In sum-
mary, these results indicate that SKP2 is a critical E3 ligase dictat-
ing MEF2C and MEF2D protein levels during the cell cycle.
Molecular determinants of the MEF2-SKP2 interaction. To
further confirm the influence of SKP2 on MEF2 stability, we si-
lenced its expression in human fibroblasts. Downregulation of
SKP2 provoked the upregulation of both MEF2C and MEF2D
proteins (Fig. 3A). The CDK inhibitor p21, a SKP2 substrate, was
used as a positive control (23). Furthermore, we also proved that
polyubiquitylation of MEF2C was reduced in SKP2-silenced cells
(Fig. 3B).
SKP2 interacts with its substrates in a phosphorylation-depen-
dentmanner (19). In order tomap the amino acid residues critical
for this interaction, we initially performed a simple deletion anal-
ysis to circumscribe the region involved. In Fig. 3C and D, sche-
matic representations of MEF2C and MEF2D TFs highlighting
their principal domains are shown. Coimmunoprecipitation ex-
periments proved that the region from positions 1 to 117 of
MEF2C is sufficient for the interaction with SKP2 (Fig. 3C). In
accordance, the carboxy terminus of MEF2D is dispensable for
this interaction (Fig. 3D). Having identified in the MEF2 ami-
no-terminal portion the region recognized by SKP2, we next
applied in silico analysis to locate putative phosphorylation
motifs. Again, as explained above, we focused the studies on
MEF2D. T22, S78, S98, S106, and S110 of MEF2D (all con-
served in MEF2C) resulted in the highest score as putative con-
sensus phosphoacceptor sites.
Single phosphodead substitutions of MEF2D were generated,
and the binding to SKP2 was tested after cotransfection of the
relative cDNAs in 293 cells. Neither the Ala/Ser nor the Ala/Thr
substitution in MEF2D abrogated the binding to SKP2. However,
a slightly reduced interaction was observed when serine 98 and
110 were replaced with alanine (Fig. 3E). We next generated
MEF2D with double dephosphomimetic substitutions. Simulta-
neousmutations of Ser 98 and 110 to Ala dramatically reduced the
binding of MEF2D to SKP2 in 293 cells (Fig. 3F). Then, we used a
GST pulldown assay to confirm the importance of Ser 98 and 110
for the interaction with SKP2. In the pulldown assay, the single
substitution S98A diminished the binding to SKP2, whereas the
double mutation S98A/S110A completely abrogated it (Fig. 3G).
We also proved that polyubiquitylation of the S98A/S110Adouble
mutant was largely compromised but not totally suppressed com-
pared to that of the wild-type (Fig. 3H). Furthermore,MG132 and
the SKP2 inhibitor increased the amounts of MEF2D-GFP and of
the phosphomimetic double mutant (S98D/S110D) but not that
of the S98A/S110A double mutant (Fig. 3I). Finally, the GST pull-
down assay established that the interaction between SKP2 and the
recombinantMEF2Dwas dramatically improved in the case of the
phosphomimetic double mutant (Fig. 3J). These results indicate
that phosphorylation of serines 98 and 110 plays an important role
in the control of MEF2D stability, by mediating the interaction
with SKP2.
MEF2D is a substrate of CDK4. To identify the kinases re-
sponsible for MEF2D phosphorylation on serines 98 and 110, we
initially arranged an in vitro phosphorylation assay using crude
cellular extracts fromNIH 3T3 cells as a source of kinase activities.
When a MEF2D-GST fusion protein comprising amino acids 1 to
190 was incubated with these cellular extracts in the presence of
radiolabeled g-ATP, it was phosphorylated (Fig. 4A). MEF2D-
GST phosphorylation was augmented when extracts were ob-
tained from cells in the G1 phase compared to quiescent G0
cells. Coomassie blue gel staining verified the amount of re-
combinant protein loaded. Under the same experimental con-
ditions, GST alone was not phosphorylated. When the MEF2D-
S98A/S110A double mutant was used, phosphorylation was
reduced but not abrogated, thus indicating that the two serine
residues are targets of some kinase and that additional amino
acids can be phosphorylated in vitro (Fig. 4A). Since S98 and
S110 share consensus phosphorylation sequences for several
kinases (ERKs, mTOR, p38, CDK2, and cyclin-dependent ki-
nase 4 [CDK4]), we tested whether the relative specific inhibi-
tors could influence MEF2D phosphorylation in our in vitro
the loading control are included. (C) Scheme of MEF2C domains. The MADS and MEF2 domains and the two transcriptional activation domains (TADs) are
indicated. HEK-293 cells were transfected with pEGFP-N1-MEF2C deletions (1.5 mg) and pFLAG-CMV5a-SKP2 or pFLAG-CMV5a (4 mg) and treated for 8 h
with 2.5 mM MG132. FLAG fusions were immunoprecipitated using an antibody against FLAG and were subjected to immunoblotting using an anti-GFP
antibody. After being stripped, the filter was probed with an anti-FLAG antibody. Inputs are included. (D) Scheme of MEF2D domains. The MADS and MEF2
domains and the two TADs are indicated. HEK-293 cells were transfected with pEGFP-C2-MEF2D deletion mutants (1.5 mg) and pFLAG-CMV5a-SKP2 or
pFLAG-CMV5a (4 mg). Experimental treatments and immunoprecipitations were performed as for panel C. The asteriskmarks the IgGs. (E)HEK-293 cells were
transfected with pEGFP-C2-MEF2D deletion mutants and phosphodead mutants (1.5 mg) and pFLAG-CMV5a-SKP2 or pFLAG-CMV5a (4 mg). Experimental
treatments and immunoprecipitations were performed as for panel C. (F) HEK-293 cells were transfected with wild-type (WT) pEGFP-C2-MEF2D and single or
double phosphodead mutants (1.5 mg) and pFLAG-CMV5a-SKP2 or pFLAG-CMV5a (4 mg). Experimental treatments and immunoprecipitations were per-
formed as for panel C. (G) GST pulldown assay. Cellular lysates from HEK-293 cells expressing WT or phosphodead mutant forms of MEF2D-GFP were
incubated with 3 mg of recombinant GST-SKP2 or GST alone. (H) HEK-293 cells were cotransfected with the HA-ubiquitin gene (2 mg) and WT MEF2D-GFP
or the double-phospho-mutant (4 mg) or GFP alone and treated for 8 h with 2.5 mM MG132 or left untreated. GFP fusions were immunoprecipitated using an
antibody against GFP and were subjected to immunoblotting using an antiubiquitin antibody. After stripping, filter was probed with an anti-GFP antibody.
Inputs are included. (I) Immunoblot analysis of MEF2D in IMR90-E1A cells transfected with the wild-type, the phosphomutant, and the phosphomimicking
forms of MEF2D fused to GFP (2 mg) and with empty pEGFP-C2 (1 mg), used as the loading control. After 12 h cells were harvested, split in three, and treated
for 12 h with DMSO, MG132, and the SKP2 inhibitor (SKP2-in), as indicated. (J) GST pulldown assay. Cellular lysates from HEK-293 cells expressing SKP2-GFP
were incubated with 2 mg of GST, GST-MEF2D, or its phosphodead and phosphomimetic mutants, as indicated.
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phosphorylation assay. Staurosporine was used as a positive
control. Only mTOR, p38, and CDK4 inhibitors reduced
MEF2D(1–190) phosphorylation, thus confirming the exis-
tence of multiple MEF2 kinases in the cellular extracts (Fig.
4B). Next, we used the MEF2D-S98A/S110A double mutant, in
order to understand which kinase could be involved in the
phosphorylation of these residues. The p38 and mTOR inhib-
itors effectively repressed phosphorylation of the double mu-
tant, whereas the CDK4 inhibitor was the less efficient (Fig.
4C). This result suggests that CDK4 is the kinase that could be
more specifically involved in the phosphorylation of S98 and
S110, whereas mTOR and p38 are principally implicated in
phosphorylating other residues. Finally, to verify the contribu-
tion of CDK4, the complex CDK4/cyclin D1 was tested for the
ability to phosphorylate MEF2D-GST. To evaluate the speci-
ficity, the related kinase CDK2/cyclin E was used for compari-
son. Only CDK4/cyclin D1 was able to phosphorylate MEF2D
in vitro and this phosphorylation was reduced but not abro-
gated when the S98A/S110A mutant was used (Fig. 4D), thus
pointing to the existence of additional phosphorylation sites.
The efficacy of both kinases was tested on GST-Rb (data not
shown). In conclusion, the 1–190 fragment of MEF2D is the
FIG 4 MEF2D is phosphorylated by CDK4. (A) (Left) Autoradiography after in vitro phosphorylation of MEF2D-GST and GST as a control, using cellular
extracts from serum-starved NIH 3T3 cells, incubated for 4 h with 10% FCS or left untreated. (Right) Autoradiography after in vitro phosphorylation of WT and
phosphodead MEF2D-GST and GST alone using cellular extracts from NIH 3T3 cells that had been serum starved and treated for 4 h with 10% FCS. Coomassie
staining was used as the loading control. Densitometric analysis is also shown. (B and C) Autoradiography after in vitro phosphorylation performed on
GST-MEF2D (B) and the phosphodead mutant (C) in the presence of the indicated kinase inhibitors or DMSO. Crude cellular extracts were obtained from NIH
3T3 cells that had been serum starved and then treated for 4 h with 10% FCS. Coomassie staining was used as the loading control. Densitometric analysis is also
provided. (D) Autoradiography after in vitro phosphorylation performed on GST-MEF2D and GST-MEF2D S98A/S110A, using recombinant cyclin D1/CDK4
or cyclin E1/CDK2. Coomassie staining was used as the loading control. Densitometric analysis is also provided. *, P , 0.05.
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target of multiple kinases in different residues, and CDK4/cy-
clin D1 can phosphorylate MEF2D on serines 98 and 110, as
well as on additional residues.
Roles of MEF2s in the regulation of cell cycle progression.
The discovery of the tight regulation of MEF2s stability during cell
cycle progression prompted us to explore the effect of artificially
altering MEF2 transcriptional activity on cell proliferation. We
used the MEF2-VP16-ER chimera and, as a control, the MEF2-
VP16-ER construct lacking the DNA-binding domain (DDBD,
amino acids 58 to 86). NIH 3T3 cells expressing transcription-
competentMEF2 are characterized by a reduced proliferative pro-
file, as indicated by the reduction in cell numbers (Fig. 5A), the
diminished percentage of cells incorporating BrdU (Fig. 5B), and
the increased number of cells in the G1 phase of the cell cycle (Fig.
5C). To strengthen this observation, we used a repressive version
of MEF2 (24), generated by fusing the MADS/MEF2 domains to
the transcriptional repressor Engrailed (MEF2-ENG). Cells ex-
pressing the repressive version of MEF2 increased their prolifera-
tion rate, as evidenced by (i) the increased number of cells (Fig.
5D), (ii) the highest percentage of BrdU incorporation (Fig. 5E),
and (iii) the reduced number of cells in G1 (Fig. 5F).
We next investigated the behavior of NIH 3T3 cells expressing
the different MEF2 versions during the G0/G1 transition following
readdition of serum to starved cells. In this study, we also com-
pared the behavior of cells expressing SKP2DDD, a hyperactive
version of the E3 ligase (Fig. 5G). As expected, the cell cycle profile
of cells expressing the hyperactive SKP2 exhibited a high percent-
age of cells in S phase also under starvation, thus indicating their
inability to enter G0. In serum-starved cells expressing the repres-
sive version of MEF2, cycling cells can still be detected (approxi-
mately 30% of the cells in S and G2 phases). Readdition of serum
elicited cell cycle reentry in GFP and DDBD cells, whereas in the
presence of the transcriptionally active MEF2, the percentage of
cells approaching S phase was diminished (Fig. 5G).
CDK inhibitors are key regulators of cell cycle progression
(25). To evaluate a possible contribution of these inhibitors in
transducing MEF2 antiproliferative signal, we took advantage of
the profile of genes repressed in NIH 3T3 cells, after expression of
a nuclear resident formofHDAC4, since the vastmajority of these
genes are MEF2 targets (7). Figure 5H shows that Cdkn1a was the
sole CDK inhibitor significantly repressed by HDAC4. We next
compared the expression patterns of some MEF2 targets and of
Cdkn1a in the cell lines engineered to express the different MEF2
variants. Cdkn1a shows a pattern of expression similar to that of
other MEF2 target genes, being increased in MEF2-VP16 and re-
duced in MEF2-ENG cell lines (Fig. 5I). The influence of the two
MEF2 chimeras on p21 was confirmed also at protein levels (Fig.
5J). We also analyzed the pattern of p21 expression following se-
rum stimulation of starved cells. Similar to the other MEF2 tar-
gets, Cdkn1a mRNA levels were upregulated at starvation and
slowly declined during the G1/S transition (9/12 h from stimula-
tion). Compared to the other MEF2 targets analyzed, Cdkn1a was
induced to a much lesser extent at early times from serum stimu-
lation (Fig. 5K).
Having defined a mechanism through which MEF2s could
suppress cell proliferation, we wanted to confirm the growth in-
hibitory activity of MEF2 in human cells. We used BJ/TERT hu-
man fibroblasts expressing a mutated p53 allele, acting as domi-
nant negative, and cells not expressing this allele. Since CDKN1A
is an important p53 target gene, we wanted to exclude an involve-
ment of this tumor suppressor in the antiproliferative activity elic-
ited byMEF2s. Induction ofMEF2-dependent transcription using
the MEF2-VP16-ER chimera dramatically suppressed cell prolif-
eration andDNA synthesis in a p53-independentmanner (see Fig.
S2A and B in the supplemental material). Upregulation of MEF2
target genes andof CDKN1A was confirmed followingMEF2 tran-
scriptional activation in both BJ/TERT and BJ/TERT/p53DN cells
(see Fig. S2C and D in the supplemental material). Upregulation
of CDKN1A was also verified by immunoblotting (see Fig. S2E in
the supplemental material). Both analyses showed that MEF2-
dependent upregulation of CDKN1A is p53 independent.
To unambiguously demonstrate the role of MEF2s in the con-
trol of cell cycle, we downregulated MEF2D expression following
lentiviral infection. Two different shRNAs were evaluated (sh15
and sh27). In BJ/TERT/p53DN cells, MEF2D downregulation was
coupled with the reduction of CDKN1A levels (Fig. 6A), an in-
crease in DNA synthesis (Fig. 6B) and augmented cell prolifera-
tion (Fig. 6C).mRNA levels ofMEF2 target genes and of CDKN1A
were reduced in cells with impaired MEF2D expression (Fig. 6D).
The specificity of the shRNAs against MEF2D with respect to
other MEF2 members was also demonstrated (Fig. 6D).
We again decided to verify the proproliferative effect of
MEF2D downregulation in a different cell line. When BJ/TERT/
E1A/RAS cells were used, the results were confirmed. Downregu-
lation of MEF2D expression was coupled to (i) a downregulation
of CDKN1A/p21 levels (see Fig. S2F in the supplemental mate-
rial), (ii) an improvement of the percentage of cells in S phase (see
Fig. S2G in the supplemental material), and (iii) an overall in-
crease of cell proliferation (see Fig. S2H in the supplemental ma-
terial). Finally, the tested MEF2 target genes were all downregu-
lated (see Fig. S2I in the supplemental material).
Small molecules targeting SKP2 show interesting anticancer
properties (26). We tested a SKP2 inhibitor for the ability to re-
strain proliferation of BJ/TERT/p53DNcells, andwe also analyzed
the contribution of MEF2D for transducing such antiproliferative
response. Figure 6E illustrates that the SKP2 inhibitor can dimin-
ish the proliferation of BJ/TERT/p53DN cells. More importantly,
the antiproliferative effect of the SKP2 inhibitor (Fig. 6F) and the
upregulation of p21 (Fig. 6G) were consistently reduced in the
absence of MEF2D. These results further confirm a key role of
MEF2 in transducing antiproliferative signals, possibly through
the engagement of p21.
CDKN1A is a key element in the antiproliferative activity of
MEF2. To elucidate the contribution of CDKN1A to the antipro-
liferative signaling of MEF2s, we silenced its expression in BJ/
TERT and BJ/TERT/p53DN cells expressing the inducible
MEF2 or its mutant with a deletion in the DNA binding do-
main (Fig. 7A).
When CDKN1A was downregulated, the antiproliferative ef-
fect and the inhibition ofDNA synthesis elicited byMEF2 upregu-
lation were almost entirely abrogated (Fig. 7B and C).
Changes in CDKN1A levels following MEF2 perturbations
could reflect either a direct involvement of MEF2s in regulating
its transcription or an indirect role, through the regulation of
other TFs, such as KLF4 (27) and KLF2 (28). To clarify these
possibilities, we scrutinized the genomic region around the
CDKN1A transcription start site for the presence of MEF2-bind-
ing consensus sequences. Figure 7D schematizes the organization
of the CDKN1A genomic region and highlights the presence of 6
putative MEF2-binding sequences in the promoter and in the first
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FIG 5 MEF2s affect NIH 3T3 fibroblasts proliferation by inducing CDKN1A expression. (A) NIH 3T3 cells expressing the two transgenes and treated with
4-OHT were grown for the indicated times. Data are means 6 SD (n 5 3). (B) Forty-eight hours after seeding, quantification of BrdU positivity of NIH 3T3 cells
expressing the indicated transgenes and treated with 4-OHT was performed. Data are means and SD (n 5 5). (C) Cell cycle profile of NIH 3T3 cells expressing
the indicated transgenes and treated with 4-OHT. Analysis was performed 48 h after seeding. Data are means and SD (n 5 4). (D) NIH 3T3 cells expressing the
two transgenes were grown for the indicated times. Data are means 6 SD (n 5 3). (E) Forty-eight hours after seeding, quantification of BrdU positivity of NIH
3T3 cells expressing the indicated transgenes was performed. Data are means and SD (n 5 5). (F) Cell cycle profile of NIH 3T3 cells expressing the indicated
transgenes. Analysis was performed 48 h after seeding. Data are means and SD (n 5 4). (G) Cell cycle profile of NIH 3T3 cells expressing the indicated transgenes,
serum starved (time zero) or at different times after serum addition. SKP2DD was used as a positive control for unrestricted proliferation. Data are means and
SD (n 5 3). (H) mRNA induction (n-fold) of the indicated CDK inhibitors, obtained by comparing their levels of expression in NIH 3T3 cells expressing
HDAC4-GFP and those expressing GFP as a control (7). (I) mRNA expression levels of MEF2 target genes (Klf2, Klf4, and RhoB) and Cdkn1a in NIH 3T3 cells
expressing the indicated transgenes and collected 36 h after the seeding. Gapdh was used as a control. Data are means and SD (n 5 3). (J) Immunoblot analysis
of p21/CDKN1A levels in NIH 3T3 cells expressing the indicated transgenes. Anti-VP16 and anti-FLAG antibodies were used to reveal the expression of the
transgenes. p120 was used as the loading control. (K) mRNA expression levels of Cdkn1a in serum-starved NIH 3T3 cells stimulated with 10% FCS as indicated.
Gapdh was used as a control. Data are means and SD (n 5 3). *, P , 0.05; **, P , 0.01; ***, P , 0.005.
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intron of CDKN1A gene. ChIP experiments using two different
anti-MEF2C antibodies indicate thatMEF2C can interact with the
CDKN1A genomic region, and the highest enrichment was ob-
tained for the MEF2 consensus sequence at kb 12.1 from the
transcription start site (TSS) (Fig. 7E). This enrichment was com-
parable to the positive control, the region containing the MEF2-
binding sequence of the RhoB promoter. Similar results were ob-
served when the ChIP experiments were performed using an
antibody against MEF2D. We verified that MEF2D also binds the
same genomic region in cells expressing mutated p53 (Fig. 7E).
The genomic region of CDKN1A bound by MEF2 was previ-
ously characterized by the ENCODEproject as enriched in histone
H3 lysine 27 acetylation (H3K27ac) and histone H3 lysine 4
monomethylation (H3K4me1) (29), two markers of active en-
FIG 6 MEF2s affect proliferation of human fibroblasts by inducing CDKN1A expression. (A) Immunoblot analysis of p21/CDKN1A in BJ/TERT/p53DN cells
silenced for MEF2D expression using two different shRNAs (sh15 and sh27). The efficiency of the downregulation was proved with an anti-MEF2D antibody.
CRADD was used as the loading control. (B) Quantification of BrdU positivity of BJ/TERT/p53DN silenced (sh15 and sh27) for MEF2D or not silenced (shCT).
Analyses were performed 48 h after seeding. Data are means and SD (n 5 4). (C) BJ/TERT/p53DN cells expressing the indicated shRNAs were grown for the
indicated times. Data aremeans 6 SD (n 5 3). (D)mRNA expression levels ofMEF2 target genes (KLF2, KLF4, and RHOB) and of CDKN1A in BJ/TERT/p53DN
cells in which MEF2D expression was downregulated using two different shRNAs, as indicated. Data are means and SD (n 5 3). (E) Quantification of the
proliferation rate of BJ/TERT/p53DN cells silenced for MEF2D or not silenced and treated for 24 h with the SKP2 inhibitor or left untreated, as indicated. Data
aremeans and SD (n 5 3). (F) Proliferation inhibition in BJ/TERT/p53DN cells knocked down for MEF2D or not knocked down and treatedwith SKP2 inhibitor
or left untreated, as indicated. Data are relative to those for untreated cells and presented as means and SD (n 5 3). (G) Immunoblot and densitometric analysis
of MEF2D and p21/CDKN1A levels in BJ/TERT/p53DN cells treated as for panel E. p62 (nucleoporin) was used as the loading control. *, P , 0.05; **, P , 0.01;
***, P , 0.005.
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FIG 7 MEF2D antiproliferative effects rely mainly on its direct regulation of CDKN1A transcription. (A) Immunoblot analysis of p21/CDKN1A in BJ/TERT
and BJ/TERT/p53DN cells expressing the indicated transgenes, treated with 4-OHT, and silenced for the p21/CDKN1A gene or not silenced, as indicated.
Anti-VP16 and anti-Ran antibodies were used, respectively, to reveal the expression of the transgenes and as the loading control. (B) Quantification of the
proliferation rate of the indicated cell lines relative to BJ/TERT/MEF2DDBD cells treated for 36 h with siRNA against the p21/CDKN1A gene or the siRNA
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hancers (30). These data suggest that MEF2 might actively regu-
late p21 transcription by binding to an active enhancer and could
itself recruit other cofactors, such as the acetyltransferase p300
(31), which in turn cooperate to maintain the open chromatin
state. To confirm this hypothesis, we performed ChIP experiment
using anti-H3K27Ac antibody. Figure 7F illustrates that the high-
est enrichment for H3K27 acetylation can be observed around kb
12.1 from the TSS in the same region where MEF2C and MEF2D
binding was observed. Furthermore, in cells with downregulated
MEF2D, the acetylation of H3K27 was clearly reduced specifically
at kb 12.1 from the TSS.
DISCUSSION
MEF2s are pleiotropic TFs, which influence different genetic pro-
grams in relation to specific posttranslational modifications
(PTMs) and the associations with other transcription factors, co-
activators, or repressors (1). The contribution of MEF2s to several
differentiation processes is well known. MEF2s supervise differ-
entiation of myoblasts (32), cardiomyoblasts (33), osteoblasts
(24), neuronal cells (10, 34), B lymphocytes, and monocytes (35).
Micewith Mef2 genes knocked out display phenotypes compatible
with defects in these differentiative programs at an advanced stage,
suggesting that MEF2s regulate the final steps of these processes (1,
24, 33, 35). Furthermore, in a wide variety of differentiated cells,
MEF2s are also engaged to modulate adaptive responses (1, 36, 37).
In this work, we investigated the still-obscure role of MEF2s in
the regulation of the cell cycle. Using human and murine fibro-
blasts as cellular models, we have demonstrated the reciprocal
influence of the cell cycle machinery on MEF2 activities and of
MEF2s on cell cycle progression. We have discovered that, in ad-
dition to previously documented engagements of MEF2s in gov-
erning the early transcriptional response to serum (immediate
early genes) (13, 14, 15),MEF2 transcriptional activity is regulated
at supplementary steps during the cell cycle.
By simultaneously monitoring the mRNAs of the MEF2 target
genes and the levels of MEF2C and MEF2D proteins, we noticed
the following. (i) During growth arrest (G0), mRNA upregulation
of three MEF2 target genes (KLF2, KLF4, and RHOB) is tightly
coupled to the stabilization of MEF2C and MEF2D proteins. (ii)
Following growth factor stimulation of serum-starved cells
(G0/G1 transition), the expression of MEF2 target genes is rapidly
and transiently upregulated. This rapid induction of the MEF2
target genes may depend on specific PTMs induced by serum,
potentiating MEF2 activity (18, 38). (iii) As cells progress toward
the G1/S phases, MEF2 protein levels drop. Again, the mRNA
levels of KLF2, KLF4, and RHOB decrease in parallel. The UPS is
responsible for this timing-regulated degradation of MEF2C and
MEF2D. Overall, the influence of the cell cycle on the half-lives of
MEF2C and MEF2D justifies their accumulation under nonpro-
liferative/quiescent conditions.
Phosphorylation plays a key role for targeting MEF2C and
MEF2D to the UPS. We provide evidence that phosphorylation of
serine residues 98 and 110 is fundamental for mediating the inter-
action with the F-box protein SKP2 and the subsequent polyubiq-
uitylation-mediated degradation of the TFs. Since residual MEF2
polyubiquitylationwas also observed in the presence of the double
phosphodead mutant (S98A/S110A) (Fig. 4I), it is possible that
additional Ser/Thr residues or different E3 ligases influence MEF2
stability during the cell cycle. Interestingly, a contribution of the
same serine residues to the regulation of MEF2C stability was
previously proposed (39).
SKP2 is a positive regulator of cell cycle progression and an
oncogenic protein that targets tumor suppressor proteins for deg-
radation (19). Hence, MEF2s polyubiquitylation lies at the core of
the machinery controlling cell cycle progression: the SCFSKP2
(SKP1–CUL1–F-box protein) superenzyme. In vitro phosphory-
lation assays using specific inhibitors and recombinant enzymes
suggest that cyclin D1-CDK4 but not cyclin E-CDK2 can phos-
phorylate serines 98 and 110 of MEF2D. Retinoblastoma tumor
suppressor protein RB1 and its family members are key substrates
of CDK4/CDK6 D-type cyclins complexes for promoting G1-S
transition (40). Interestingly, a catalogue of new substrates of
these kinases has been generated. Althoughmore precise informa-
tion about amino acid involvement is not available, in accordance
with our discovery, MEF2D was listed in the catalogue as a CDK4/
CDK6 substrate (41).
When we experimentally affected MEF2 levels and activities,
the overt evoked phenotype was a reduction of cell proliferation.
The importance of the growth-suppressive activity of MEF2s
stems also from the diminished antiproliferative impact of the
SKP2 inhibitor, when MEF2D expression was downregulated by
specific shRNAs.
We have discovered that an important element of the antipro-
liferative pathway engaged by MEF2s is CDKN1A (Fig. 7G). In
agreement with our observations, a recent study demonstrated
that ectopically expressed MEF2D can upregulate p21 expression
(42). CDKN1A transcription fluctuates during the cell cycle, ac-
cumulating in G0 and showing a peak after serum stimulation
(43). In human fibroblasts, this pattern is strictly dependent on
the presence of MEF2D (see Fig. S3 in the supplemental material).
We have shown that MEF2C and MEF2D bind a genomic region
within the first intron, at kb 12.1 from the TSS of the CDKN1A
gene, a region characterized by an open chromatin status (29). We
have also provided evidence thatMEF2D is important for favoring
H3K27 acetylation, a well-known marker of active/open chroma-
tin, within the CDKN1A gene, in proximity to its binding site. This
epigenetic modification may be governed through the engage-
ment of p300/CBP (31), a well-known MEF2 partner (44, 45, 46).
MEF2D is critical for the upregulation of the immediate early
genes response to serum. However, at least in BJ/hTERT/p53DN
control. Data are means and SD (n 5 3). (C) Quantification of BrdU positivity of the indicated cell lines, treated as for panel B. Data are means and SD (n 5 4).
(D) Representation of the CDKN1A gene structure and its promoter region 10 kb upstream and downstream from the transcription start site (TSS). The putative
MEF2 binding sites are highlighted (green). The coding (orange) and the noncoding (light blue) exons and the ATG leader are also indicated. (E) ChIP of
BJ/TERT and BJ/TERT/p53DN cells. Chromatin was immunoprecipitated using two distinct antibodies against MEF2C and one against MEF2D. Normal rabbit
serum (NRS) and anti-Flag antibody were used as relative controls. The RHOB promoter was used as a positive control, and an internal region (kb 14.7 from the
TSS) of the CDKN1A genewas used as a negative control. Data aremeans and SD (n 5 3). (F) ChIP of BJ/TERT/p53DN cells in which MEF2D was knocked down
with shRNA 15. The H3K27 acetylation status of the putative MEF2 binding sites on CDKN1A promoter is shown. Chromatin was immunoprecipitated with
antibodies against acetylated H3K27 (H3K27ac), and normal rabbit serum (NRS) was used as a relative control. Data are means and SD (n 5 3). (G) Model
representing the cell cycle-mediated regulation of MEF2 levels and MEF2 feedback activity on cell cycle progression. *, P , 0.05; **, P , 0.01; ***, P , 0.005.
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cells, a reduction of MEF2D activity and the consequent upregu-
lation of MEF2 target genes during G0/G1 transition did not affect
entry into S phase (see Fig. S3 in the supplemental material). Cer-
tainly, we cannot exclude the possibility that in other cellular con-
texts, this early activation makes an important contribution to cell
cycle progression.
A double role of MEF2 during different phases of the cell cycle
could explain the apparent conflicting results about MEF2s’ anti-
proliferative and proproliferative activities found in the literature
(14, 15, 47). In particular, MEF2C has been reported to be re-
quired for B cell proliferation and survival after BCR stimulation
but not after Toll-like receptor stimulation (12); in contrast,
MEF2A decreases the proliferation and the migration rates of vas-
cular smooth muscle cells (VSMCs) (48).
A tight and ordered control of the progression through the cell
cycle ensures a harmonic regulation of cell proliferation. Progres-
sion through the different phases of the cell cycle is orchestrated by
the activity of different TFs, which operate under the influence of
the cell cycle machinery and allow the ordered (hierarchical) tran-
scription of cell cycle-regulated genes (49). Our studies add
MEF2s to the list of the transcriptional regulators, which are an
integral part of the machinery that controls the cell cycle.
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Abstract The prospect of intervening, through the use of
a specific molecule, with a cellular alteration responsible
for a disease, is a fundamental ambition of biomedical
science. Epigenetic-based therapies appear as a remarkable
opportunity to impact on several disorders, including can-
cer. Many efforts have been made to develop small
molecules acting as inhibitors of histone deacetylases
(HDACs). These enzymes are key targets to reset altered
genetic programs and thus to restore normal cellular
activities, including drug responsiveness. Several classes of
HDAC inhibitors (HDACis) have been generated, charac-
terized and, in certain cases, approved for the use in clinic.
A new frontier is the generation of subtype-specific
inhibitors, to increase selectivity and to manage general
toxicity. Here we will discuss about a set of molecules,
which can interfere with the activity of a specific subclass
of HDACs: the class IIa.
Keywords SAHA  HDAC3  HDAC4  HDAC5 
HDAC7  HDAC9  MEF2  p21  Therapy  Apoptosis 
Cell cycle  Anti-cancer  Neurodegeneration 
Inflammation
Introduction
Why to target HDACs?
Every complex cellular adaptation and behavior is super-
vised by changes in the transcriptional machinery, which
align the gene expression profile of a specific cell type to
the general requirements of the organism. The harmonic
regulation of genes transcribed in a specific instant is the
result of an integrated and complex network of signals that
controls the activity of different transcriptional players.
Transcription factors (TFs), epigenetic regulators and
‘‘structural’’ proteins, constituting the chromatin are the
chief protagonists under the tight influence of the envi-
ronment. Alterations in the signaling networks or in the
transcriptional players are responsible for aberrations in
tissue homeostasis and triggering events in several differ-
ent diseases, from neurodegeneration up to cancer [1, 2].
The opportunity to reset the transcriptional subverted
context, with the therapeutic perspective of curing/allevi-
ating diseases, straightway attracted scientist’s attention [3,
4].
Perhaps the simplest approach to develop new drugs is
the identification of small molecules, acting as inhibitors of
an enzymatic activity that is imperative in a specific dis-
ease. In the context of gene transcription, post-translational
modifications (PTMs) of histones represent realistic targets
for the development of epigenetic therapies aimed to
amend transcriptional alterations. Acetylation of lysines,
placed in histones but also in TFs is an important PTM,
exerting both positive (H3K4, 9, 14, 17, 23; H4K5, 8, 12,
16) and negative (in the case of specific TFs) effects on
gene expression [5, 6]. Being acetylation reversible and
under the scrutiny of different family of enzymes: HATs
(histone acetyl transferases) and HDACs (histone deacet-
ylases), it has attracted several interests as a druggable
PTM [7]. In particular, during the past decades, many
efforts have been made to isolate, synthesize and charac-
terize small molecules targeting HDACs [8]. HDACis are
nowadays represented as a considerable fraction of the
epigenetic drugs under study and in some circumstances
E. Di Giorgio  E. Gagliostro  C. Brancolini (&)
Dipartimento di Scienze Mediche e Biologiche, Universita` degli
Studi di Udine, P.le Kolbe, 4, 33100 Udine, Italy
e-mail: claudio.brancolini@uniud.it
Cell. Mol. Life Sci.
DOI 10.1007/s00018-014-1727-8 Cellular and Molecular Life Sciences
123
these compounds have been approved for the use in clinic
(see below). Importantly, epigenetic drugs in cancer ther-
apy represent an opportunity to revert drug-resistance-
associated epigenomes and to prevent or reverse non-
responsiveness to anti-cancer drugs [2].
Copious studies on cancer cells’ epigenomes have fully
justified the rationale of applying HDACis in anti-cancer
therapies. Three major intrinsic features of the neoplastic
cells could be subject of specific intervention, thanks to
HDACis: (1) cancer cells are characterized by an enhanced
degree of heterochromatinization compared to normal
cells; which makes cancer genomes inaccessible to DNA-
damage response enzymes [9]. The treatment of cancer
cells with HDACis relaxes chromatin and allows the acti-
vation of the DNA-damage response [9]. (2) Several tumor
suppressor genes, including some pro-apoptotic genes, are
inactivated in cancer cells because of ipo-acetylated pro-
moters [3, 10, 11]. (3) Alterations of the epigenetic
machineries embracing HDACs are frequently observed in
tumors [12, 13].
Despite the considerable literature debating the use in
epigenetic therapies of pan-HDACi and of class I HDACs
specific inhibitors [10, 11, 14–22], reviews specifically
discussing of molecules acting as inhibitors of class IIa
HDACs, are quite rare. In this manuscript we will discuss
specifically of them.
Class IIa HDACs: to be or not to be a lysine deacetylase
In humans there are 18 HDACs grouped into five different
classes according to phylogenesis and sequence homology
[7]. Class I HDACs (including HDAC1, 2, 3 and 8), class
IIb HDACs (including HDAC6 and 10), class III HDACs
or Sirtuins (including all Sirtuins from 1 to 7) and class IV
(HDAC11) all displaying enzymatic activities [23]. By
contrast, when we discuss about class IIa HDACs
(HDAC4, 5, 7 and 9) as histone deacetylases, it should be
taken into account that these proteins show an extremely
low enzymatic activity against acetylated lysines [24, 25]
and are rarely associated with histone tails [26].
Structurally, class IIa HDACs can be divided into two
parts: the N- and the C-terminal regions (Fig. 1). The
N-terminal regulates the nuclear import and contains a
coiled-coil glutamine-rich domain that is peculiar of the
family. This region is highly devoted to protein–protein
interactions both in terms of homo- and of heterotypic
partners. The C-terminal region contains the catalytic
‘‘deacetylase’’ domain and the nuclear export sequence
(Fig. 1). These enzymes are under the control of different
signaling pathways, which operate through specific PTMs
to influence peculiar aspects of the class IIa biology,
including the nuclear/cytoplasmic shuttling (for reviews [7,
12, 27, 28]).
The deacetylase domain is made up of approximately
400 residues (aa) arranged into 21 a-helices and 10 b-
strands organized in a single domain, structured around a
central ‘‘catalytic’’ Zn2? ion [29]. Likewise to class I
HDACs, 2 aspartates and an histidine coordinate this
Zn2? while 2 other aspartates (Fig. 2a), another histidine,
a serine and a leucine coordinate two potassium ions
[29–31]. Despite this high similarity, in vertebrates class
IIa possess a bigger active site than class I HDACs
(Fig. 2b), which impacts on their druggability [26, 29].
The evolution-related event responsible for this structural
peculiarity is the mutation of a tyrosine into a histidine,
Y967H in HDAC4 [25]. Histidine is sterically less
cumbersome and induces the relaxation of the structure.
As a consequence, this histidine is far from the central
Zn2? and not able to form hydrogen bonds with the
intermediate of the enzymatic reaction (Fig. 2a). The
intermediate is, therefore, very unstable, thus resulting in
an ineffective reaction. Nevertheless, class IIa can effi-
ciently process alternative substrates such as
trifluoroacetyl-lysine. Mechanistically, the presence of
the trifluoro group should destabilize the amide bond,
hence favoring the reaction even in the absence of
transition-state stabilization [25].
Importantly, replacing back the His with Tyr generates
class IIa HDACs with a catalytic efficiency 1,000-fold
higher compared to the wild-type (wt) form [25, 31].
Nonetheless, this mutant does not show enhanced repres-
sion respect to the wt, at least in the instance of MEF2-
dependent transcription, a well-known class IIa partner
[25].
Fig. 1 Schematic representation of class IIa HDACs highlighting the principal domains. As prototype of class IIa we selected HDAC4. Certain
interaction partners, as well as the relative HDAC4 sequences involved, are illustrated
E. Giorgio et al.
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Another distinctive feature of class IIa HDAC catalytic
site is the existence of a Zinc Binding Domain (ZBD). This
ZBD consists in a b-hairpin surrounded by two antiparallel
b-strands, forming a pocket-like structure that accommo-
dates a second ‘‘structural’’ zinc ion [29]. In the case of
HDAC4 three cysteines (667, 669, 751) and one histidine
Class IIa HDACs inhibitors
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(675), conserved only among class IIa HDACs, coordinate
this Zn2? and made the so-called ‘‘core’’ of the domain
[31] (Fig. 2c). Importantly, the inhibitor-bound structure is
shown in this figure, where, respect to the Apo-structure,
Cys 669 and His 675 replace His 665 and His 678 in the
coordination of the Zn2?.
This domain is extremely flexible and the oxidation of
the cysteines involved in Zn2? coordination (667 and 669
in HDAC4) is sufficient to free the metal, with the conse-
quent opening and deconstruction of the ZBD [31].
Because this domain is head-to-head to the active site
(Fig. 2c), it contributes to make the class IIa HDACs’
catalytic site more accessible than that of class I HDACs
(Fig. 2b) and does not allow the formation of an efficient
hydrophilic tunnel necessary for the release of the acetate
reaction product [30, 31].
Old structures and new functions
The enzymatic ineptitude of vertebrates’ class IIa deace-
tylase domain raises several questions and opens the door
to different hypothesis. First, they are not completely
silenced enzymes. Because class IIa is capable of pro-
cessing trifluoroacetyl-lysine with high efficiency, still
undiscovered new natural substrates could exist [25].
Alternatively, the described enzymatic activity could sim-
ply mark a lab finding, without biological implications.
Second, as anticipated above, the absence of improved
repressive influence in the case of the gain of function His/
Tyr substitution in HDAC4, further demonstrates that class
IIa HDACs can repress transcription independently from
the deacetylase domain [25]. The relevance of the deace-
tylase-independent repression is testified by MITR, a splice
variant of HDAC9 lacking the deacetylase domain [32].
The existence of MITR supports the possibility that the
HDAC domain is of little relevance for the functions of
class IIa HDACs and may lead to believe that it is an
evolutionary heritage intended to being missed. However,
since class IIa deacetylase domain has been preserved
behind two duplication events occurred during evolution of
vertebrates, evolutionists deny the hypothesis that this
domain would be subjected to a negative purifying selec-
tion [33].
Although there are evidences pointing to deacetylase-
independent activities of class IIa, generation of a mouse
model in which, mutated versions of this domain can be
analyzed in a physiological context will help our under-
standing. This point is of crucial relevance for the design
and development of class IIa inhibitors.
Along with the enzymatic activity, the deacetylase
domain can operate as a scaffold for the recruitment of
multi-protein complexes containing class I HDAC3 and
other co-repressors [31]. HDAC4 interacts with the RD3
domain of N-CoR [24, 34], while HDAC3 binds the
SAINT domain [35] and, as a matter of fact, HDAC4 binds
N-CoR/SMRT regardless of HDAC3 and only in a second
time the deacetylase is recruited [36]. However, the precise
order of the sequential molecular interactions driving the
assembly of the multi-protein complex is still waiting for a
final verification.
When class IIa HDACs are isolated under native con-
ditions, a lysine deacetylase activity can be measured. This
activity is due to class I HDACs co-purified with class IIa
[24, 37, 38]. The existence of a heterogeneous repressive
complex complicates the assessment of effectiveness and
specificity of HDACis, when tested on proteins purified
from cells or tissues.
A final consideration refers to a fascinating hypothesis,
which attributes to class IIa deacetylase domain the func-
tion of acetylated lysine reader [26]. In this view, class IIa
could act as readers and interpreters of the histone code,
thus orchestrating the epigenetic status thanks to their
capability of recruiting additional enzymes, such as meth-
ylases [39] or deacetylases [24, 36]. A scenario where class
IIa HDACs, acting as molecular scaffolds supervise the
introduction of different epigenetic markers, onto specific
regions of chromatin or in proximity of different acetylated
cellular protein. In this context inhibitors of the deacetylase
domain could in principle both interfere with the reading
activity or, by promoting structural changes, with the
possibility of recruiting additional co-repressors.
bFig. 2 Representation of class I and class IIa catalytic sites (a,
b) and the zinc binding domain (c). a Superimposition of the inhibitor
(TFMK)-bound ribbon structure of class I HDAC8 (green) and of
class IIa HDAC4 (white) catalytic sites. As mentioned in the text the
His 976 is rotated away from the active site differently from Tyr 308
in HDAC8. b Surface representation of class I HDAC8 (green) and
class IIa HDAC4 (white) catalytic sites. The figure shows the
hydrophilic tunnel necessary for the release of the reaction product in
HDAC8 (green), while in HDAC4 (white) the His/Tyr substitution
prevents tunnel formation. c Superimposition of the inhibitor
(TFMK)-bound ribbon structure of class I HDAC8 (green) and of
class IIa HDAC4 (white) catalytic site (right) and zinc binding
domain of HDAC4 (left). b3 and b4 are the two antiparallel b-strands
involved in the formation of the pocket-like structure in the zinc
binding domain. Importantly, His 665 and His 678 in this inhibitor-
bound structure are replaced by Cys 669 and His 675 in the
coordination of the zinc ion in the Apo-structure. Unfortunately the
crystallization of Apo-HDAC4 was unsuccessful and these differ-
ences are deduced from crystallographic studies of the mutant GOF
(H976Y) of HDAC4 [31]. The coordinates of the protein structures
were retrieved from the protein data bank. Amino acids discussed in
the text are labeled and shown in stick representation. The accession
codes for the protein structures are: 2VQJ (HDAC4) and 1T69
(HDAC8). Figures are edited using PyMOL Molecular graphics
system, Schro¨dinger, LLC
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Unresolved issues
Biochemically, the enzymatic activity associated to class
IIa HDACs could be explained by the recruitment of class I
enzymes [24]. Moreover, all the point mutants of the
HDAC4 deacetylase domain which, accordingly to Finnin
model [40], abrogate its enzymatic activity (H803A,
G811A, D838A, D840A, H842A, N845D, D934 N,
E973G) demonstrate a perfect correlation between enzy-
matic activity and the ability to recruit HDAC3 [24].
Classic deacetylase activity is not associated with a cyto-
plasmic HDAC7 or HDAC4 immunoprecipitated from
HEK293 cells and therefore, weakly associated to the
mainly nuclear HDAC3 [24, 36]. Similarly, HDAC4
mutants that have lost the ability of binding to N-CoR/
SMRT drop the deacetylase activity [24]. Despite in vitro
binding experiments prove that the fraction of HDAC3 in
complex with HDAC4 is relevant, in vivo HDAC3 pref-
erentially forms homodimers, rather than heterodimers
with HDAC4 [41]. Furthermore, the fraction of HDAC4
co-purified with HDAC3 in mammalian cells is extremely
low [24, 35, 37].
As aforementioned, another peculiar feature of class IIa
deacetylase domain is its sensitivity to redox conditions
[31, 42]. Particularly, in HDAC4 the oxidation of cysteines
667 and 669 induces the formation of a disulphide bond
that causes the exposition of the NES, the export in the
cytoplasm and also the detachment of HDAC3 [31, 42, 43].
This oxidation causes the de-structuration of the HDAC
domain because Cys 667 and Cys 669 are directly involved
in the ‘‘structural’’ Zn2? coordination and substrate binding
[29, 31] (Fig. 2c). These findings show that researchers
should be extremely cautious in verifying the redox status
when studying class IIa deacetylase domain.
In addition to nuclear roles of class IIa HDACs,
recently, a cytoplasmic enzymatic activity has been
reported towards non-histone substrates [reviewed in 44].
During muscle denervation HDAC4, which plays a pro-
atrophic role in this context [45, 46] can deacetylate and
activate MEKK2 [47]. Kinase engagement culminates in
AP-1 activation and cytokines production that stimulate
muscle remodeling [47]. Interestingly only the wild-type
form, capable of shuttling between the nucleus and the
cytoplasm and not a nuclear resident mutant of HDAC4
deacetylated MEKK2. Importantly, this activity is inde-
pendent from HDAC3 and is not shared with HDAC5 [47].
Paradoxically, MEKK2 activation should activate ERK5
and therefore MEF2s, thus pointing to a positive rather than
repressive influence of HDAC4 versus MEF2s [48, 49]. A
similar cytoplasmic KDAC (lysine deacetylase) activity of
class IIa HDACs was reported towards HIF-1a and STAT-
1. Also in these circumstances class IIa deacetylase activity
seems to be independent from class I HDACs [44].
Another unresolved issue is the requirement of addi-
tional factors to exert the full enzymatic activity. Class I
HDACs require particular cofactors both for histone and
non-histone substrates [35, 41, 50]. For the enzymatic
activity of class IIa HDACs towards the synthetic trifluo-
roacetyl-lysine or against these cytoplasmic partners, any
cofactor seems to be dispensable [25].
The rationale for developing class IIa HDACs inhibitors
HDACis have entered multiple clinical trials principally in
virtue of their anti-neoplastic properties [10]. Much more
emphasis has been pushed on the identification, synthesis
and characterization of class I HDACis. Commonly
HDACis show a selective cytotoxicity against tumor cells
and weak effects on normal ones [11, 51, 52]. These
molecules display cytostatic effects, especially through the
induction of p21 and blockage of the cell cycle [53, 54] or
by triggering apoptosis via multiple mechanisms [11, 53,
55, 56]. Some HDACis in vivo stimulate also the clearance
of tumor cells from the immune system [57, 58] or block
angiogenesis [59, 60]. Despite these promising anti-neo-
plastic properties, entering of HDACis in clinic is slower
than expected, principally due to some side effects and
toxicity displayed during early-phase clinical trials [14,
61]. In fact, up to now only two HDACis have been
approved for the treatment of cutaneous T cell lymphoma:
SAHA (Zolinza) in 2006 and Romidepsin/FK-228 in 2009.
In 2011 the depsipeptide FK-228 has been further approved
for the treatment of peripheral T-cell lymphoma [15].
Considering the recent evidences about a pro-oncogenic
potential of class IIa HDACs [12, 37, 38, 62–64] and their
impact on epigenetics [65], a stratagem to circumvent the
side effects of class I HDACs inhibitors might consist in
targeting class IIa HDACs.
Theoretically, targeting class IIa HDACs with specific
inhibitors has three major drawbacks:
1. The high similarity of the catalytic site of these
proteins to class I HDACs, which makes selective
targeting rather difficult to achieve;
2. The formal question about the legitimacy of hitting the
catalytic site of proteins that are almost enzymatically
inactive against acetylated lysines. About this consid-
eration the work of Bottomley et al. [31] explains how
targeting of the catalytic site of class IIa HDACs and
in particular the Zn2? atom could impact on the
structure of the C-terminus of the proteins, thus
compromising their capability to interact with the
super complex HDAC3/N-CoR/SMRT. Therefore,
targeting class IIa HDAC domain could be an indirect
strategy to impact on class I HDACs. By releasing
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only class IIa driven deacetylation, a more selected
transcriptional re-setting can be achieved, which could
favor a drop in toxicity.
3. The methodological approach to measure class IIa
HDAC inhibition. Up to now the best-characterized
substrate for probing the elusive catalytic activity of
vertebrate class IIa histone deacetylases is trifluoro-
acetyl-lysine [25, 66]. The activity of class I HDACs
towards this molecule is indiscernible. Its use as a
substrate for the validation of an inhibitor efficiency
could exclude all class I HDACs as off-targets. Class
IIa HDAC enzymatic activity measured with other
methods or with classical substrates (e.g., acetylated
H3) or commercial assays, generally based on acetyl-
Lys, is extremely low when recombinant proteins are
used [24]. Instead, when class IIa are purified from
vertebrates the enzymatic activity can be provided by
associated class I or IIb enzymes [24, 25, 31, 67].
Therefore, a double check approach should be used to
test the potency and specificity of a class IIa
HDACis. The potency of the compound should be
evaluated by employing trifluoroacetyl-lysine, as a
class IIa specific substrate, while its inhibitory
activity against other HDAC classes should be
excluded using ‘‘classical’’ substrates, such as acet-
ylated lysines. A simplified screening could take
advantage from the recently developed trifluoroace-
tyl-lysine derivative, a trifluoro acetyl-lysine
tripeptide named substrate 6, which can be processed
by all HDACs, with the exclusion of HDAC10 and
11. This molecule looks like a promising tool for
single-run screening aimed to isolate/characterize
subtype specific HDACis [68].
Class IIa inhibitors
Three different peculiarities of class IIa HDACs have been
exploited to design specific inhibitors:
a. The catalytic site, and in particular the Zn2? atoms.
b. The nuclear/cytoplasmic shuttling.
c. The N-terminal region and the binding to specific
partners, such as the MEF2 family of TFs.
Targeting the Zn2? binding domain
In accordance to the connecting unit (CU) linker chelator
pharmacophore model [16, 69], a classical HDACi is
composed of three parts [17]:
1. The MBG (metal binding group or zinc binding group
ZBG), which is a group capable of chelating the Zn2?
in the catalytic site of HDACs (with the exception of
sirtuins).
2. The connecting unit (CU), generally a linker hydro-
phobic region of five or more carbons, that mimics the
acetyl-lysine. It could be linear or aromatic and it
perfectly fits to the hydrophobic catalytic site of the
targeted HDAC.
3. The CAP hydrophobic domain (usually aromatic) that
interacts with aminoacids delimiting the border of the
deacetylase catalytic site.
Slight modifications of the described structure impact
both on the specificity and potency of the inhibitor.
The availability of the crystal structure of the class IIa
deacetylase domain [29, 31] has encouraged the devel-
opment and synthesis of many hydroxamates stemmed
from SAHA, with the purpose of selectively influencing
class IIa HDACs. In particular to improve specificity,
many efforts have been spent in the modification of the
CAP and of the ZBG of SAHA. In principle, the selective
targeting of class IIa HDACs would require only some
changes in the linker region, to better fit the peculiar
catalytic site of class IIa HDACs. A recent study effec-
tively demonstrated that slight modifications only in the
linker region of SAHA increase the selectivity towards
class IIa and class IIb HDACs [70]. However, the
achieved results were not as promising as those obtained
after modification of both the CAP and the linker region
of SAHA [71]. This double tuning seems to be the better
strategy to produce SAHA derivatives specific for class
IIa HDACs. In a next future, new generation class IIa
HDACis could stem from Tasquinimod (described below)
that selectively targets the ‘‘structural’’ and not the ‘‘cat-
alytic’’ Zn2?. This peculiarity should increase the
specificity because, as discussed above, this ‘‘structural
zinc’’ is unique of class IIa HDACs. A summary of the
literature data is shown in Fig. 3.
The most characterized of these hydroxamate-like
drugs, are:
– MC1568 and MC1575 (Fig. 3, please note that in Fig. 3
we provide for MC1568 the recently reassigned structure
[72]) are two class II HDACs inhibitors specific for
HDAC4 and HDAC6 [73–76]. They are derivatives of
classical class I HDACs inhibitors aroyl-pyrrolyl–hydrox-
yamides (APHAs), showing selectivity towards class IIa
HDACs. The modified linker region provides this selec-
tivity. Compared to the original class I inhibitors, they
exhibit a decreased cytotoxic effect [73]. Despite this fact,
MC1568 and MC1575 show some cytostatic effects in
melanoma cells [76] and in ER ? breast cancer cells
[74]. The anti-proliferative effect is provoked by a block
in the G1 phase of the cell cycle, through the induction of
the Cdk inhibitor p21/Cip1/Waf1 [74]. MC1568 efficacy
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in cancer cells finds rationality in the capability of up-
regulating the tumor suppressor Brahma, repressed by
HDAC9 [77]. Curiously, MC1568 has been reported
stabilizing the HDAC4-MEF2D complex in differentiated
C2C12 myoblasts, thus impairing instead of favoring
myogenesis [78].
– LMK235 (N-((6-(hydroxyamino)-6-oxoh exyl)oxy)-
3,5-dimethylbenzamide) is a hybrid between two
Fig. 3 Structures and summary of the available literature data on the IC50 for the proposed class IIa inhibitors
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classes of class I HDACis: the hydroxamic acids and
the benzamides (Fig. 3) [71]. The specificity towards
HDAC4 and HDAC5 is conveyed by the hydrophobic
dimethyl substituted phenyl ring, which acts as a CAP
group, matching class IIa active site better than class I
[71]. This modification makes the molecule less toxic
and more suitable for the treatment of some malig-
nances, when compared to class I HDACis.
Furthermore, LMK235 is able to re-sensitize cancer
cells to cisplatin, better than SAHA [71].
– TMP269 and 195 (Figs. 3, 5) are two recently devel-
oped class IIa HDACis in which the classical
hydroxamic Zn2? binding domain is substituted by a
trifluoromethyloxadiazolyl group (TFMO) [26] that
highly resembles the trifluoromethylketone (TFMK)
adopted by Bottomley and colleagues in their bio-
chemical study of the ZBD [31]. The ring structure of
the TFMO group increases its stability with respect to
the highly unstable TFMK series of compounds [79].
Moreover, this TFMO moiety, differently from hy-
droxamate, acts as a non-chelating metal binding
group, which interacts with the ‘‘catalytic’’ Zn2?,
through weak electrostatic interactions. As a conse-
quence, the TFMO series has fewer off-targets
compared to hydroxamates. Augmented selectivity is
indirectly proved by gene expression profile studies in
(PHA)-activated human peripheral blood mononuclear
cells (PBMC) (Fig. 5). In these cells SAHA modulates
the expression of 4,556 genes, whereas TMP195
regulates only 76 genes [26]. Curiously this finding is
in accordance to what was observed in fibroblasts,
where HDAC4 directly modulate only 76 genes [38].
To better characterize the transcriptome profile induced
by their TFMO series of compounds, Lobera and
colleagues purified T cells (CD3?), B cells (CD19?)
and monocytes (CD14?) from the PHA-stimulated
PBMC population and separately treated the three sub-
populations with TMP195. T and B cells turned out to
be very low sensitive to TMP195 (17 and 36 genes
regulated, respectively); on the contrary the effect of
the compound on monocytes was impressive (587
genes) and was not due to an increase in the expression
of class IIa HDACs in these cells compared to the other
two cell types. In particular the inhibitor interfered with
monocytes to macrophages M-CSF (macrophage col-
ony-stimulating factor)-induced differentiation. These
findings candidate class IIa HDACs as druggable
targets for immunological diseases [18, 71].
– N-hydroxy-2,2-diphenylacetamide and N-hydroxy-9H-
xanthene-9-carboxamide (respectively, compound 6
and 13 in the original manuscript) are two diphenylm-
ethylene hydroxamic acids characterized by Besterman
group as class IIa HDACs specific inhibitors active in
the lM range [80]. Both molecules exhibit a certain
degree of symmetry and the second compound could be
considered as the rigidification of the diphenyl moiety
of the first (Fig. 3). This modification increases the
specificity of the molecule towards HDAC7 [80].
– N-lauroyl-(l)-phenylalanine is a class IIa HDACi active
in the lM range (Fig. 3) [81]. It was identified during a
screening of a commercial available library of com-
pounds. The specificity was scored not merely by
classical measurements of HDAC activity but also
through a fluorescence assay, which exploits the
competition between a fluorescent substrate and the
putative inhibitor for each purified HDAC [81]. This
molecule shows anti-tumoral properties against ER?
breast cancer cells and can influence the expression of
some MEF2-target genes (Fig. 5) [37].
– Ethyl 5-(trifluoroacetyl)thiophene-2-carboxylate [67] is
the founder of a class of compounds, the trifluoroace-
tylthiophenes, that targets class II HDACs (class IIa
and HDAC6) with some specificity. It was identified
during a screening of a commercially available library
of compounds using both the wt and the GOF mutant of
HDAC4 as targets. It is a tripartite molecule charac-
terized by: (i) a trifluoromethyl ketone group that
chelates the active site zinc in a bidentate manner, (ii)
the central thiophene ring that fits perfectly to class IIa
active site and (iii) the amide group that interacts with
the surrounding residues. The chemistry and the tri-
functional nature of this compound justify its
specificity.
– Tasquinimod (Fig. 4) is a promising drug for the
treatment of advanced castration resistant prostate
cancers [82, 83]. It acts by perturbing the tumor
microenvironment. Differently from the aforemen-
tioned molecules it was not rationally designed or
screened to target HDACs. Nevertheless, this carbox-
amide is able to enter the ZBD of HDAC4, keeping it in
the inactive form and thus reorganizing the HDAC4
catalytic site. Tasquinimod-induced structural changes
are causative of N-CoR/SMRT/HDAC3 displacement
[43]. This finding is surprisingly considering the
pronounced steric hindrance of the molecule, which is
profoundly different from all SAHA derivatives. How-
ever, by virtue of its selective targeting of the
‘‘structural’’ Zn2?’’, Tasquinimod molecular backbone
could substitute SAHA as starting model for the
development of specific inhibitors. From a molecular
point of view the inactivation of HDAC4 prevents HIF-
1a deacetylation, thus inducing its destabilization.
Clinically, in hypoxic conditions the activation of
HIF-1a transcriptional program stimulates the differ-
entiation of tumor infiltrating myeloid derived
suppressor cells into tumor-associated macrophage,
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which secrete pro-angiogenic factors [84]. Authors,
therefore, proposed Tasquinimod as an anti-angioge-
netic drug, which anti-cancer efficacy is being
evaluated in pre-clinical models [43].
These last three molecules are considered unconven-
tional inhibitors because, even though characterized by a
tripartite motif, they are not SAHA derivatives.
Targeting the nuclear-cytoplasmic shuttling
In 2011, Brown group made the first attempt of blocking
class II HDACs in the cytoplasm [85]. Starting from the
structure of SAHA, they generated a couple of molecules
by substituting the amino-phenyl group with a fluorescent
dansyl group. This modification increases the specificity
for class II HDACs in spite of a loss of reactivity against
class I HDACs. If used in the lM range, the most effective
molecule of the series, named compound 2 (Fig. 3),
increases the fraction of cytoplasmic HDAC4 in prostate
cancer cells PC3. The authors suggested that since the
inhibitor accumulates in the cytoplasm, it binds HDAC4,
thus impeding the interaction with importin-1a. As a
consequence, the inhibitor increases the fraction of cells in
the G1 phase of the cell cycle, the levels of p21/Cip1/Waf1,
of acetylated H3 and tubulin. The increase of tubulin
acetylation is probably due to the inhibition of HDAC6
[86] and seems to be unrelated to the suppression of class
IIa [85].
It must be underlined that the IC50 values of these new
inhibitors have been estimated by measuring the enzymatic
activities of HDACs purified from mammalian cells, using
the Fluor–de-Lys substrate [85]. Therefore, in the case of
class IIa HDACs, it must be intended as indirect, deriving
principally from the associated class I HDACs.
The strategy of interfering with class IIa HDACs nuclear
accumulation could be attractive in oncology, as increasing
evidences demonstrate that nuclear resident class IIa can
display oncogenic functions [37, 38], but it might also
present some drawbacks. First of all, class IIa HDACs
possess also cytoplasmic functions [reviewed in 44], which
could be amplified after inhibition of their nuclear import.
Moreover, the cytoplasmic accumulation of class IIa
HDACs is sometimes an indirect still uncertain effect of
class I inhibition. For example the class I/II inhibitor
LBH589, which is a SAHA derivate, confines HDAC4 in
the cytoplasm in irradiated non-small cell lung cancer cells
[87]. Considering all these drawbacks, the nucleus/cyto-
plasmic shuttling of class IIa HDACs seems to be the less
druggable feature of these proteins.
Class IIa HDACs N-terminus, which allows their
interaction with some partners, such as MEF2 family
of TFs
As discussed above, class IIa HDACs’ N-terminal region
(Fig. 1) mediates the interaction with multiple partners and
contains a glutamine-rich domain (with the exception of
HDAC7) that allows homo- and heterodimerization among
the different class IIa members [12, 88]. The best-charac-
terized class IIa transcriptional partners are the MEF2s
proteins [49, 89]. Several of the biological functions
attributed to class IIa HDACs are the results of the MEF2s
transcriptional repression [27, 37, 38]. The phenotype of
the single knock-out of class IIa HDACs could be
explained as the effect of MEF2 over-activation in bone
(HDAC4), heart (HDAC5/9) and cardiovascular system
(HDAC7), in relation to the district in which the single
HDACs are more abundant [90–92]. Hence, the design of
an inhibitor that displaces class IIa HDACs from MEF2s
could be a good approach to selectively interfere with this
specific repressive exploit. A limitation to this strategy
concerns the promiscuity of the class IIa HDACs sequence
required for this interaction (aa 166-184 in HDAC4). In
fact, this stretch of amino acids is also involved in the
interaction with additional partners, among which, the
nucleoporin Nup155 [93] and the demethylase JARID1B
[94] (Fig. 1). An alternative plan to influence the MEF2-
Fig. 4 Structure and binding
interference properties of
BML210 and Tasquinimod, two
compounds capable of altering
interaction of class IIa HDACs
with their partners
Class IIa HDACs inhibitors
123
HDAC axis could be targeting the region of MEF2s that
interacts with class IIa HDACs. Using this approach, BML-
210 (Figs. 3, 4, 5), a weak class I HDAC benzamide
inhibitor, was found to interact through its aminophenyl-
group with the hydrophobic residues of MEF2s (aa 66-69)
thus displacing class IIa HDACs [95]. Using the crystal
structure of the HDAC9–MEF2B complex as a guide [96],
authors generated a panel of more powerful BML-210
derivatives. In the next future it will be important to further
improve the specificity of these compounds to exclude
residual targeting of class I HDACs.
Conclusions and perspectives
The identification of molecules that could reset the tran-
scriptional profile in neoplastic cells has raised many hopes
for new anti-cancer therapies [97]. Unfortunately today this
goal has been only partially reached. Nevertheless an epi-
genetic therapy against cancer is still subject of intense
research. A new impetus in this field was given by the
discovery of the demethylases [98, 99] and the synthesis of
their specific inhibitors [100]. A more niche-research
concerns class IIa HDACs and their selective inhibitors,
which are hypothesized to be less powerful than pan-
HDACis but more specific. However, these studies are still
in their infancy and the applicability of class IIa HDACis in
clinic requires still intense laboratory characterization.
Additional experiments and data are mandatory to char-
acterize and understand the contribution of these molecules
to epigenetic changes in vivo. Up to now, information
about the impact of class IIa HDACis on RNA non-coding
world and the role of class IIa HDACs in stemness main-
tenance are very limited [101]. In parallel the efforts trying
to design, isolate and characterize new compounds, acting
as epigenetic regulators must persist. In addition, a robust
in vitro pre-clinical characterization of molecules already
available is needed to define: their molecular mechanism of
action, their ideal context of utilization and off-targets
effects. All these efforts are justified by the benefits that
drug-induced genetic reprogramming could exert on dif-
ferent diseases.
Certainly anti-cancer therapy is the first and most
important scope. Nevertheless, the involvement of class IIa
HDACs in the regulation of Glut4 [102–105], of the NF-kB
pathway [106, 107] and of many neuronal activities [108–
111] could stimulate studies about the employment of class
IIa HDACis for the treatment of diseases other than cancer,
such as diabetes [112], neurodegenerative disorders [113,
114] and inflammatory diseases [26, 115–118]. There are
opportunities out there; we just have to find out what is the
best compound for each specific application.
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